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ABSTRACT
This study aimed at elucidating molecular pathways behind muscular dystrophies, 
inherited disorders causing progressive weakness and loss of skeletal muscle, with 
the perspectives of demonstrating the pathogenicity of newly identified mutations, 
understanding the biology of muscle diseases, and finding options for their treat-
ment.
Tibial muscular dystrophy (TMD) and limb-girdle muscular dystrophy type 
2J (LGMD2J) are caused by mutations in the C-terminal (M-band) part of the 
sarco meric protein titin, whereas LGMD2A results from mutations in the muscle -
specific protease calpain 3 (CAPN3). In yeast two-hybrid studies aiming at identi-
fying  proteins secondarily affected in the diseases, the multifunctional TRIM-relat-
ed protein myospryn (CMYA5) was identified as a novel binding partner for both 
M-band titin and CAPN3. The interactions were confirmed by coimmunoprecipita-
tion, and localization of myospryn at the M-band level was supported by multiple 
methods. Coexpression studies identified myospryn as a proteolytic substrate for 
CAPN3, and suggested that myospryn may attenuate its autolytic activation. The 
biological role of the titin–myospryn interaction remained unresolved, and the 
mouse model of TMD/LGMD2J showed normal myospryn localization. However, 
since the TMD/LGMD2J mutations disrupt the myospryn binding site in titin, they 
are likely to have a downstream functional effect on myospryn.
LGMD1D is caused by dominant mutations in the ubiquitous co-chaperone 
DNAJB6. LGMD1D muscle showed a myofibrillar pathology, with cytoplasmic 
 accumulations of DNAJB6, aggregated Z-disc-associated proteins, and autophagic 
rimmed vacuoles. Expression of DNAJB6 constructs in zebrafish embryos con-
firmed a toxic effect of the mutant cytoplasmic DNAJB6b isoform, and cell culture 
studies demonstrated a slower turnover and impaired anti-aggregation activity of 
mutant DNAJB6. Protein interaction studies indicated an association of DNAJB6 
with the chaperone-assisted selective autophagy (CASA) pathway, and a modula-
tory effect of BAG3 on DNAJB6 pathogenicity in zebrafish suggested that CASA 
has active role in the pathogenesis of LGMD1D.
Welander distal myopathy (WDM) results from a dominant mutation in the 
prion-related domain (PRD) of the RNA-binding protein TIA1, a regulator of 
 splicing and translation, and a component of stress granules (SGs). RT-PCR analy-
sis of selected TIA1 target genes did not show splicing changes in WDM muscle, 
suggesting that the pathogenesis does not involve extensive mis- splicing. IF micro-
scopy revealed accumulation of TIA1 and other SG proteins in WDM muscle, while 
image analysis of transfected cells, and fluorescence recovery after photobleaching 
(FRAP) studies indicated a mild increase in the SG-forming propensity of mutant 
TIA1. These findings suggest that increased aggregation of the TIA1 PRD causes 
muscle pathology in WDM, either directly through inappropriate protein aggrega-
tion or indirectly by compromising cellular metabolism.
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TIIVISTELMÄ
Lihasrappeumat ovat perinnöllisiä sairauksia, jotka johtavat luurankolihasten ete-
nevään heikkouteen ja surkastumiseen. Ne aiheutuvat geenivirheistä useissa lihas-
syyn rakenneosissa, ja monet sairauteen johtavista molekyylitason meka nismeista 
tunnetaan huonosti. Tässä väitöskirjassa tutkittiin joidenkin lihasrappeumien 
tauti mekanismeja, tavoitteena osoittaa tunnistettujen geenivirheiden patogeeni-
suus sekä ymmärtää lihastautien molekyylibiologiaa, esi merkiksi hoitojen kehit-
tämistä ajatellen.
Suomalaiseen tautiperintöön kuuluvat tibiaalinen lihasdystrofia (TMD) ja 
hartia- lantiotyypin lihasrappeuma 2J (LGMD2J) aiheutuvat virheistä  titii nissä, 
sarkomeerien keskeisessä rakenne- ja säätelyproteiinissa. Tutkimuksessa tun -
nis tettiin titiinin viallisen osan sitoutumiskumppaniksi myospryyni (myo -
spryn, CMYA5), joka toimii solun kalvoliikenteessä ja viestinvälityksessä. 
TMD/LGMD2J-hiirimallin lihaksessa ei havaittu poikkeavaa myospryynin 
 sijoittumista, mutta toiminnallinen vaikutus myospryyniin on todennäköinen. 
Myo spryyni tunnistettiin myös LGMD2A-lihasrappeuman taustalla olevan kal-
paiini 3 -proteaasin substraatiksi ja mahdolliseksi säätelijäksi. Kuvatut prote iini-
vuorovaikutukset lisäävät lihaksen molekyylibiologian perustuntemusta ja voivat 
jatkossa auttaa TMD/LGMD2J- ja LGMD2A-tautien synnyn ymmärtämisessä.
Hartia-lantiotyypin lihasrappeuma 1D (LGMD1D) aiheutuu proteiinien laadun-
valvontakoneistoon kuuluvan kaitsijaproteiini DNAJB6:n geenivirheistä, joiden 
seurauksena lihassyihin kertyy proteiinisakkautumia. DNAJB6:n virheellisen 
muodon todettiin aiheuttavan lihastautia seeprakalan alkiossa tuotettuna, mikä 
sopii yhteen LGMD1D:n vallitsevan periytymismallin kanssa. Soluviljelmissä ha-
vaittiin, että geenivirheet hidastavat DNAJB6:n hajotusta sekä haittaavat kaitsija-
proteiinin kykyä estää proteiinien aggregaatiota. Tutkimuksissa onnistuttiin myös 
vahvistamaan DNAJB6:n epäilty vuorovaikutus hiljattain kuvatun ja lihaksen 
toiminnalle tärkeäksi todetun CASA-mekanismin (chaperone-assisted selective 
auto phagy, kaitsijaproteiiniavusteinen selektiivinen autofagia) kanssa sekä saatiin 
viittei tä tämän autofagiareitin suorasta osallisuudesta LGMD1D:n synnyssä.
Ruotsissa ja Suomessa melko yleinen Welanderin distaalinen myopatia (WDM) 
aiheutuu geenivirheistä TIA1:ssä, joka on lähetti-RNA:n silmukoinnin ja proteiini-
translaation säätelijä sekä soluihin stressitilanteissa muodostuvien stressijyvästen 
(stress granule) rakenneosa. Tutkittujen TIA1:n kohdegeenien silmukoinnissa ei 
todettu muutoksia WDM-lihaksessa. Sen sijaan lihasnäytteissä nähtiin TIA1:n ja 
muiden proteiinien kasaumia, ja soluviljelmissä tehdyissä toiminnallisissa kokeis-
sa havaittiin virheellisen TIA1:n muodostavan stressijyväsiä hieman normaali-
proteiinia tehokkaammin. Tulosten perusteella WDM vaikuttaa siis johtuvan poik-
keavasta stressijyväsproteiinien käyttäytymisestä, joka on viime aikoina havaittu 
merkittäväksi ilmiöksi myös hermorappeumasairauksien synnyssä.
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1 INTRODUCTION
Muscular dystrophies are a large group of inherited disorders affecting the skeletal 
muscles and causing progressive weakness and loss of muscle mass. The disease 
group is heterogeneous both genetically and clinically: Muscular dystrophies can 
be inherited in a recessive or dominant manner. The symptoms may be evident 
at birth, or appear as late as middle age. The diseases can affect most groups of 
skeletal muscles or show striking selectivity of muscle involvement. Some mus-
cular dystrophies may be associated with symptoms in other organs such as the 
heart or the brain. A common denominator in the diseases is gradual death of the 
muscle  fibres or myofibres—the long, multinucleated muscle cells (Fig. 1A)—in the 
 affected  muscles (Mercuri & Muntoni 2013, Rahimov & Kunkel 2013).
Muscular dystrophies have been traditionally classified into a few major 
 categories based on the mode of inheritance and the pattern of muscle involve-
ment (Walton & Nattrass 1954). During the past twenty years, however, mapping 
of disease genes and identification of the gene defects at an ever-accelerating pace 
has revealed a surprising genetic diversity underlying the diseases. For example, 
limb-girdle muscular dystrophies (LGMD), characterized by preferential involve-
ment of proximal limb muscles, are currently known to exist in at least eight domi-
nant (LGMD1) and 17 recessive (LGMD2) genetic subtypes (Kaplan & Hamroun 
2012). In total, mutations causing muscular dystrophy have been found in over 
fifty genes, whose protein products have diverse functions and reside in virtually 
all compartments of the muscle fibre (Kaplan & Hamroun 2012).
A major group of proteins affected by dystrophy-causing mutations are those 
constituting the dystrophin–glycoprotein complex (DGC) on the sarcolemma—the 
plasma membrane of the muscle fibre (Fig. 1B). Mutations in dystrophin, under-
lying the archetypal Duchenne muscular dystrophy, and in other DGC components 
impair the function of the entire complex and compromise the integrity of the 
Figure 1. The muscle fibre (facing page)
A Skeletal muscle cells or muscle fibres are elongated cells comprised of myofibrils, parallel bundles 
of contractile filaments. The repeating functional units of the myofibrils are the sarcomeres, whose 
regular organization gives rise to the cross-striated appearance of the fibres. Each myofibril is 
surrounded by membranes of the sarcotubular system. Multiple myonuclei are normally situated at 
the fibre periphery, beneath the plasma membrane or sarcolemma.
B A close-up of the region boxed in (A) illustrates schematically the central structures of the muscle 
fibre. The myofibrils are composed of the thin (actin) filaments, thick (myosin) filaments, the titin 
filaments, and the associated proteins, arranged into serially connected sarcomeres. The thin 
filaments are anchored to the Z-discs at the ends of the sarcomere, while the thick filaments are 
bound together by the M-band in the middle of the sarcomere. The titin filaments span over the 
half-sarcomere from Z-disc to M-band, overlapping at both ends. Costameres link the 
subsarcolemmal cytoskeleton to the extracellular matrix at the Z-disc and M-band levels. The 
sarcotubular system comprises the T-tubules (transverse tubules; invaginations of the sarcolemma) 
and the sarcoplasmic reticulum (SR), junctioning at the triads. The proteins underlying the disorders 
investigated in this study—titin, calpain 3, DNAJB6, and TIA1—are highlighted in red.
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sarcolemma by a mechanism that is not yet entirely known. Adverse downstream 
effects such as perturbed signalling and increased proteolysis are at least partly 
due to an increased influx of calcium ions into the muscle fibre (Hopf et al. 2007, 
Rahimov & Kunkel 2013).
Another common theme in many muscular dystrophies is aggregation of pro-
teins within the muscle fibres. The myofibril, comprised of sarcomeres—basic con-
tractile units of the muscle—is a highly ordered structure (Fig. 1B), and mutations 
disrupting the structural protein interactions or interfering with the correct turn-
over of the proteins frequently lead to aggregation of the mutant protein itself or 
other myofibrillar components (Goebel & Müller 2006, Schröder & Schoser 2009).
For many of the muscular dystrophies, however, the detailed molecular mech-
anisms by which mutations in the underlying genes lead to disease are largely 
unknown. The studies presented in this thesis aimed at shedding light on the 
 molecular pathomechanisms behind a few of these diseases—the distal myo pathies 
tibial muscular dystrophy (TMD) and Welander distal myopathy (WDM), and the 
limb-girdle muscular dystrophies of types 1D, 2A, and 2J. These muscular dys-
trophies are caused by mutations in four very different proteins. Titin, under lying 
both TMD and LGMD2J, is a gigantic filamentous protein of the sarcomere with 
structural, mechanical, and regulatory functions. Calpain 3 (CAPN3), mutated in 
LGMD2A, is a proteolytic enzyme predominantly expressed in skeletal muscle. 
DNAJB6, mutated in LGMD1D, is a ubiquitously expressed co-chaperone of the 
J-protein family, and hence a part of the protein quality control machinery. Finally, 
TIA1, responsible for WDM, is a ubiquitous RNA-binding protein involved in the 
regulation in splicing and protein expression.
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2 REVIEW OF THE LITERATURE
2.1 M-band titinopathies TMD and LGMD2J
Tibial muscular dystrophy (TMD, MIM #600334) and limb-girdle muscular dys-
trophy type 2J (LGMD2J, MIM #608807) are muscular dystrophies caused by 
 mutations in the C-terminus of titin. As the affected part of the titin protein is 
situated in the M-band of the sarcomere, the diseases can be described as M-band 
titino pathies. TMD is the autosomal dominant distal myopathy phenotype caused 
by heterozygous titin mutations, whereas the recessive limb-girdle phenotype seen 
in the few described patients homozygous for TMD-causing mutations is designat-
ed LGMD2J (Hackman et al. 2002, Udd et al. 2005). For simplicity, the collective 
term TMD/LGMD2J will be used here for the whole spectrum of M-band titino-
pathies caused by extreme C-terminal titin mutations, although the dominant and 
recessive phenotypes may partly depend on distinct pathomechanisms.
2.1.1 Genetics of TMD/LGMD2J
Mutations so far reported to cause TMD/LGMD2J are located in the two last  exons 
of TTN, Mex5 (exon 362) and Mex6 (exon 363), encoding the is7 region and M10 
domain of the titin protein (Hackman et al. 2002, Van den Bergh et al. 2003, 
 Hackman et al. 2008, Pollazzon et al. 2010, Suominen et al. 2012). The Finnish 
founder mutation FINmaj is a deletion–insertion of 11 base pairs in Mex6, caus-
ing the exchange of four amino acid residues (EVTW→VKEK) in the M10 domain 
(Hackman et al. 2002). The other reported mutations, summarized in Table 1, 
 include missense changes, truncations due to frameshift or nonsense mutations, 
and a small in-frame deletion.
The FINmaj mutation, accounting for most of the known TMD/LGMD2J cases, 
is common in the Finnish population, where the estimated prevalence of TMD is 
Table 1. TMD/LGMD2J-causing mutations in titin
Mutation Protein change Domain Reference
French C p.S33315QfsX10 is7 Hackman et al. 2008
FINmaj p.E33359_W33362delinsVKEK M10 Hackman et al. 2002
Italian p.H33378P M10 Pollazzon et al. 2010
Belgian p.I33379N M10 Van den Bergh et al. 2003
French A p.L33388P M10 Hackman et al. 2002
Spanish p.K33395NfsX9 M10 Hackman et al. 2008
French B p.Q33396X M10 Hackman et al. 2008
Swiss p.Q33396_G33398delinsH M10 Suominen et al. 2012
Sequence numbers refer to the RefSeq record NP_596869.4.
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20/100,000 (Udd 2013). While families with other mutations have been identified 
in other European countries, the only mutations thus far encountered in the homo-
zygous state in LGMD2J patients are FINmaj (six cases in Finland) and Q33396X 
(one case in France) (Pénisson-Besnier et al. 2010, Suominen et al. 2012).
Of note, the TMD/LGMD2J-causing mutations are concentrated in the ex-
treme C-terminus of the titin protein. Mutations in other parts of titin are known 
to cause hypertrophic and dilated cardiomyopathies, hereditary myopathy with 
early respiratory failure (HMERF), and early onset myopathy with fatal cardio-
myopathy  (Salih myopathy) (Satoh et al. 1999, Gerull et al. 2002, Lange et al. 
2005a,  Carmignac et al. 2007, Ohlsson et al. 2012, Pfeffer et al. 2012).
2.1.2 Clinical pictures of TMD and LGMD2J
TMD belongs to distal myopathies, muscular dystrophies preferentially affecting 
the distal muscles of the limbs. Typical TMD has late onset, the symptoms start-
ing on the fourth decade or later with impaired ankle dorsiflexion. The weakness 
progresses slowly, leading to foot drop and mild difficulties in walking and climbing 
the stairs. The disease affects selectively the muscles of the anterior compartment 
of the lower leg—tibialis anterior (TA), extensor digitorum longus, and extensor 
hallucis longus—although weakness of thigh and hip muscles can develop later in 
life. Walking is usually preserved until a very late age or throughout the life (Udd et 
al. 1993, 2005, Udd 2013). Approximately 10% of TMD patients heterozygous for 
the FINmaj mutation, as well as patients with other mutations, may show a disease 
different from the typical TMD phenotype. Atypical manifestations can include 
abnormally early onset, marked involvement of posterior or proximal lower-limb 
muscles, upper limbs, or bulbar muscles, or persistent asymmetric weakness (Udd 
et al. 1993, 2005, Hackman et al. 2008).
Due to the small number of confirmed cases, the natural history of LGMD2J is 
not well characterized. The onset is early, usually in the first decade. The disease 
leads to generalized dystrophy involving most groups of skeletal muscles, and even-
tually to loss of ambulation within 20–30 years of disease onset. Although the dia-
phragm is among the least affected muscles, fatal respiratory failure may  develop 
in the late course of the disease. Clinically manifest cardiomyopathy has not been 
diagnosed, but autopsy did reveal mild left ventricular cardiac hyper trophy in one 
patient (Udd et al. 1991, 2005, Udd 1992, Pénisson-Besnier et al. 2010).
2.1.3 Muscle pathology in TMD and LGMD2J
Affected muscles in both TMD and LGMD2J show myopathic–dystrophic 
 changes—fibre size variation, central nuclei, split fibres, and fibrosis. At the end 
stage, the affected muscles are entirely replaced by fatty and fibrous infiltration 
(Udd et al. 1992, 1993, 2005). Myonuclear apoptosis has been found in both dis-
eases (Haravuori et al. 2001). Rimmed vacuoles, while present in the affected 
 muscles in TMD, have not been found in muscle biopsies from LGMD2J patients 
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(Udd et al. 1992, 1993). The normal or mildly elevated serum creatine kinase level, 
and normal appearance of dystrophin in immunofluorescence (IF) microscopy in-
dicate that sarcolemmal integrity is not primarily compromised (Udd et al. 1992).
Electron microscopy (EM) of TMD muscles has not revealed alterations in 
the sarcomere ultrastructure, whereas autophagic vesicles, myeloid figures, fila-
mentous inclusions, and cellular debris are found at the rimmed-vacuolar regions 
(Udd et al. 1998).
2.1.4 Mouse model for TMD/LGMD2J
A knock-in (KI) mouse carrying the FINmaj mutation in the Ttn gene has been 
generated for studying the pathomechanisms of TMD/LGMD2J (Charton et al. 
2010). The mouse model recapitulates the central clinical features of human TMD/
LGMD2J. Mice heterozygous for the FINmaj mutation develop a mild myopathy 
with late onset (~9 months of age) and selective muscle involvement, TA being 
most severely affected. The homozygotes have an early onset disease (~1 month) 
and more widespread muscle involvement, with the soleus muscle first and most 
severely affected. Specific force production is reduced in the soleus of homozygous 
mice, and the same trend is observed in heterozygotes (Charton et al. 2010). In 
contrast to human TMD/LGMD2J patients, the homozygous FINmaj KI mice 
 develop, in addition to skeletal muscle defects, a progressive dilated cardiomyo-
pathy with myocardial fibrosis and systolic dysfunction (Charton et al. 2010).
The skeletal muscle pathology in FINmaj KI mice is of myopathic–dystrophic 
type and generally comparable to that in humans, although fibrosis is only seen in 
the most severely affected muscles of FINmaj homozygous animals. The absence of 
rimmed vacuoles in light microscopy and the corresponding changes in EM in both 
heterozygous and homozygous mice, however, contrasts the human pathology. The 
sarcomere ultrastructure is normal, similarly to human TMD/LGMD2J. In addi-
tion, EM reveals in FINmaj homozygotes vacuolar changes proposed to represent 
enlarged sarcoplasmic reticulum (SR) or T-tubules, and mitochondrial disorgani-
zation (Charton et al. 2010).
The original FINmaj KI mouse strain on the 129 background exhibited embry-
onic lethality, starting around embryonic day 12 and leading to prenatal death in 
~50% of heterozygotes and ~90% of homozygotes. However, the surving mutant 
mice did not show increased mortality postnatally (Charton et al. 2010). The em-
bryonic lethality was prevented in FINmaj KI mice heterozygous for CAPN3 knock-
out (KO) (see 2.1.5.2) and, according to preliminary results, by backcrossing the 
FINmaj mutation to the C57BL/6 background, suggesting that it was caused by a 
genetic modifier specific to the 129 strain (Charton et al. 2010) and possibly related 
to developmental CAPN3 expression.
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2.1.5 Molecular pathomechanism of TMD/LGMD2J
2.1.5.1 Effect of TMD/LGMD2J mutations on titin
Western blotting studies with the antibody M10-1, raised against a peptide epitope 
in the titin M10 domain, indicate loss of this epitope in muscle extracts of TMD/
LGMD2J patients and FINmaj KI mice. TMD patients and heterozygous  FINmaj 
mice show a ~50% reduction in C-terminal titin fragments reacting with this anti-
body, whereas in LGMD2J patients and homozygous mice, the loss is pronounced 
or complete (Hackman et al. 2008, Charton et al. 2010). Findings are similar in 
 cardiac samples from the mouse model (Charton et al. 2010). This loss of immuno-
reactivity suggests that the FINmaj mutation leads to breakdown of C-terminal 
titin, possibly via proteolysis (Charton et al. 2010).
Absence of C-terminal titin is corroborated by IF microscopy showing a com-
plete loss of M10 signal in skeletal and cardiac muscles of homozygous FINmaj KI 
mice (Charton et al. 2010). Moreover, IF studies indicate that the effect extends 
beyond the mutated M10 domain: staining for domains M8–M9 is also negative 
in LGMD2J and homozygous FINmaj KI skeletal muscles. In contrast, staining of 
the domains A169–A170 at the A-band/M-band boundary (Hackman et al. 2002, 
Charton et al. 2010) and the M-is4 region (Anna Vihola, personal communication) 
are normal, suggesting that most of M-band titin remains intact. Also the major 
 M-band crosslinking protein myomesin stains normally in LGMD2J and FINmaj 
KI muscles (Hackman et al. 2002, Fukuzawa et al. 2008, Charton et al. 2010).
Comparison with Salih myopathy, caused by mutations leading to premature 
titin termination at M5 and is6 (Carmignac et al. 2007), may be useful for estimat-
ing the degree of titin truncation in TMD/LGMD2J. The more benign phenotype 
of LGMD2J could suggest that FINmaj leads to less extensive truncation of titin 
than seen in Salih myopathy, and this would place the breakage point C-terminally 
from the is6 region. However, since other factors such as overall reduction of titin 
expression could add to the severity of Salih myopathy (discussed in 2.3.5.7), this 
comparison may not provide an accurate prediction either.
Even without knowledge on the exact cleavage site, IF evidence suggests that 
FINmaj—and possibly other TMD/LGMD2J mutations—disrupt at least the ex-
treme C-terminal domains M9–is7–M10 of titin, and consequently affect the pro-
tein interactions of this titin region. As pointed out by Charton et al. (2010), the 
loss of titin C-terminus is in itself unlikely to be pathogenic, as titin shows similar 
behaviour both in affected and in non-affected muscles of FINmaj KI mice.
2.1.5.2 Role of calpain 3 in TMD/LGMD2J
The titin region disrupted by the TMD/LGMD2J mutations contains M-is7, the 
M-band binding site of the protease calpain 3 (CAPN3) (Sorimachi et al. 1995) 
(see 2.4.3.1 for further discussion on the interaction). Accordingly, secondary re-
duction of the CAPN3 protein is evident in LGMD2J muscles, and minor CAPN3 
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 deficiency of variable degrees has also been seen in some TMD cases (Haravuori 
et al. 2001, Pénisson-Besnier et al. 2010). This is replicated in FINmaj KI mice, 
with CAPN3 levels decreased moderately in heterozygotes and markedly in homo-
zygotes ( Charton et al. 2010). The unchanged Capn3 transcript levels in FINmaj 
KI mice indicate that the lower steady-state level of the protein is due to its in-
creased turnover (Charton et al. 2010). The activability of CAPN3, reflecting the 
ratio of proteolytic activity of CAPN3 to its expression level, is similar or increased 
in  FINmaj homozygotes (Charton et al. 2010).
Titin has been suggested to regulate the activity of CAPN3 by preventing its au-
tolytic activation (Sorimachi et al. 1995), but the specific roles of the binding sites 
in the M-band and I-band are not understood. The CAPN3 deficiency and  absence 
of C-terminal titin in TMD/LGMD2J and FINmaj KI suggest that the mutations 
inhibit the binding of CAPN3 to its M-band binding site, possibly by changing 
the conformation of the titin C-terminus, thus leading to dysregulation of CAPN3 
and inappropriate proteolysis of its substrates, including titin itself (Charton et al. 
2010). 
An active adverse role of CAPN3 deregulation in the pathogenesis of TMD/ 
LGMD2J is indicated by the fact that crossing the FINmaj KI mouse to CAPN3 
KO ameliorated the phenotype caused by the titin mutation: mice heterozygous 
for both FINmaj and CAPN3 null allele showed markedly less severe pathology 
compared to FINmaj alone. Such improvement by CAPN3 reduction was not evi-
dent in skeletal or cardiac muscles of FINmaj homozygotes, suggesting that the 
severe recessive phenotype may be caused by another, CAPN3-independent patho-
mechanism (Charton et al. 2010).
As mentioned above, heterozygosity for CAPN3 KO also prevented the death 
of FINmaj heterozygous and homozygous mouse embryos in utero (Charton et al. 
2010), suggesting that the embryonic lethality is CAPN3-mediated. The observed 
onset of lethality at E12 is well compatible with the onset of CAPN3 expression in 
mouse embryos between E11.5 and E12.5 (Herasse et al. 1999, Charton et al. 2010). 
Problems in cardiac development would be an obvious explanation for embryonic 
lethality due to a titin mutation; however, CAPN3 may not be expressed in the 
murine heart during the development (Fougerousse et al. 2000b).
2.1.5.3 Role of the obscurin proteins in TMD/LGMD2J
Obscurin (OBSCN) and its homologue obscurin-like 1 (OBSL1) interact with the 
M10 domain and mediate its interaction with myomesin (discussed in more de-
tail in 2.3.5.6.). In addition to the indirect effect through titin cleavage, these 
inter actions can be directly disrupted or weakened by TMD/LGMD2J mutations 
( Fukuzawa et al. 2008). Although obscurin is localized at the M-band in the mus-
cles of LGMD2J patients and FINmaj KI mice, its sharp colocalization with myo-
mesin is lost, demonstrating that the titin mutations do have some kind of an effect 
on obscurin (Fukuzawa et al. 2008, Charton et al. 2010). This could have adverse 
22
Review of the literature
functional or structural downstream consequences on the link between myofibrils 
and the surrounding membrane systems. As proposed by Charton et al. (2010), the 
vacuolar changes observed in FINmaj KI mice could represent SR disorganization 
possibly caused by the obscurin defect.
2.2 Limb-girdle muscular dystrophy 2A (LGMD2A)
Limb-girdle muscular dystrophy type 2A (LGMD2A, MIM #253600) results from 
recessive mutations in the protease calpain 3 (CAPN3) (Richard et al. 1995). The 
clinical course of LGMD2A is highly variable. The age of onset can vary from early 
childhood to the middle age, and the severity of the symptoms ranges from the 
typical pelvifemoral phenotype to isolated hyper-CK-emia. The muscle weakness 
is typically symmetrical and involves first the muscles of the pelvic girdle and later 
the shoulder girdle, although a subset of patients show a scapulohumeral pheno-
type with preferential involvement of shoulder girdle muscles (Angelini & Fanin 
2012).
The Leiden Open Variation Database (Fokkema et al. 2011) lists around 400 
possibly pathogenic sequence variants in CAPN3, localized throughout the gene. 
These include all kinds of mutations—missense, nonsense, and truncating changes 
and large rearrangements (reviewed by Kramerova et al. 2007). Most mutations 
lead to the loss of CAPN3 activity in muscle by inactivating the enzyme or prevent-
ing its expression. However, some missense mutations, predicted or demonstrated 
not to affect the proteolytic activity, have been shown to disturb the interaction of 
CAPN3 with titin, affecting one or both of its binding regions (discussed in 2.4.3) 
(Ono et al. 1998, Kramerova et al. 2004, 2007). Some mutations may also affect 
the proposed non-proteolytic functions of CAPN3 at the triads, leading to altered 
calcium signalling (Kramerova et al. 2012).
2.3 Titin
Titin (TTN, also known as connectin) is the largest polypeptide known in nature 
(Maruyama 1976, Wang et al. 1979, Bang et al. 2001a). The human TTN gene 
contains 363 exons, with a total of 114.4 kb of coding sequence. The overall pro-
tein-coding capacity is 38,138 amino acid residues, corresponding to a molecular 
weight of 4.2 MDa (Bang et al. 2001a). However, titin isoforms containing all the 
exons are not known to exist, the largest reported variants being 3.7–3.8 MDa in 
size (Vikhlyantsev et al. 2004, Guo et al. 2010).
Titin is expressed in all striated muscles, where it has essential functions in 
muscle development, structure, mechanics, and signalling. With single molecules 
spanning over the half-sarcomere from Z-disc and to M-band, titin forms an elas-
tic filament system—sometimes referred to as the “third filament”—alongside the 
thick myosin filaments and thin actin filaments (Fürst et al. 1988). Titin filaments 
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restore the sarcomere length after muscle stretch and contraction, distribute forces 
evenly between sarcomeres, and keep the thick filaments centred in the sarcomere, 
ensuring symmetric force generation (Horowits & Podolsky 1987, Horowits et al. 
1989, Helmes et al. 1996).
Titin is one of the first muscle-specific proteins expressed in differentiating 
myoblasts (Fürst et al. 1989). As the sole structure that spans the whole half- 
sarcomere, it can act as a molecular blueprint that determines the localization of 
other sarcomeric components, and as a building scaffold for the sarcomere. In the 
developing myofibres, Z-discs and M-bands are assembled independently, and as 
titin interacts with both the nascent thin and thick filaments, it is thought to co-
ordinate their integration into mature sarcomeres (Trinick 1994, Whiting et al. 
1989, Kontrogianni-Konstantopoulos et al. 2006a, 2009).
The sensory and signalling functions of titin are concentrated in the signalling 
hubs located at Z-disc, the N2A and N2B elements of the I-band, and the M-band. 
Titin-based protein complexes in these regions are thought to sense the stress and 
strain of the sarcomeres and transduce signals to pathways regulating gene expres-
sion, protein turnover, and cell survival (Voelkel & Linke 2011).
The following review will mainly focus on the role of titin in mature skeletal 
muscle, and on the functions of its M-band part harbouring the TMD/LGMD2J-
causing mutations.
2.3.1 Overall structure of titin
Titin is modular in structure: most of the protein is comprised of repeated immuno-
globulin-like (Ig) and fibronectin type 3 -like (FN3) domains, often allegorized as 
beads on a string. These are interspersed by unique insertion sequences (is) that 
show little or no similarity to other proteins. The unique sequences are enriched 
in the titin regions with specialized functions: the Z-disc, N2A and N2B elements 
of the I-band, and the M-band (Labeit et al. 1992, Labeit & Kolmerer 1995, Bang 
et al. 2001a).
Z-repeats
Z-disc:
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I-band:
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Figure 2. Modular structure of titin
A schematic view of the titin protein (skeletal muscle N2A isoform). I-band titin is comprised of 
tandemly repeated Ig domains, split into proximal and distal tandem Ig regions by the N2A element 
and the PEVK region. A-band titin contains both Ig and FN3 domains, most of them arranged into 
super-repeats of 7 and 11 domains. Unique sequence regions are enriched in the Z-disc and M-band 
parts of the protein.
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In the widely used domain nomenclature by Bang et al. (2001a), the Ig and 
FN3 domains are labelled with a letter prefix indicating the sarcomeric region (Z, 
I, A, M) followed by the ordinal number of the domain within that region accord-
ing to the entire genomic sequence (e.g. A168 denotes the 168th domain in the 
 A-band  region of titin). Similar nomenclature is applied to the insertion sequences 
in  Z-disc and M-band titin, although the prefix can be omitted depending on the 
context (e.g. M-is7 or is7).
The modular structure of skeletal muscle titin is schematically shown in Fig. 2.
2.3.2 Z-disc titin
The N-terminal parts of titin molecules from adjacent sarcomeres span through 
the Z-disc, overlapping in an antiparallel fashion. The most N-terminal Ig domains 
Z1 and Z2 are located on Z-disc periphery, on the side of the adjacent sarco mere 
( Gregorio et al. 1998). These domains interact with telethonin (TCAP; also known 
as titin-cap or T-cap) that glues together the N-termini of two parallel  titin mol-
ecules with a tight β-sheet sandwich, and has importance for both Z-disc struc-
ture and signalling (Kontrogianni-Konstantopoulos & Bloch 2003, Zou et al. 2006, 
Knöll et al. 2011). The same titin domains interact with the small ankyrin iso-
form (sAnk) of the SR, and may regulate SR organization surrounding the  Z-disc 
( Kontrogianni-Konstantopoulos & Bloch 2003).
The width of the Z-disc is spanned by Z-is1, located between domains Z2 and 
Z3. This long insertion sequence contains unique sequence and up to seven al-
ternatively spliced Z-repeats of 45 amino acids. The Z-repeats and the adjacent 
unique sequence region bind α-actinin, which crosslinks titin to the thin filaments 
( Sorimachi et al. 1997, Gregorio et al. 1998, Young et al. 1998). Z-is1 also interacts 
with the C-terminal SH3 domain of nebulin, the ruler protein of thin filaments 
(Witt et al. 2006), and with filamin C that may connect titin to the cortical actin 
cytoskeleton (Labeit et al. 2006).
The Ig domains Z3–Z9 and the interspersed unique sequences Z-is2–Z-is7 are 
located at the Z-disc/I-band transition zone, extending ~100 nm from the Z-disc 
centre. This titin region binds actin and associates with the thin filament in an in-
extensible fashion, in contrast to the elastic I-band titin (Fürst et al. 1988, Linke et 
al. 1997, Trombitás & Granzier 1997).
2.3.2.1 Signalling functions of Z-disc titin
In the Z-disc, key players in titin-based signalling are telethonin and MLP ( muscle 
LIM protein; officially CSRP3, cysteine-rich protein 3), thought to constitute a 
mechano sensory signalling module on Z-disc titin together with ZASP (Z-disc al-
ternatively spliced protein; officially LDB3, LIM-domain binding protein 3) and 
myozenins (Knöll et al. 2002, Frey & Olson 2002). Telethonin interacts with sever-
al proteins with signalling roles (Faulkner et al. 2000, Frey & Olson 2002, Knöll et 
al. 2002, Nicholas et al. 2002, Kontrogianni-Konstantopoulos & Bloch 2003, Kojic 
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et al. 2004, Witt et al. 2005, Tian et al. 2006, Nakano et al. 2007, Mihatsch et al. 
2009, Knöll et al. 2011). In cells subjected to biomechanical and oxidative stress, 
telethonin can localize to nuclei where it has an antiapoptotic function through 
modulation of p53 turnover (Knöll et al. 2011). MLP, interacting with titin through 
telethonin and α-actinin, is required for targeting of calcineurin (protein phos-
phatase 2B) and myozenin 2 to the Z-disc and for stretch-induced activation of 
calcineurin–NFAT (nuclear factor of activated T-cell) signalling (Knöll et al. 2002, 
Heineke et al. 2005). MLP can act as a transcriptional coactivator of myogenic 
regulatory factors (Kong et al. 1997), and its translocation to nuclei in response to 
mechanical stimulation is essential for the hypertrophic response and sarcomeric 
remodelling (Boateng et al. 2009).
2.3.3 I-band titin
I-band titin is largely composed of tandemly repeated Ig domains, divided into 
proximal (Ig domains I1–I83) and distal (I84–I118) tandem Ig regions (Bang et al. 
2001a). The two tandem Ig regions are separated by a repetitive sequence  region, 
termed PEVK for its high content of proline (P), glutamate (E), valine (V) and lysine 
(K) residues (Labeit & Kolmerer 1995). The PEVK region, composed of repeated 
PPAK motifs (named after the first four residues in the motif) and glutamate-rich 
PolyE segments, folds into short interconverting polyproline II helices, β-turns, 
and random coils, and seems to lack a tertiary structure (Greaser 2001, Ma et al. 
2001, Ma & Wang 2003).
I-band titin undergoes extensive alternative splicing, with the number of prox-
imal Ig domains and the length of the PEVK region accounting for most of the 
variation in titin size. In addition, I-band titin contains two alternatively spliced 
sequence elements, named N2A and N2B due to their originally presumed locali-
zation near the sarcomeric N2 line. The cardiac-specific N2B element, encoded by 
a single exon in the middle of the proximal tandem Ig region, comprises three Ig 
domains (I24–I26) and a unique sequence region N2B-us. The N2A element con-
tains the last Ig domains of the proximal tandem Ig region interspersed by unique 
sequence stretches (Labeit & Kolmerer 1995, Bang et al. 2001a).
Titin isoforms can be classified into three major groups based on I-band struc-
ture. The shortest (~3 MDa) isoforms are the cardiac-specific N2B titins that con-
tain only N2B of the two N2 elements and have very short proximal tandem Ig and 
PEVK regions. Cardiac N2BA forms (~3.3 MDa) contain both N2B and N2A ele-
ments separated by a variable number of Ig domains, and also have a longer PEVK 
region compared to the N2B forms. The N2A titins, expressed in skeletal muscle, 
contain exclusively the N2A element; in these isoforms, both the proximal Ig and 
PEVK regions are longer than in cardiac titins. Their length varies considerably 
between muscle types, the size of the whole molecule ranging from ~3.4 MDa in 
fast muscles to ~3.7 MDa in slow muscles.
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In contrast to the alternatively spliced proximal Ig and PEVK regions, the 
distal tandem Ig region is constitutively expressed (Freiburg et al. 2000). This 
part of  I-band titin hexamerizes in a side-by-side fashion, likely forming the end- 
filaments, rod-like structures seen in electron microscopy at the ends of the thick 
filaments (Houmeida et al. 2008).
2.3.3.1 Biomechanical functions of I-band titin
The elastic behaviour of titin is conferred by the I-band part of the protein. The 
tandem Ig region, the PEVK region, and in heart the N2B-us, act as serially  coupled 
springs that have different biomechanical properties and extend independently. 
Upon sarcomere stretch, the linkers between the Ig domains straighten first, fol-
lowed by unravelling of the PEVK region and finally by the N2B-us (Linke et al. 
1998, 1999). Although unfolding of domains was first thought to contribute to  titin 
elasticity (Soteriou et al. 1993, Erickson 1994), large-scale unfolding–refolding 
does not seem to take place in physiological conditions (Linke et al. 1999,  Minajeva 
et al. 2001).
Lengths of the spring elements affect the overall elasticity of the titin mole-
cule, and titin-based passive tension can be controlled by adjusting the ratio of 
stiffer short isoforms and more compliant longer isoforms (Freiburg et al. 2000, 
 Trombitás et al. 2001). In the heart, N2B and N2BA isoforms can be coexpressed 
in the same sarcomere (Trombitás et al. 2001). In skeletal muscle, single fibres 
can coexpress titin isoforms of different lengths (Prado et al. 2005), but coexpres-
sion on sarcomere level has not been reported. Adaptive changes in titin isoforms 
 occur during cardiac development and disease (Lahmers et al. 2004, Neagoe et al. 
2002), and in response to altered loading of skeletal muscle (Kasper & Xun 2000).
In addition to long-term changes achieved by alternative splicing, titin elastici-
ty can be modulated in a time frame of seconds to meet the physiological demands. 
In the heart, phosphorylation of the N2B-us and the PEVK region by a number 
of kinases reduces titin-based passive tension (Yamasaki et al. 2002, Krüger et 
al. 2009, Hidalgo et al. 2009, 2013), whereas binding of Ca2+ to the PEVK PolyE 
segments increases tension especially in skeletal muscle titins (Labeit et al. 2003). 
Transient interactions of the proximal tandem Ig and PEVK regions with actin and 
tropomyosin of the thin filament also modulate sarcomere mechanics (Kulke et al. 
2001, Yamasaki et al. 2001, Raynaud et al. 2004). 
2.3.3.2 Signalling functions of I-band titin
At the cardiac-specific N2B element, titin-based signalling involves members of the 
FHL (four-and-a-half LIM domain protein) family, localizing to multiple subcellu-
lar compartments and linked to a plethora of signalling pathways  (Johannessen 
et al. 2006, Shathasivam et al. 2010). FHL1 interacts with the N2B-us of titin and 
with components of MAPK (mitogen-activated protein kinase) cascade—with a 
proposed role in stretch-induced hypetrophic MAPK signalling—and modulates 
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compliance of titin by inhibiting its phosphorylation by ERK2 (extracellular- 
signal-regulated kinase 2) (Sheikh et al. 2008, Raskin et al. 2012). FHL2 interacts 
directly with the N2B-us, and can also dimerize with FHL1 (Lange et al. 2002). 
While the binding of FHL2 to titin can mediate compartmentalization of metabolic 
enzymes (Lange et al. 2002), its importance in titin-based signalling has not been 
established. Stretching of the N2B-us has been proposed to increase binding of 
FHL proteins, thereby potentiating hypertrophic signalling (Granzier et al. 2009), 
but this awaits experimental confirmation.
N2A-based signalling, involving CAPN3 and the muscle ankyrin repeat  proteins, 
will be discussed in 2.4.7.
2.3.3.3 Novex-3 titin
A special feature of I-band titin is the novex-3 exon, encoding an alternative titin 
C-terminus composed of Ig domains and unique sequence stretches. The resulting 
short (~625 kDa) titin isoform designated “novex-3 titin” is expressed on a low 
level in both skeletal and cardiac muscle, but its functions are not characterized. 
The N-terminus of novex-3 titin integrates to the Z-disc normally, but the protein 
extends only 100–200 nm to the I-band where it interacts with obscurin through 
its C-terminus (Bang et al. 2001a).
2.3.4 A-band titin
The largest part of titin is located at the sarcomeric A-band. This constitutively ex-
pressed region of ~2 MDa comprises a total of 170 repeated Ig and FN3 domains, 
most of which are organized into six super-repeats of seven domains and 11 super-
repeats of 11 domains (Labeit et al. 1992, Bang et al. 2001a). A-band titin is tightly 
associated with the thick filaments, each thick filament binding six titin molecules 
(Fürst et al. 1988, Whiting et al. 1989, Liversage et al. 2001). This involves direct 
interactions of titin FN3 domains with the S1 subfragment of heavy meromyosin, 
and likely another separate interaction of titin with light meromyosin (Labeit et al. 
1992, Houmeida et al. 1995, Muhle-Goll et al. 2001). Titin interacts with myosin 
also indirectly through myosin binding protein C (MyBP-C) that binds the first Ig 
domain in each of the 11-domain super-repeats (Freiburg & Gautel 1996).
2.3.5 Structure and functions of M-band titin
The C-terminal 250 kDa of titin are located at the M-band. This part, encoded 
by TTN exons Mex1–Mex6 (358–363), comprises the kinase domain (TK), Ig 
 domains M1–M10, and the unique sequences M-is1–M-is7 (is1–is7) (Gautel et al. 
1993, Obermann et al. 1996, Kolmerer et al. 1996). According to the ultrastructural 
 localization of titin epitopes, this part of titin spans through the entire  M-band, 
with TK located at the M-band periphery and the C-terminal M10 domain extend-
ing ~60 nm over the M-band centre. Titin C-termini from adjacent half-sarco-
meres thus overlap in an antiparallel fashion (Obermann et al. 1996). Of note, 
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this  arrangement of titin molecules places the extreme C-terminus and the TK 
domain of the antiparallel titin molecules in spatial proximity with each other at 
the  M-band periphery (Fig. 3), and functional interactions between these parts of 
M-band titin could hence be possible.
The structures and functions of the M-band unique sequences are mostly un-
known. The is3, is5, and is7 regions (the last of which mediates the interaction 
with CAPN3; see 2.3.5.4. and 2.4.3.1.) have been suggested to act as flexible linkers 
between Ig domains (Gautel et al. 1993). The long is2, situated between domains 
M3 and M4, is likely to show an extended conformation, resulting in a substantial 
overlap of the antiparallel is2 regions at the M-band centre. As the secondary struc-
ture of is2 is predicted to be α-helical with a potential for coiled coils, it has been 
proposed to mediate dimerization or multimerization of titin molecules (Gautel et 
al. 1993, Obermann et al. 1996), which could involve either parallel or antiparallel 
titin strands. 
The ten Ig domains of M-band titin show more sequence variation than the 
highly similar A-band domains, likely reflecting their specialized interactions in 
M-band structure and functions (Gautel et al. 1993). However, surprisingly few 
protein interactions have been established for this titin region.
Fig. 3 shows schematically the structure of C-terminal titin and its overlapping 
arrangement in the M-band, and summarizes the known protein interactions.
2.3.5.1 MURF proteins and M-band titin
M-band titin associates with at least two of the muscle RING finger (MURF) 
 proteins. The three members in this subfamily of the TRIM (tripartite motif) pro-
teins—MURF1 (TRIM63), MURF2 (TRIM55), and MURF3 (TRIM54)—are pre-
dominantly expressed in striated muscle where they show characteristic expres-
sion patterns. In skeletal muscle, MURF1 predominates in fast fibres and MURF2 
in slow fibres, whereas MURF3 is expressed in both fibre types (Spencer et al. 
2000, Centner et al. 2001, Perera et al. 2012). MURFs are thought to form homo- 
and hetero dimers by their coiled-coil motifs, and interactions have been detected 
between all the family members (Centner et al. 2001, Mrosek et al. 2007).
The MURF proteins show variable localization within myofibres. MURF1 is 
predominantly localized at the M-band, where also MURF2 and MURF3 have been 
detected. In addition, MURFs can localize at the Z-disc (MURF1 and 3), micro-
tubules (MURF2 and 3), and nuclei (MURF1 and 2), and as a diffuse cytoplasmic 
pool (Spencer et al. 2000, Centner et al. 2001, Pizon et al. 2002, McElhinny et al. 
2004, Gregorio et al. 2005, Hirner et al. 2008).
The functions of the three proteins are partly overlapping. This is especially 
evident for MURF1 and MURF2 in their role of regulating muscle trophic state: 
the two proteins share many of their interaction partners, and knockout of both 
genes in mice is necessary for producing the phenotype characterized by dramatic 
hypertrophy of heart and skeletal muscles (Witt et al. 2005, 2008, Willis et al. 
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2013). On the other hand, MURF2 and MURF3 appear to have redundant func-
tions in microtubule dynamics and myofibrillogenesis (Spencer et al. 2000, Pizon 
et al. 2002, McElhinny et al. 2004, Perera et al. 2011). All three MURFs have E3 
ubiquitin ligase activity, accounting for some of their cellular functions (Bodine et 
al. 2001, Kedar et al. 2004, Koyama et al. 2008), and MURF1 has also been con-
nected to the SUMO (small ubiquitin-like modifier) modification machinery (Dai 
& Liew 2001, McElhinny et al. 2002).
The MURF proteins, notably MURF1 and MURF2, are considered as key 
 regulators of muscle mass, trophic state, and metabolism. Upregulated in atrophy-
causing conditions, they promote catabolism of muscle proteins while inhibiting 
anabolic processes and carbohydrate metabolism (Bodine et al. 2001, Witt et al. 
2005, 2008, Hirner et al. 2008, Koyama et al. 2008). Through polyubiquitina-
tion, MURFs can directly mediate turnover of myofibrillar proteins and meta-
bolic enzymes. While ubiquitination of some proteins (such as troponin I, actin, 
 myosin heavy chain, and creatine kinase) has been demonstrated, others (such as 
titin and nebulin) have been implied as substrates by protein interactions ( Bodine 
et al. 2001, Kedar et al. 2004, Polge et al. 2011, Witt et al. 2005, Clarke et al. 
2007, Koyama et al. 2008). Increased protein synthesis levels in MURF1/MURF2 
 double KO mice have suggested that MURFs also suppress production of new pro-
teins, partly by their interactions with the translation machinery (Witt et al. 2008, 
 Koyama et al. 2008). Furthermore, by modulating the levels and localization of 
transcription factors and signalling proteins, MURFs can affect signalling and gene 
expression programs regulating muscle hypertrophy and atrophy (McElhinny et 
al. 2002, Arya et al. 2004, Koyama et al. 2008, Willis et al. 2013). Absence of overt 
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Figure 3. M-band titin
A schematic view of the C-terminal part of titin, situated in the sarcomeric M-band. M-band titin is 
comprised of the kinase domain, the Ig domains M1–M10, and the unique sequence regions is1–is7. 
Also the domains A168–A170 at the A-band/M-band boundary are functionally included in M-band 
titin. All the known TMD/LGMD2J mutations are located in is7 and M10, in the extreme C-terminus 
of the protein. The alternatively spliced is7 region is indicated by dashed outlines and the lighter 
blue colour. Protein interactions reported in the myofibrillar context are summarized below the 
diagram. Two overlapping, antiparallel molecules are shown to illustrate the layout of titin in the 
M-band; the exact relationship of the molecules is unknown.
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muscle atrophy in MURF1-overexpressing mice, however, indicates tight regula-
tion of these processes also by other factors (Hirner et al. 2008).
Interaction with M-band titin was first characterized for MURF1 that binds the 
titin domains A168–A170 at the A-band/M-band boundary. The three domains 
form a rigid tandem structure with a surface groove likely to accommodate one 
MURF1 dimer (Centner et al. 2001, Mrosek et al. 2007). MURF2 can also bind 
titin directly within the same region (Pizon et al. 2002, Witt et al. 2005), and the 
roles of these interactions could be similar. In addition, MURF2 interacts with the 
kinase domain of titin through NBR1 and SQSTM1 (Lange et al. 2005a); this inter-
action will be further discussed below.
The function of the interaction between MURF1 (and MURF2) with the titin 
domains A168–A170 is currently unknown. As overexpression of MURF1 or the 
 interacting titin domains in cultured cardiomyocytes disrupts the M-band and 
thick filament structures, binding of MURF1 to titin was proposed to destabilize 
the sarcomeric structure and thereby facilitate the turnover of myofibrillar pro-
teins (McElhinny et al. 2002, Kedar et al. 2004). This view is, however, challenged 
by the normal sarcomeric ultrastructure observed in mice overexpressing MURF1 
in skeletal muscles (Hirner et al. 2008).
The interaction with titin could involve the ubiquitin ligase activity of MURF1. 
In addition to mediating titin degradation, ubiquitination could have a regula-
tory function on titin, for example by modifying its protein interactions (Witt et 
al. 2005). In line with this possibility, Witt et al. (2005) detected ubiquitin in the 
M-band in immuno-EM and showed immunoreactivity of titin with ubiquitin anti-
bodies in western blot. Ubiquitination of titin by MURF1 has not, however, been 
directly demonstrated.
Proximity of the titin kinase domain has prompted a link between MURF1 and 
TK signalling. In this line of thought, Centner et al. (2001) proposed that MURF1 
could present substrates to TK, or regulate its activity. Another possibility is regu-
lation of MURF1 by TK, possibly in a strain-dependent manner (Witt et al. 2005, 
2008). Binding to titin A168–A170 could also serve to concentrate MURFs in the 
vicinity of TK, hence facilitating their recruitment to the TK-based signalosome 
(see below).
With regard to M-band titinopathies, the reported binding of MURF1 and 
MURF2 with titin domains M8–M10 (Witt et al. 2008) is of high interest. These 
interactions were detected in pairwise yeast two-hybrid studies, but their bio-
chemical confirmation has not been published nor their functional importance ad-
dressed. Of note, the overlapping arrangement of titin in the M-band ( Obermann 
et al. 1996) may place the C-terminal domains M8–M10 close in space to the 
MURF-binding site at A168–A170. The interactions of MURFs with the two titin 
sites could thus be functionally related, extending the possible consequences of 
TMD/LGMD2J mutations to the MURF proteins.
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2.3.5.2 Kinase domain of titin
The kinase domain of titin (TK) is a serine/threonine kinase related to myosin 
light chain kinases (Labeit et al. 1992). TK has a dual autoinhibitory mechanism, 
its  activation requiring removal of the C-terminal regulatory tail blocking the ATP 
binding pocket, and phosphorylation of a tyrosine side chain blocking the catalytic 
residue (Mayans et al. 1998, Puchner et al. 2008). The conformational changes 
relieving the autoinhibition are induced mechanically: physiological levels of strain 
expose the ATP binding site and allow autophosphorylation of the autoinhibitory 
tyrosine residue. This mechanical activation was predicted by molecular dy namics 
simulations (Gräter et al. 2005), and experimentally demonstrated by single- 
molecule measurements with atomic force microscopy (Puchner et al. 2008, 
 Puchner & Gaub 2010). The phospho-mimickry mutant TK can also be activated 
by Ca2+/calmodulin, but this may not be physiologically relevant (Mayans et al. 
1998, Puchner et al. 2008). In addition, TK constructs are transphosphorylated by 
extracts of differentiating C2C12 myoblasts (Mayans et al. 1998), suggesting that 
alternative modes of activation are possible.
In mature muscle, TK exerts its functions through a signalosome complex com-
posed of the zinc-finger protein NBR1 (next-to-BRCA1), SQSTM1 (sequestosome 
1, also known as p62), and MURF2—of these, NBR1 and SQSTM1 are in vitro sub-
strates of TK (Lange et al. 2005a). Binding of the complex to titin is mediated by 
NBR1 and requires a semiopen conformation of TK, mimicking the mechanically 
activated state. In mechanically arrested cardiomyocytes and denervated muscle, 
the complex dissociates from the M-band and MURF2 relocates to nuclei. This 
displaces SRF (serum response factor) from the nuclei by a yet uncharacterized 
mechanism and represses transcription of SRF target genes (Lange et al. 2005a). 
TK can hence modulate gene expression in response to mechanical activity of 
 muscle. Whether TK also regulates direct effects of MURFs, NBR1, and SQSTM1 
on protein turnover is currently unknown (Lange et al. 2005a, Braun & Gautel 
2011). The importance of TK-based signalling is demonstrated by a TK missense 
mutation disrupting the interaction with NBR1. In muscles of HMERF (heredi-
tary myo pathy with early respiratory failure) patients carrying this mutation, nor-
mal localization of NBR1 to Z-discs and M-bands is disrupted, and MURF2 shows 
prominent  nuclear localization (Lange et al. 2005a).
Also MURF1 has been reported to interact with SQSTM1 (Witt et al. 2008). 
While nuclear localization of MURF1 was not seen by Lange et al. (2005a) in 
HMERF patients, it was reported by Ochala et al. (2011) in immobilized rats (a 
model for critical illness myopathy). Although suggested by the similarity of the 
proteins, interchangeability of MURF1 and MURF2 in TK-based signalling has not 
been experimentally demonstrated.
TK seems to have functions also during muscle development. The observations 
that TK phosphorylates telethonin in differentiating C2C12 myoblasts and that ex-
pression of constitutively active TK disrupts myofibrillogenesis suggested that TK 
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plays a key role in early muscle development (Mayans et al. 1998). However, nor-
mal initial formation of cardiac sarcomeres in mouse embryos lacking TK argues 
against this idea (Weinert et al. 2006), and the importance of telethonin phospho-
rylation remains elusive. In light of recent findings emphasizing the signalling role 
and mobility of telethonin (Knöll et al. 2011), shuttling of telethonin to M-band for 
phosphorylation is also a possibility.
2.3.5.3 FHL2 and metabolic enzymes in the M-band
The M-is2 region, as well as the cardiac-specific N2B element, interact with FHL2 
and target it to the sarcomere. As the metabolic enzymes creatine kinase, phospho-
fructokinase, and adenylate kinase also bind FHL2 and co-localize with it, titin 
and FHL2 were suggested to concentrate these enzymes to the sarcomeric regions 
of high metabolic activity (Lange et al. 2002). Given the multiple functions of 
FHL2 in signalling and gene regulation (reviewed by Johannessen et al. 2006), 
its interaction with M-band titin could have additional signalling functions. These 
mechanisms are likely to be relevant only in the heart, as the expression of FHL2 in 
skeletal muscle is very low (Chan et al. 1998, Chu et al. 2000, Scholl et al. 2000).
2.3.5.4 Alternatively spliced M-is7
The M-is7 region (hereafter is7) is situated between the two C-terminal Ig domains, 
M9 and M10 (Fig. 3) (Gautel et al. 1993). This unique sequence region, 101 ami-
no acid residues in length, has a remarkably high content of serine (32 residues) 
and methionine (10 residues). It has been predicted to be an unstructured linker 
( Gautel et al. 1993), but nothing is known about its three-dimensional organization 
in the M-band.
The TTN exon Mex5 (362), coding for is7, undergoes alternative splicing. This 
results in the expression of M-band titin as Mex5+ (is7+) and Mex5– (is7–) isoforms 
(Kolmerer et al. 1996). Detailed knowledge on the expression and functions of the 
two isoforms is, however, lacking.
Kolmerer et al. (1996) reported exclusive expression of is7+ in human heart and 
some is7– forms in rabbit and mouse hearts. Northern blotting and RT-PCR analy-
ses of rabbit skeletal muscles showed variable levels of Mex5 inclusion. The iso-
form ratio correlated with muscle type, with fast-twitch muscles showing a higher 
proportion of is7– titin (Kolmerer et al. 1996). This was supported by RT-PCR 
studies by Ojima et al. (2007), showing approximately equal amounts of is7+ and 
is7– forms in mouse quadriceps femoris and exclusive is7+ expression in soleus. 
However, there is no information on is7 expression differences on the single-fibre-
level. During development, the expression of is7– forms is negligible, as indicated 
by in situ hybridization on mouse embryos and RT-PCR analysis of cultured mouse 
myotubes (Kolmerer et al. 1996, Ojima et al. 2007). On the RNA level, Mex5 skip-
ping may be promoted by the splicing regulator MBNL1 (Muscleblind-like 1), as 
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suggested by increased pro portion of is7+ titin in the Mbnl1 knockout mouse and 
in the HSALR mouse, a model of myotonic dystrophy with secondarily distrurbed 
MBNL1 function (Lin et al. 2006).
The is7 region mediates the interaction of M-band titin with CAPN3 (Kinbara 
et al. 1997). This interaction, discussed in more detail in 2.4.3.1., is likely of major 
importance for regulation of CAPN3 in muscle (Haravuori et al. 2001, Charton 
et al. 2010). The variable inclusion of is7 may hence indicate a need to adjust the 
titin–CAPN3 interaction in a muscle-specific manner. The exclusive expression of 
is7+ isoforms in heart, where CAPN3 is practically absent (Kolmerer et al. 1996, 
Fougerousse et al. 1998), suggests that the is7 region is likely to have other func-
tions apart from CAPN3 binding.
2.3.5.5 M-band titin and the myomesin proteins
Proteins of the myomesin family—myomesin (MYOM1), myomesin 2 (MYOM2; 
also known as M-protein), and myomesin 3 (MYOM3)—form elastic filaments that 
crosslink the M-band through their interactions with myosin and titin ( Obermann 
et al. 1995, Lange et al. 2005b, Schoenauer et al. 2005, 2008, Fukuzawa et al. 
2008). The exact organization of the myomesin proteins in the M-band is still 
poorly known; despite their identical domain structures, the three proteins seem to 
have distinct layouts and functions (Obermann et al. 1996, Fukuzawa et al. 2008, 
Schoenauer et al. 2008). While myomesin 1 is a constitutive M-band component 
in all striated muscles, the fibre-type-dependent expression of myomesins 2 and 
3, and EH-myomesin (a splice variant of MYOM1) may modulate the mechanical 
properties of the M-band (Agarkova et al. 2000, Schoenauer et al. 2005, 2008).
Myomesins are mainly composed of Ig and FN3 domains (Vinkemeier et al. 
1993, Schoenauer et al. 2008). Antiparallel homodimerization through the C-ter-
minal Ig domains has been shown for MYOM1 and MYOM3 (Lange et al. 2005b, 
Pinotsis et al. 2008, Schoenauer et al. 2008), whereas myosin binding through 
the N-terminal parts has been demonstrated for MYOM1 and MYOM2 (Obermann 
et al. 1997, 1998). Myomesins interact with M-band titin at least indirectly, as 
 demonstrated by co-purification of myomesins 1 and 2 with titin (Nave et al. 1989). 
Obermann et al. (1997) identified direct binding of myomesin to the titin M4 
 domain in membrane overlay assays with purified protein fragments; this inter-
action was found to involve the central FN3 domains My4–My6 of myomesin and to 
be prevented by phosphorylation of the linker region between My4–5 ( Obermann 
et al. 1997). The interaction was, however, not corroborated by pulldown and yeast 
two-hybrid (Y2H) assays by Fukuzawa et al. (2008), who demonstrated the in-
volvement of the same myomesin region in obscurin binding. The phosphoryla-
tion-regulated interaction of myomesin with titin M4 was hence proposed to be in-
significant in mature muscle but of potential relevance during sarcomere assembly 
(Fukuzawa et al. 2008). 
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2.3.5.6 M-band titin and the obscurin proteins
C-terminal titin and myomesin 1 are engaged in ternary interactions with the 
 obscurin protein (OBSCN) and its shorter homologue obscurin-like 1 (OBSL1) 
(Fukuzawa et al. 2008). The two obscurin proteins, highly alike in their N-termini, 
will be here referred to as OBSCN/OBSL1.
The ternary complex between titin, myomesin, and OBSCN/OBSL1 is formed 
through independent interactions of myomesin and titin with OBSCN/OBSL1, with 
no direct binding occurring between myomesin and titin. The third Ig domain (Ig3) 
in OBSCN/OBLS1 interacts with the linker region My4–My5 of myomesin. This 
interaction is specific for MYOM1 and is unaffected by myomesin phosphorylation. 
The N-terminal Ig domain (Ig1) of OBSCN/OBSL1, on the other hand, interacts 
with the titin M10 domain. Y2H and pulldown studies indicated this interaction to 
be abolished or severely impaired by two of the TMD/LGMD2J-causing mutations 
( FINmaj and L33388P), whereas the I33379N mutation was reported to have no 
effect (Fukuzawa et al. 2008).
Interactions with titin M10 and myomesin are required for the correct locali-
zation of OBSCN/OBSL1 to the M-band. This was shown in cultured cardiomyo-
cytes, where expression of various constructs comprising the above-mentioned 
inter action sites had dominant negative effects on the localization of endogenous 
OBSCN and OBSL1, and in C2C12 cells, where the constructs inhibited sarcomere 
formation (Fukuzawa et al. 2008). The importance of titin for the organization of 
this complex is further demonstrated by the altered obscurin–myomesin colocali-
zation in M-band titinopahies (Fukuzawa et al. 2008, Charton et al. 2010).
The diverse functions of obscurin and OBSL1 have only recently begun to un-
ravel. During myofibrillogenesis, obscurin is highly expressed, shows variable lo-
calization to Z-discs and M-bands, and seems to have both structural and signal ling 
functions. Although some studies have suggested that obscurin has an essential role 
in myofibrillogenesis, knockout mice have proven the dispensability of the protein 
(Young et al. 2001, Borisov et al. 2004, 2006, Kontrogianni- Konstantopoulos et al. 
2006b, Raeker et al. 2006, Ackermann et al. 2009, Lange et al. 2009). In mature 
muscle, obscurin is mostly found at the M-band level (Young et al. 2001, Bagnato 
et al. 2003, Bowman et al. 2007). Interacting with titin through its N-terminus and 
with ankyrins through its C-terminus, it links myo fibrils to the surrounding sarco-
plasmic reticulum (SR) and sarcolemma. This has been shown to be important 
for the organization of the SR, the subsarcolemmal microtubular network, and the 
dystrophin–glycoprotein complex, and for sarcolemmal integrity (Bagnato et al. 
2003, Kontrogianni-Konstantopoulos et al. 2003, 2006b, Cunha & Mohler 2008, 
Lange et al. 2009, 2012, Randazzo et al. 2013). Obscurin also targets a variant form 
of MyBP-C to the M-band at the myofibril periphery in skeletal muscles, with yet 
uncharacterized importance for M-band structure and function (Ackermann et al. 
2009). 
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OBSL1 is expressed in multiple isoforms with presumably different localiza-
tions to cytoskeletal structures. Lacking the ankyrin-binding and signalling do-
mains of obscurin, it has been suggested to have a structural role as a cytoskeletal 
adaptor (Geisler et al. 2007, Fukuzawa et al. 2008).
2.3.5.7 Developmental and structural effects of M-band titin deletions
To study the functions of M-band titin in vivo, Gotthardt and colleagues have em-
ployed a series of mouse models with constitutive or tissue-specific conditional 
deletions of exons Mex1–Mex2 (Gotthardt et al. 2003, Peng et al. 2005, 2007, 
Weinert et al. 2006, Ottenheijm et al. 2009). Although the primary goal has been 
to study the importance of the titin kinase, the in-frame deletion of 1974 amino 
acid residues spans the domains from A169 to M7, removing most of M-band titin.
Constitutive deletion of Mex1–2 in all tissues (Weinert et al. 2006) and an early 
developmental conditional deletion in the heart (Gotthardt et al. 2003) have simi-
lar outcomes, both leading to early embryonic lethality due to cardiac dysfunction. 
In constitutive knockouts, the heart develops normally up to E9.0 and initiates 
beating. Unaltered localization of titin epitopes at the Z-disc, N2B element, and 
 I-band/A-band boundary indicate that cardiac sarcomeres develop and incorpo-
rate mutant titin normally. In contrast, domains M8–M9 fail to show periodic 
localization, suggesting that titin C-terminus is not properly assembled into the 
M-band. After normal sarcomere formation, myofibrils lacking M-band titin show 
impaired lateral growth and are disassembled (Weinert et al. 2006).
A conditional Mex1–2 KO targeting cardiac and skeletal muscle later in devel-
opment through the muscle creatine kinase promoter avoids embryonic lethality 
(Gotthardt et al. 2003). The mice develop generalized muscle weakness and wast-
ing, and die around the age of five weeks. Sarcomeres show first normal ultrastruc-
ture in EM, but upon gradual replacement of wild-type titin by the deleted protein, 
they develop pale M-bands and undergo disassembly that progresses from M-band 
to Z-disc (Gotthardt et al. 2003, Peng et al. 2005). In contrast to the constitutive 
deletion model, mutant titin seems to be incorporated to the sarcomeres all the way 
to the M-band level, possibly due to a stabilizing effect of other M-band proteins 
in pre-existing sarcomeres or due to different expression of titin-binding proteins 
in embryonic and adult sarcomeres (Gotthardt et al. 2003, Weinert et al. 2006). 
Increased separation of the M8/M9 epitope doublets suggests, however, that the 
deleted titin C-termini do not overlap in the M-band (Gotthardt et al. 2003).
Sarcomere disassembly seen in late stage pathology of all Mex1–2 knockout 
models has been suggested to result from structural instability of the M-band 
 resulting from a disturbed interaction of titin with myomesin (Gotthardt et al. 
2003, Weinert et al. 2006). In the constitutive knockout model, myomesin— 
although it does localize to the M-band—shows abnormally diffuse staining that 
was suggested to reflect the absence of myomesin-binding M4 domains of titin 
(Weinert et al. 2006). Abnormal myomesin organization could also be explained 
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by altered localization of the M10 domain that interacts with myomesin through 
obscurin/OBSL1 (Fukuzawa et al. 2008). 
The studies by Miller et al. (2003a) and Musa et al. (2006) both utilized de-
letion models encompassing the entire titin C-terminus starting from the kinase 
domain. In murine myoblasts, the deletion was found to interfere with myogenic 
differentiation already in the heterozygous state (Miller et al. 2003a). The cells 
showed impaired fusion and formed poorly ordered myofibrils, with Z-discs and 
M-bands out of register. Titin, α-actinin, myosin, MURF2, and obscurin were dis-
organized, while myomesin localization was relatively well preserved (Miller et al. 
2003a).
In mouse embryonic stem cells induced to differentiate into cardiomyocytes, 
the heterozygous deletion only caused subtle differences in M-band structure 
(Musa et al. 2006). In the homozygous state, however, a total disruption of myo-
fibrillogenesis was observed, with all the analyzed sarcomeric components— 
including α-actinin and telethonin— showing abnormal localization. This dem-
onstrated that M-band titin is essential for myofibrillogenesis, and suggested the 
proper formation of M-band regulates also Z-disc assembly, possibly through 
 TK-based signalling. The difference to skeletal myoblasts, where a single deleted 
allele had deleterious effects, was proposed to reflect differences in the efficacy of 
TK signalling between the cell types (Musa et al. 2006).
The difference between the total C-terminal deletion that abolishes the myo-
fibrillogenesis completely, and the Mex1–2 deletion that allows the development 
of beating cardiomyocytes, is noteworthy, as it suggests an important role for the 
domains M8–M10 in myofibrillogenesis (Gotthardt et al. 2003, Musa et al. 2006, 
Weinert et al. 2006).
A complementary view on the importance of M-band titin comes from Salih 
myopathy, a human disease caused by homozygous absence of the titin C-terminus 
(Carmignac et al. 2007). The two described mutations are frameshift-causing dele-
tions in Mex1 and Mex3, leading to premature termination codons and truncation 
of C-terminal titin at M5 and is6, respectively. Heterozygotes are symptomless, 
presumably explained by mutant transcripts undergoing nonsense-mediated de-
cay (NMD). In homozygotes, all titin protein, translated from mutant transcripts 
escaping NMD, lacks the most C-terminal domains (Carmignac et al. 2007).
The patients present with congenital skeletal myopathy of moderate severity 
and slow progression, followed in the childhood by rapidly progressive dilated 
cardio myopathy and arrhythmia that ultimately lead to heart failure. Skeletal 
muscle patho logy shows minicore-type lesions, predominance of type 1 fibres, and 
central nuclei, and later dystrophic changes. EM reveals sarcomeric disruption, 
with changes in the M-band more pronounced than in the Z-disc (Carmignac et 
al. 2007).
The truncated titin molecules in Salih myopathy are integrated to the sarco-
mere, and they allow seemingly normal sarcomere development, demonstrating 
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that the extreme C-terminal titin domains are not required for this process. The 
mutations remove the M-band binding site of CAPN3, and muscles show second-
ary CAPN3 deficiency similar to that seen in TMD/LGMD2J (discussed in 2.1.5.2). 
Lack or dysregulation of CAPN3 may contribute to the skeletal-muscle phenotype, 
but it is unlikely to explain the cardiomyopathy, given the low level of CAPN3 ex-
pression in postnatal heart (Carmignac et al. 2007).
Sarcomeric disarray in Salih myopathy resembles that seen in Mex1–2 knock-
out mice, and it was suggested that mechanical instability of the M-band, result-
ing from incomplete overlap of the titin molecules, could underlie the phenotype 
in both cases (Carmignac et al. 2007). It is also possible that the pathogenesis of 
Salih myopathy is partly due to impaired titin production capacity. If most of the 
transcribed mRNAs are degraded by NMD, insufficient translation of new titin 
molecules may lead to a reduction in total titin expression and hamper the fibre’s 
ability to renew myofibrils. 
2.3.6 Titin in smooth muscle and non-muscle cells
In addition to their established central role in striated muscles, products of the 
TTN gene have been reported in other tissues and cell types. Adult smooth mus-
cles express short titin isoforms of ~1 MDa, containing exons from all titin regions 
but apparently excluding TK and the extreme C-terminus. Fetal smooth muscles 
express titin isoforms similar in size and composition to skeletal muscle forms 
( Labeit et al. 2006).
Expression of titin on a low level has been detected also in several non-muscle 
cell types (Eilertsen & Keller 1992, Cavnar et al. 2007, Qi et al. 2008, Mikelsaar et 
al. 2010, 2012). The non-muscle isoforms, termed “cellular titin” or c-titin, utilize 
unique exon patterns and are at least partly distinct from both striated and smooth 
muscle titins (Cavnar et al. 2007). In non-muscle cells, titin has been suggested to 
participate in the organization of cytoskeletal structures such as stress fibres and to 
provide them with passive tension, to participate in biomechanical sensing, and to 
modify the mechanical properties of the tissue (Eilertsen & Keller 1992, Eilertsen 
et al. 1994, 1997, Cavnar et al. 2007, Schwarz et al. 2008).
2.3.6.1 Nuclear titin
A growing body of evidence suggests that titin has functions also in the nucleus. 
After the initial description of nuclear titin by Machado and colleagues (1998),  titin 
has been detected in association with chromosomes, the nuclear matrix and enve-
lope, the mitotic spindle, and the centrioles (Machado & Andrew 2000, Zastrow 
et al. 2006, Mikelsaar et al. 2010, 2012), and biochemically purified from isolated 
nuclei (King & Jhou 2010). Furthermore, N-terminal titin constructs have been 
found to  activate β-catenin signalling in transfected cells, suggesting a signalling 
role for nuclear titin (Qi et al. 2008).
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With regard to M-band titinopathies, the findings of Zastrow et al. (2006) are 
of potential interest. This study identified an interaction of C-terminal titin with 
lamins, intermediate filaments of the nuclear matrix and lamina. Each of the do-
mains M7–M10 as well as M-is7 were found to have affinity for lamins, and func-
tional importance of this interaction was supported by disrupted nuclear morpho-
logy in HeLa cells transfected with a nuclear-targeted M-is7 construct. An antibody 
against M-is6 exhibited a diffuse or punctate nuclear localization pattern in HeLa 
cells, whereas in Caenorhabditis elegans two antibodies against the worm titin 
orthologue stained the nuclear envelope and the mitotic spindle. By interacting 
with lamins, titin was proposed to participate in the organization of nuclear archi-
tecture, condensation of the chromosomes, and assembly and disassembly of the 
nuclear envelope (Zastrow et al. 2006). Interestingly, mutations in lamins can, 
among other diseases, cause muscular dystrophy and cardiomyopathy (reviewed 
by Schreiber & Kennedy 2013).
The diverse results of the aforementioned studies regarding the composition, 
localization and functions of titin in nucleus are difficult to consolidate, and the 
whole concept of nuclear titin is under debate. Indeed, negative findings obtained 
in some studies challenge the existence of nuclear titin altogether: Expression 
analyses on a titin exon microarray did not show any detectable titin transcript 
in HeLa and HL cells (Labeit et al. 2006, Takata et al. 2007), whereas proteomics 
studies have failed to reveal titin in chromosomes and centrosomes (Andersen et 
al. 2003, Takata et al. 2007).
2.4 Calpain 3 (CAPN3)
Calpain 3 (CAPN3; also known as p94) is an intracellular protease belonging to 
the family of calpains, Ca2+-activated papain-like cysteine proteases (Sorimachi et 
al. 1989). Members of this protease family are regarded as modulator proteases, 
involved in regulation of their substrates through specific proteolytic processing 
events, rather than in degradation (Ono & Sorimachi 2012). 
2.4.1 Structure of CAPN3
CAPN3 contains the domains common to classical calpains: the cysteine protease 
core domain split into subdomains PC1 and PC2 (previously designated as IIa and 
IIb), a Ca2+- and phospholipid-binding C2-like domain (C2L, domain III), and a 
penta-EF-hand domain (PEF, domain IV). In addition, it contains three CAPN3-
specific sequences, the N-terminal sequence (NS), and insertion sequences IS1 and 
IS2 (Sorimachi et al. 1989, 1990, Ono & Sorimachi 2012). IS1, located within the 
PC2 subdomain, acts as an internal propeptide (Sorimachi et al. 1993, Diaz et al. 
2004). IS2, located between the C2L and PEF domains, modulates the activation 
properties of CAPN3, is involved in titin binding, and contains an apparently func-
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tional nuclear localization signal (encoded by exon 15) (Sorimachi et al. 1989, 1993, 
1995). The structure of CAPN3 is schematically presented in Fig. 4.
In contrast to the canonical calpains CAPN1 (µ-calpain) and CAPN2 (m-cal-
pain), CAPN3 does not heterodimerize with the calpain small subunit (Sorimachi 
et al. 1995, Ono & Sorimachi 2012). CAPN3 can homodimerize through the PEF 
domain and it is purified as a dimer (Kinbara et al. 1998, Ravulapalli et al. 2005), 
but whether it within myofibres exists as monomers or dimers is unknown.
Alternative splicing produces several isoforms of CAPN3. The full-length 
 canonical form of 821 amino acids and 94 kDa (RefSeq NP_000061), designated 
isoform a, is the only form present in significant amounts in mature skeletal myo-
fibres (Richard et al. 1995, Herasse et al. 1999, Ojima et al. 2007). Isoforms lack-
ing exons 6 (encoding IS1) and 15–16 (together encoding most of IS2) in different 
combinations are expressed in myoblasts and during skeletal muscle development 
(Richard et al. 1995, Herasse et al. 1999, Ojima et al. 2007). In addition, a va-
riety of minor CAPN3 isoforms, some of which utilize exons not included in the 
canonical form, have been shown to be expressed in lymphocytes, rodent eyes, or 
 ubiquitously (Fougerousse et al. 2000b, Fukiage et al. 2002, Kawabata et al. 2003, 
De Tullio et al. 2003).
2.4.2 Expression and localization of CAPN3
CAPN3 is predominantly expressed in skeletal muscle, and as mentioned above, 
tissue-specific or ubiquitous isoforms exist at low levels (Sorimachi et al. 1989, 
Fougerousse et al. 1998, 2000b, Fukiage et al. 2002, Kawabata et al. 2003, 
De  Tullio et al. 2003). Importantly, although CAPN3 is expressed during car-
diac development, and its transcripts have been detected in adult human heart, 
the level of CAPN3 protein in the mature heart is very low (Sorimachi et al. 1989, 
 Fougerousse et al. 1998, 2000a, Taveau et al. 2002). The expression within pig 
skeletal muscles has been reported to show a difference between fibre types, with 
isolated fast fibres showing an approximately threefold level of CAPN3 in WB com-
pared to slow fibres (Jones et al. 1999). However, a recent large-scale proteomics 
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Figure 4. Structure of calpain 3
A schematic view of the CAPN3 protein, comprised of the protease core (subdomains PC1 and PC2), 
a C2-like domain (C2L), a penta-EF-hand (PEF) domain, and the CAPN3-specific insertions NS, IS1, 
and IS2. Positions of the catalytic residue C129 and the nuclear localization signal (NLS) are shown.
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study did not report differential CAPN3 expression between murine slow and fast 
muscles (Drexler et al. 2012).
Within skeletal myofibres, most of CAPN3 is tightly associated with myofibrils 
(Murphy & Lamb 2009). Endogenous CAPN3 and transfected constructs have been 
detected in three sarcomeric regions: I-band, M-band, and Z-disc. Different stud-
ies have shown variable distribution of CAPN3 between these regions, variability 
remaining mostly unexplained (Keira et al. 2003, Taveau et al. 2003, Ojima et al. 
2005, 2007, 2010, Murphy & Lamb 2009). In cultured mouse myotubes, CAPN3 
was found to show predominant M-band localization during late myofibrillo-
genesis, whereas the typical pattern in fully mature myotubes and  muscles consists 
of a major doublet band at the I-band region and a minor band at the M-band 
(Keira et al. 2003, Ojima et al. 2007, 2010, Murphy & Lamb 2009).
The variable amount of CAPN3 detected at the Z-disc may represent an 
 N-terminal fragment rather than the full-length protein. This was suggested by 
Ojima et al. (2007), who showed stronger Z-disc labelling with a CAPN3 antibody 
raised against the NS region, and detected an interaction between CAPN3 NS and 
α-actinin. The biological role for this possible Z-disc targeting of calpain fragments 
is yet unknown.
Some CAPN3 is found in myonuclei (Baghdiguian et al. 1999, Keira et al. 
2003). This may depend on a lysine-rich motif in IS2, as CAPN3 constructs lacking 
the IS2 region do not show nuclear localization in transfected cells (Sorimachi et 
al. 1993). Tissue fractionation experiments by Murphy and coworkers (2011) indi-
cated that ≤10% of total CAPN3 in human and rat muscles is nuclear, and this does 
not change in response to eccentric exercise. CAPN3 in the nuclear pool was found 
to be mostly in the autolyzed (i.e. activated) state, in contrast to the myofibril-
bound pool (Murphy et al. 2011).
2.4.3 Interactions between CAPN3 and titin
In line with its predominant localization at the I-band and M-band, interactions of 
CAPN3 with titin have been described at these sarcomeric regions (Sorimachi et al. 
1995, Hayashi et al. 2008). 
2.4.3.1 Interaction of CAPN3 with M-band titin
The interaction of CAPN3 with the extreme C-terminus of titin (domains M9–is7–
M10) was identified in a yeast two-hybrid screen (Sorimachi et al. 1995). In further 
Y2H studies, M9–is7, but not M9 alone, showed binding to CAPN3, demonstrat-
ing that at least is7 is required for the interaction (Kinbara et al. 1997). Studies 
addressing the importance of M9 for CAPN3 binding have not been reported. The 
interaction seems to require the whole three-dimensional structure of CAPN3, 
as none of the calpain deletion constructs tested by Kinbara et al. (1997) showed 
binding to C-terminal titin in Y2H. The interaction of CAPN3 and C-terminal titin 
has been later confirmed in a solid-phase binding assay (Kramerova et al. 2004).
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Y2H studies by Herasse et al. (1999) indicated that developmental CAPN3 iso-
forms show different interactions with C-terminal titin. CAPN3 isoforms lacking 
the exon 16, and hence most of the IS2 segment (i.e. ex6–15–16– and ex15–16–), 
showed dramatically stronger interaction signals with M-band titin, whereas 
 exclusion of exons 6 or 15 alone or together resulted in slightly or clearly weaker 
binding compared to the full-length form. This suggests that IS2 modulates the 
interaction with C-terminal titin, but given the low and temporally restricted ex-
pression of the CAPN3 ex16– isoforms (Herasse et al. 1999, Ojima et al. 2007), the 
importance of this phenomenon is unclear.
The exact biological function of the CAPN3–titin interaction in the M-band is 
unknown, but the secondary CAPN3 deficiency seen in TMD/LGMD2J patients 
and the FINmaj knock-in mouse (Haravuori et al. 2001, Charton et al. 2010) sug-
gests that C-terminal titin plays a key role in regulating the functions and stability 
of CAPN3. Moreover, the differential localization of CAPN3 to the M-band and 
N2A regions, with the apparent correlation to sarcomere length (Ojima et al. 2007, 
2010) (discussed in 2.4.5.), highlights the dynamic nature of the interaction.
In addition to regulation of CAPN3, the interaction could indicate that C-termi-
nal titin is a substrate for CAPN3. In line with this, the ability of CAPN3 to cleave 
C-terminal titin has been demonstrated in coexpression experiments. In studies by 
Taveau et al. (2003) on mouse myoblasts, a novel band of 18 kDa was produced 
in cotransfections of a titin construct with active CAPN3 but not with the C129S 
mutant. However, small amounts of the fragment were also detected in co-trans-
fections of the titin construct with the CAPN3 ex6– isoform and the activation-
incompetent Y274A mutant (Taveau et al. 2003), indicating possible contribution 
by endogenous CAPN3 or other proteases. Kramerova et al. (2004) showed that 
the titin construct M6–M10 is cleaved by active CAPN3 when coexpressed in insect 
cells, producing a C-terminal fragment of ~40 kDa. This would place the cleavage 
in the M-is6 region, N-terminally from the described binding site.
2.4.3.2 Interactions of CAPN3 with I-band titin
CAPN3 binds I-band titin at three identified binding sites. The “primary” binding 
site, identified in the same Y2H screen that revealed the M-band interaction, en-
compasses the domains I82–I83 of the N2A element (Sorimachi et al. 1995, Ono 
et al. 2004). CAPN3 binds this titin site through a short peptide (V573–L580) at 
the beginning of the IS2 region. The binding peptide is included in the CAPN3 
ex15–16– isoforms that lack most of IS2, and these developmental CAPN3 variants 
accordingly bind the N2A element with a similar efficiency as the full-length iso-
form (Herasse et al. 1999, Ono et al. 2006).
Two additional CAPN3 binding sites in I-band titin, termed “secondary” 
sites, were later identified in CoIP studies by Hayashi et al. (2008), and regions 
 mediating the interactions were defined with deletion constructs. One such site en-
compasses the I80 domain and the N2A unique sequence region, thus overlapping 
42
Review of the literature
titin’s binding site for muscle ankyrin repeat proteins (see 2.4.7.), and the other is 
found within the PEVK region. The whole structure of CAPN3 seems to be needed 
for the former interaction, whereas the latter is mediated by a short peptide in early 
IS2, adjacent to the site binding the N2A Ig domains (Hayashi et al. 2008). 
2.4.4 Activation of CAPN3
The active site of CAPN3 is blocked by an internal autoinhibitory propeptide 
formed by the IS1 region; to activate the enzyme, this must be removed by an auto-
lytic mechanism (Rey & Davies 2002, Taveau et al. 2003, Diaz et al. 2004). The 
autolytic activation is responsible for the rapid degradation of CAPN3—occurring 
in many heterologous expression systems and upon muscle homogenization—that 
has complicated biochemical studies on the native protein (Sorimachi et al. 1993, 
Kinbara et al. 1998). The proteolytically inactive C129S mutant is incapable of 
auto lysis (Sorimachi et al. 1993), and it has been widely used in molecular studies 
on CAPN3.
Molecular mechanisms of CAPN3 activation have been extensively studied in 
vitro with CAPN3 constructs containing point mutations or truncations, and with 
CAPN3 isoforms showing altered autolytic properties. These studies have revealed 
that the autolysis involves sequential cleavages at several sites in the IS1 and NS 
 regions. The exact cleavage sites identified in different studies differ somewhat, like-
ly indicating slightly different structures of the utilized deletion mutant  constructs 
(Rey & Davies 2002, Taveau et al. 2003, Diaz et al. 2004, Ono et al. 2006, 2008, 
2010). The autolysis can proceed through both intramolecular and intermolecular 
reactions. The initial cleavage events have been regarded as strictly intramolecular 
(Rey & Davies 2002, García Díaz et al. 2006), but the ability of wild-type CAPN3 to 
autolyse the inactive C129S mutant suggests that inter molecular autolysis could be 
possible from the beginning (Taveau et al. 2003).
Key events in CAPN3 activation are cleavages within the IS1 region, resulting 
in the disappearance of the full-length protein and producing the characteristic 
C-terminal fragments of 55–60 kDa in WB. These cleavages lead to detachment of 
IS1, while the N- and C-terminal moieties constituting the active enzyme remain 
non-covalently associated (Kinbara et al. 1998, Rey & Davies 2002, Taveau et al. 
2003, Diaz et al. 2004, Ono et al. 2006). Autolytic cleavages occur also within the 
NS sequence, resulting in loss of the original N-terminus from the protein. How-
ever, the timing of these N-terminal cleavages relative to other autolytic events is 
unclear due to conflicting results, and their biological importance is unknown (Rey 
& Davies 2002, Diaz et al. 2004, Ono et al. 2006). Another autolytic cleavage, pro-
ducing a C-terminal fragment of ~32 kDa, has been reported in the N-terminal part 
of IS2. This was suggested to cause dissociation and inactivation of CAPN3 (Ono et 
al. 2006), but conclusive evidence for this is still lacking.
In contrast to the ubiquitous calpains that require Ca2+ at micro- or millimolar 
concentrations for activity, CAPN3 was first described to be calcium-independent 
43
(Kinbara et al. 1998). This apparent Ca2+-independence is due to the extremely 
high Ca2+ sensitivity of CAPN3: submicromolar Ca2+ concentrations (in the order 
of 200 nM) are sufficient for its activation in vitro (Branca et al. 1999, García Díaz 
et al. 2006, Murphy & Lamb 2009). Similarly to ubiquitous calpains, the activation 
involves realignment of the catalytic triad induced by binding of two Ca2+ ions to 
the protease core, but the presence of IS2 in CAPN3 increases the calcium sensitiv-
ity by a yet unknown mechanism (Sorimachi et al. 1993, García Díaz et al. 2006, 
Ono et al. 2008). A recent report by Ono et al. (2010) suggested that CAPN3 can 
also be activated by Na+, likely through one of the Ca2+ binding sites in the  protease 
core. Na+ binding was proposed to enhance the responsiveness of CAPN3 to 
physio logical Ca2+ concentrations or to modulate the substrate specificity (Ono et 
al. 2010). However, since significant amounts of contaminant Ca2+ can be present 
in reagents (notably, NaCl) and containers (García Díaz et al. 2006), the suggested 
Na+ dependency could be artefactual.
In a physiological setting, detectable autolysis of CAPN3 has only been demon-
strated to occur following eccentric exercise—a condition known to cause a small 
but prolonged increase in the resting Ca2+ concentration inside myofibres (Murphy 
et al. 2007, 2011, Ojima et al. 2010). CAPN3 activation has not been detected after 
vigorous or prolonged concentric exercise, nor after tetanic stimulation known to 
cause very high but short-lived Ca2+ peaks in myofibres (Murphy et al. 2006, 2009).
The presence of intact CAPN3 in the myofibrillar fraction isolated from muscle 
and its rapid autolysis upon purification have suggested that binding to titin pro-
tects CAPN3 from autolysis (Sorimachi et al. 1993, 1995, Kinbara et al. 1998). In 
support of this idea, coexpression of the titin fragment I81–I83, encompassing one 
of the CAPN3 binding sites in the N2A region, was shown to suppress the autolysis 
of a CAPN3 construct in a yeast-based reporter gene assay, whereas a C-terminal 
titin construct containing the M-band CAPN3 binding site did not show such an 
effect (Ono et al. 2006). Since CAPN3 can be successfully produced in cells lacking 
myofibrils and it may, in the absence of Ca2+, remain inactive in solution for hours, 
titin binding is not a prerequisite for its stabilization (Branca et al. 1999, Murphy & 
Lamb 2009). Interaction with titin through IS2 could, however, modulate the Ca2+ 
sensitivity of CAPN3 activation or limit the mobility of activated CAPN3 molecules, 
thus inhibiting the propagation of the activation through intermolecular autolysis 
(suggested by Taveau et al. 2003).
In vivo additional factors, possibly coordinated by titin, are likely to regulate 
the activation of CAPN3. The autolysis of CAPN3 in single-fibre preparations is 
significantly attenuated in the absence of ATP, however in a manner independent 
of rigor. This could be explained by binding of ATP to CAPN3 or to one of its myo-
fibrillar partners, or by a phosphorylation event (Murphy & Lamb 2009). In line 
with the latter possibility, CAPN3 isolated from the myofibrillar fraction may be 
phosphorylated, as indicated by staining with a phosphate-reactive dye (Ermolova 
et al. 2011).
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2.4.5 Dynamics of CAPN3 localization and activity
The relationship between the activity and localization of CAPN3 has been ad-
dressed in recent studies, but the results have been somewhat conflicting.
Based on a correlation between sarcomere length and CAPN3 staining pattern 
in fixed muscle samples, Ojima and coworkers (2007, 2010) proposed that the myo-
fibrillar localization of CAPN3 changes with sarcomere length. A more pronounced 
staining of the I-band in longer sarcomeres was concluded to reflect relocation of 
CAPN3 from M-band to the N2A element upon sarcomere stretch. This shuttling 
appeared to be partly dependent on protease activity, as the inactive CAPN3 C129S 
showed a slightly higher degree of M-band localization at a given sarcomere length. 
Similar results were obtained with CAPN3 constructs in cultured myocytes (Ojima 
et al. 2007) and with the endogenous proteins in muscles of wild type and C129S 
KI mice (Ojima et al. 2010). Also FRAP (fluorescence recovery after photobleach-
ing) experiments with GFP-tagged CAPN3 constructs suggested altered mobility 
of the C129S mutant protein at the M-band (Ojima et al. 2010). Moreover, eccen-
tric exercise was reported to cause the translocation of CAPN3 from the myofibril-
lar to the soluble fraction in mice. As this was not seen in C129S KI, detachment 
from myofibrils was suggested to depend on the activation of CAPN3 (Ojima et al. 
2010). The connection between the mobility of CAPN3 and its proteolytic activity 
was proposed to depend on conformational changes induced by autolysis (Ojima 
et al. 2010), but the different behaviour of the wild-type and C129S proteins could 
also reflect a difference in their biochemical or biophysical properties unrelated to 
the protease activity.
The findings by Murphy and colleagues (Murphy & Lamb 2009, Murphy et 
al. 2011) argue against some of the aforementioned notions. In experiments per-
formed on skinned myofibres, stretching was found not to cause autolysis of CAPN3 
nor its mobilization from myofibrils. Furthermore, activation of CAPN3 in isolated 
myofibres and human muscles—induced by Ca2+ treatment or eccentric exercise, 
respectively—did not cause its translocation to the cytosol. The majority of CAPN3 
was reported to remain myofibril-associated even after autolysis, and conversely, 
most of the cytosolic CAPN3 was full-length (Murphy & Lamb 2009, Murphy et 
al. 2011). These studies did not directly address the effect of sarcomere length on 
the spatial distribution of CAPN3 within the sarcomere. According to Murphy and 
Lamb (2009), the sarcomere-length-dependent localization differences observed 
by Ojima et al. (2007) in cultured myotubes could reflect local increases in Ca2+ 
concentration, causing both the observed sarcomere hypercontraction (and a cor-
responding hyperextension in the vicinity) and CAPN3 autolysis. This mechanism 
is, however, unlikely to explain the similar, albeit less dramatic, effect seen in 
mouse muscles.
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2.4.6 Substrates and proteolytic functions of CAPN3
In contrast to many proteases and similarly to the ubiquitous calpains, CAPN3 
does not have a strict requirement for the cleavage site. The substrate specificity of 
calpains is considered to depend largely on structural features, with a preference 
for unstructured protein segments such as interdomain linkers (Ono & Sorimachi 
2012). However, based on sequence analysis of reported substrates, de Morrée 
and colleagues (2010) reported the primary sequence motif [LIMV]X4[LIMV]
X2[LIMV][DE] to mediate recognition and cleavage by CAPN3. Introducing the 
motif to reporter constructs was shown to transform them to CAPN3 substrates, 
whereas mutagenesis of key residues inhibited the cleavage. As the motif was also 
able to predict novel substrates from a sequence database, it may prove a powerful 
tool for identifying substrates of CAPN3 and studying its functions (de Morrée et 
al. 2010).
Different strategies have been employed for identifying CAPN3 substrates ex-
perimentally. Several studies have tested and confirmed the cleavage of candidate 
substrates by coexpressing them with CAPN3 (Baghdiguian et al. 1999, Guyon et 
al. 2003, Taveau et al. 2003, Kramerova et al. 2004, Hayashi et al. 2008, Huang 
et al. 2008), whereas proteomics analyses of cells and muscles overexpressing 
CAPN3 have been used for identification of novel substrates (Cohen et al. 2006, 
Ono et al. 2006). While these studies have identified a number proteins that can be 
cleaved by CAPN3, it is yet unknown which substrates are physiologically relevant. 
Among both confirmed and predicted substrates, cytoskeletal and sarcomeric pro-
teins are a significant group, and remodelling of these structures is hence consid-
ered to be a major function of CAPN3 in mature muscle (Kramerova et al. 2005, 
Cohen et al. 2006, Duguez et al. 2006, Beckmann & Spencer 2008, de Morrée et 
al. 2010). Also the association of activated CAPN3 with the myofibrils, suggesting 
that its physiological substrates are in the vicinity, supports a primary function in 
cytoskeletal and sarcomeric processing (Beckmann & Spencer 2008, Murphy et 
al. 2011). Moreover, CAPN3 KO mice show impaired sarcomeric remodelling in 
response to muscle unloading and reloading. The failure of CAPN3 KO  muscles to 
accumulate ubiquitinated protein conjugates during the remodelling process sug-
gests that CAPN3 is required for releasing proteins components from the myo-
fibrils, a prerequisite for their further turnover by the ubiquitin–proteasome path-
way (Kramerova et al. 2005).
In addition to its apparent major function in cytoskeletal remodelling, the iden-
tified substrates of CAPN3 suggest its involvement in the regulation of processes 
such as muscle development and regeneration, membrane repair, SUMOylation, 
fat and energy metabolism, and apoptosis (Baghdiguian et al. 1999, Cohen et al. 
2006, Kramerova et al. 2006, Huang et al. 2008, de Morrée et al. 2010, Stuelsatz 
et al. 2010). Furthermore, the protease activity of CAPN3 is suggested to modulate 
signalling mediated by the titin N2A element and the muscle ankyrin repeat pro-
teins, discussed below.
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2.4.7 CAPN3, MARPs, and the titin N2A element in signalling
The muscle ankyrin repeat proteins (MARPs)—ANKRD1 (MARP1; CARP, cardiac 
ankyrin repeat protein), ANKRD2 (MARP2; ARPP, ankyrin repeat protein with 
PEST and proline-rich region), and ANKRD23 (MARP3; DARP, diabetes-related 
ankyrin repeat protein)—are a group of ankyrin repeat domain (ANKRD) proteins 
predominantly expressed in skeletal and cardiac muscles with characteristic ex-
pression patterns. Upregulation of MARPs has been reported in various muscle 
diseases and in response to immobilization, denervation, eccentric contractions, 
strenuous exercise, and metabolic challenge, suggesting their importance in 
 muscle remodelling (reviewed by Kojic et al. 2011). 
MARPs are suggested to have dual roles as structural and regulatory proteins. 
Myofibres from mice lacking all three MARPs have altered mechanical properties 
(Barash et al. 2007), and MARPs have been proposed to mechanically stabilize 
the contractile machinery (Tee & Peppelenbosch 2010). The regulatory role of 
MARPs, probably representing the more important aspect of their functions, is 
demonstrated by their nuclear localization, DNA binding (shown for ANKRD1), 
and inter actions with a multitude of signalling proteins and transcription factors, 
and supported by wide-spread changes in gene expression following MARP over-
expression or knockdown (Chu et al. 1995, Kojic et al. 2004, Laure et al. 2010, 
Belgrano et al. 2011, Kojic et al. 2011).
MARPs show dual localization to the sarcomeric I-band and nuclei, and 
 ANKRD23 can also localize to intercalated discs (Bang et al. 2001b, Miller et al. 
2003b). All three bind the N2A element of titin (Miller et al. 2003b), as well as myo-
palladin, a muscle-restricted Ig-domain protein showing either Z-disc or I-band 
localization (Bang et al. 2001b, Miller et al. 2003b). Although MARPs, CAPN3, 
and myopalladin were suggested to constitute a mechanosensory complex at the 
titin N2A element a decade ago (Miller et al. 2003b), not much is known about the 
relationships of the proteins, and no mechanosensory function for the proposed 
complex has been demonstrated. Recent studies have, however, provided some in-
sight into the intricate system (Hayashi et al. 2008, Laure et al. 2010).
Both ANKRD1 (Laure et al. 2010) and ANKRD2 (Hayashi et al. 2008) are 
proteo lytic substrates of CAPN3. Cleavage of ANKRD1 may increase its binding 
to titin and reduce its nuclear shuttling, thereby inhibiting the effects of ANKRD1 
on gene expression (Laure et al. 2010). The cleavage of ANKRD2 is, on the other 
hand, possibly enhanced by titin binding (Hayashi et al. 2008). Unlike ANKRD1, 
the cleavage of ANKRD2 does not seem to affect its affinity towards titin (Hayashi 
et al. 2008), suggesting that the myofibrillar association of the two proteins is not 
regulated in a similar fashion. The possible cleavage site in ANKRD2 is close to a 
serine residue whose phosphorylation promotes nuclear translocation of the pro-
tein (Cenni et al. 2011), and phosphorylation has been proposed to cooperate with 
CAPN3-mediated cleavage in regulating the localization of ANKRD2 (Belgrano et 
al. 2011). These functions may also be modulated by competitive interactions of 
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the MARPs and CAPN3 with their common binding site in the titin N2A element 
(Hayashi et al. 2008).
Additional clues about the N2A-based functions come from the murine mdm 
(muscular dystrophy with myositis) mutation, a rearrangement ultimately deleting 
83 amino acids from the titin N2A element (Garvey et al. 2002). Mice homozygous 
for the mutation develop a severe dystrophy of skeletal muscles, whereas the hetero -
zygotes only exhibit gait abnormalities (Garvey et al. 2002, Huebsch et al. 2005). 
The mdm mice show a reduction in CAPN3 levels, and before the identifi cation of 
the gene defects at different parts of titin, mdm was suggested to be a natural mouse 
model for TMD/LGMD2J (Haravuori et al. 2001, Garvey et al. 2002). The mdm 
deletion disrupts the binding of CAPN3 at titin domains I82–I83 and prevents the 
suppressive effect of this titin region on CAPN3 autolysis (Witt et al. 2004, Ono et 
al. 2006). However, the overall defect may involve more complex changes in the 
titin–CAPN3–MARP system, possibly involving impaired interactions of ANKRD1 
and ANKRD2 with titin and altered proteolysis of I-band titin by CAPN3 and other 
calpains (Hayashi et al. 2008). Interestingly, dysregulated CAPN3 activity does 
not seem to mediate the primary pathogenesis of mdm, as knockout of CAPN3 was 
reported not to affect the mdm phenotype. On the other hand, CAPN3 overexpres-
sion was shown to exacerbate the muscular dystrophy in mdm homozygotes, but to 
correct the gait abnormality in heterozygotes (Huebsch et al. 2005).
2.4.8 Non-proteolytic functions of CAPN3
The CAPN3 KO mice have a more severe dystrophic phenotype than the knock-
in model expressing the proteolytically inactive C129S form of CAPN3, indicat-
ing that CAPN3 has functions not requiring its proteolytic activity (Richard et al. 
2000, Kramerova et al. 2004, Ojima et al. 2010). One such non-proteolytic role 
was suggested by recent studies that identified interactions of CAPN3 with aldo-
lase A (AldoA) ryanodine receptor (RyR), and other protein components of the 
triads, contact points between T-tubules and SR (Kramerova et al. 2008, Ojima et 
al. 2011) (Fig. 1). Association with the triads was also supported by the presence 
of CAPN3 in membrane fractions isolated from mouse muscles (Kramerova et al. 
2008); however Murphy et al. (2011) failed to detect CAPN3 in enriched or purified 
SR vesicles.
CAPN3 KO mice showed impaired localization of AldoA to triads and a de-
creased amount of RyR, resulting in a diminished Ca2+ release, blunted CaMKII 
(Ca2+/calmodulin protein kinase II) signalling, and impaired adaptation to exercise 
(Kramerova et al. 2008, 2012). Such changes were not observed in C129S KI mice, 
implying that CAPN3 has a structural rather than proteolytic role in  stabilizing the 
triad-associated protein complex (Kramerova et al. 2008, Ojima et al. 2011). How-
ever, the majority of CAPN3 in single-fibre preparations is bound to myofibrils, 
and resistant to detergent extraction in conditions that cause a nearly complete 
washout of triad proteins (Murphy & Lamb 2009, Murphy et al. 2011). Hence, the 
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proportion of CAPN3 localized to triads is very low, or triad-associated CAPN3 is 
simultaneously bound to myofibrils. In line with the latter possibility, CAPN3 was 
proposed by Ojima et al. (2011) to provide a structural connection between myo-
fibrils and triads by interacting with both the titin N2A element and triad proteins.
Based on thick filament misalignment observed in CAPN3 KO mouse but not 
in C129S KI (Kramerova et al. 2004, Ojima et al. 2010), a structural role was pro-
posed for CAPN3 also in the myofibrils (Ojima et al. 2011).
2.5 Limb-girdle muscular dystrophy 1D (LGMD1D)
LGMD1D or DNAJB6 myopathy is an autosomal dominant limb-girdle muscular 
dystrophy, identified as a distinct 7q36-linked disease entity by Speer and col-
leagues (1999) in two families from the USA. The nomenclature for this disease 
entity has been confusing: the HUGO Gene Nomenclature Committee lists 7q36-
linked LGMD as LGMD1D (ID 6576; HGNC Database). The MIM database has used 
both designations LGMD1D and 1E, and currently lists the disease as  LGMD1E 
(MIM #603511). Here, the term LGMD1D will be used.
Before this study, mutations underlying LGMD1D were unknown. Causative 
mutations in the DNAJB6 gene (DnaJ homolog, subfamily B, member 6), de-
scribed in publication II, were first identified in Finnish families, and also found 
in Italian and the original American families. Additional mutations have been re-
ported in LGMD1D families from the USA and Japan (Harms et al. 2012, Sato et 
al. 2013). All the known mutations are missense changes affecting the glycine/
phenylalanine-rich (G/F) domain of the protein (Table 2, Fig. 5). The mutations 
show marked clustering: all five reported mutations are located within a range of 
eight amino acid residues, three of them affecting the same residue, F93 (II, Harms 
et al. 2012, Sato et al. 2013).
2.5.1 Clinical picture of LGMD1D
LGMD1D typically presents with a limb-girdle phenotype—slowly progressive 
 muscle weakness and atrophy, most prominent in the proximal parts of the limbs. 
Both pelvic and shoulder girdle muscles are affected, the lower limbs usually show-
ing earlier onset and greater severity of symptoms. Of distal leg muscles, soleus and 
medial gastrocnemius are most severely affected (Sandell et al. 2010,  Hackman et 
al. 2011, Harms et al. 2012, Sato et al. 2013). In a few patients carrying the P96R 
mutation, Harms et al. (2012) described onset of symptoms in distal legs and arms, 
followed by progression to proximal muscles. Bulbar symptoms, apart from in-
frequent dysphagia, have not been reported, nor are there cardiac or respiratory 
problems (Speer et al. 1995, Sandell et al. 2010, Hackman et al. 2011, Harms et al. 
2012, Sato et al. 2013).
The age of onset varies considerably, from the 3rd to the 6th decade, and some 
cases with a possible childhood onset have been reported. The symptoms begin 
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with difficulties in walking, running, climbing stairs, or getting up from the floor. 
Weakness progresses slowly, and walking ability is usually preserved until a late 
age (Sandell et al. 2010, Hackman et al. 2011, Harms et al. 2012, Sato et al. 2013).
2.5.2 Muscle pathology in LGMD1D
Muscles affected by LGMD1D show myopathic and later dystrophic changes: 
atrophic and regenerating fibres, fibre size variation, and internal nuclei. Rimmed 
vacuoles are variably present, ranging from infrequent to abundant (Sandell et al. 
2010, Hackman et al. 2011, Harms et al. 2012, Sato et al. 2013).
Muscle fibres contain eosinophilic protein inclusions, sometimes in the 
rimmed-vacuolar regions. These have been shown to stain positive for DNAJB6, 
as well as several proteins typically accumulating in myofibrillar myopathies (myo-
tilin,  αB-crystallin, desmin, ectopic dystrophin, and TARDBP), and components 
of the chaperone-assisted selective autophagy (CASA) pathway (BAG3, STUB1, 
HSPA8, and HSPB8) (Sandell et al. 2010, Hackman et al. 2011, Harms et al. 2012, 
Sato et al. 2013). Subsarcolemmal accumulation of DNAJB6 (Harms et al. 2012), 
and nuclear DNAJB6 staining (Sato et al. 2013) has also been reported in some 
affected fibres.
Electron microscopy shows myofibrillar disorganization starting with Z-disc 
disintegration—a typical finding in myofibrillar myopathies. Rimmed vacuoles are 
correlated on the EM level by autophagic vacuoles with myeloid bodies, small vesi-
cles, and debris material. Tubulofilamentous inclusions may be found in the sarco-
plasm and infrequently in myonuclei (Sandell et al. 2010, Hackman et al. 2011, 
Harms et al. 2012, Sato et al. 2013).
Sarcolemmal markers such as dystrophin and sarcoglycans appear normal in 
LGMD1D muscle, consistent with the mild to moderate elevation of serum creatine 
kinase levels in patients (Sandell et al. 2010, Hackman et al. 2011).
2.5.2.1 Myofibrillar myopathies
Based on muscle pathology alone, LGMD1D can be classified to the group of myo-
fibrillar myopathies (MFM). These diseases, showing clinical and genetic hetero-
geneity, share common pathological features: myofibrillar disintegration begin-
Table 2. LGMD1D-causing mutations in DNAJB6
cDNA change Protein change Reference
c.265T>A p.Phe89Ile II
c.277T>C p.Phe93Leu II, Harms et al. 2012
c.277T>A p.Phe93Ile Sato et al. 2013
c.279C>G p.Phe93Leu II, Sato et al. 2013
c.287C>G p.Pro96Arg Harms et al. 2012
Sequence numbers refer to the RefSeq records NM_005494.2 (cDNA) and NP_005485.1 (protein).
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ning at the Z-disc and accumulation of proteins—especially Z-disc material—within 
the muscle fibres, characteristic dark and hyaline changes on trichrome stain, and 
 vacuolar degeneration (Selcen 2011, Udd 2013). MFMs can be regarded as diseases 
of the Z-disc as most of the mutated proteins are structural components of the 
 Z-disc (myotilin, desmin, filamin C, and ZASP) or are involved in Z-disc main-
tenance (BAG3 and αB-crystallin) (Selcen 2011).
2.6 DNAJB6
DNAJB6 belongs to the DNAJ family of co-chaperones, also known as the  J-protein 
or heat shock protein 40 (Hsp40) family (Seki et al. 1999, Qiu et al. 2006). The 
protein was first described as MRJ (mammalian relative of DnaJ) (Seki et al. 1999), 
and this name has been widely used especially in the earlier literature. Also the 
alias HSJ2 has been used (Hanai & Mashima 2003), although this term can also 
refer to DNAJA1.
2.6.1 J-proteins and the HSPA chaperone system
J-proteins are essential cofactors or co-chaperones for the HSPA (Hsp70) proteins, 
a family of ubiquitous molecular chaperones with central roles in the regulation of 
protein folding and turnover (Kampinga & Craig 2010). The main cytosolic mem-
bers of the HSPA family are the stress-induced Hsp70 (encoded by the HSPA1A 
and HSPA1B genes with nearly identical protein products), and the constitutively 
 expressed HSPA8 (also known as Hsc70, heat-shock cognate 70; Hsp73) ( Daugaard 
et al. 2007).
Functions of the HSPA chaperones are based on the recognition of exposed 
hydro phobic protein stretches characteristic of unfolded proteins. In the ATP-
bound open state, HSPAs bind and release their client proteins rapidly, whereas 
the ADP-bound closed state is needed for high-affinity binding that promotes re-
folding of the client protein. As the inherent ATPase activity of HSPAs is very low, 
the conformation switch depends on J-proteins that interact with HSPAs with their 
J-domains and stimulate ATP hydrolysis, thus stabilizing the binding of HSPAs 
to their client proteins. J-proteins can also recognize and bind the client proteins 
 before presenting them to the HSPA component, conferring specificity to the other-
wise unselective HSPA machinery (Kampinga & Craig 2010).
The classical role of the HSPA chaperones is to prevent the aggregation of un-
folded proteins and promote their folding to the native conformation. However, 
association of different sets of co-chaperones with the core chaperone can affect 
the fate of the client proteins, targeting them to the proteasomal or autophagic 
turnover pathways (Esser et al. 2004). An example of such a mechanism is the 
recently described chaperone-assisted selective autophagy (CASA) pathway (Arndt 
et al. 2010).
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2.6.2 Structure of DNAJB6
The N-terminal part of DNAJB6 harbours a J-domain of ~70 amino acid residues. 
This domain, a defining feature of J-proteins, is required for the interaction with 
HSPA chaperones and stimulation of their ATPase activity (Seki et al. 1999, Qiu et 
al. 2006).
The J-domain is followed by a G/F-domain, harbouring all the described 
 mutations causing LGMD1D. This domain of ~45 amino acids, rich in glycine 
and phenylalanine residues, is present in all type I (DNAJA) and type II (DNAJB) 
 J-proteins (Chuang et al. 2002, Qiu et al. 2006). The function of the G/F-domain in 
DNAJB6 has not been characterized, but in bacterial and yeast homologues it has 
been suggested to participate in recognition of partially unfolded client proteins 
(Wall et al. 1995, Yan & Craig 1999, Perales-Calvo et al. 2010). The G/F- domain 
may also contribute to the interaction of DNAJB6 with HSPA8 (see 2.6.5.1.), since 
a construct containing the G/F-domain shows a stronger interaction signal in a 
yeast two-hybrid assay compared to J-domain alone (Izawa et al. 2000).
The C-terminal domain (CTD) shows less similarity to other J-proteins. Its 
most notable feature is the serine-rich region, termed the SSF–SST domain based 
on its sequence boundaries in the closely related DNAJB8 protein (Hageman et 
al. 2010). Two DNAJB6 isoforms, differing in the C-terminal regions, are gener-
ated by alternative splicing. The long isoform DNAJB6a [RefSeq NP_490647; 
also known as MRJ(L)] contains 326 amino acids and has a molecular weight of 
36 kDa, whereas the short isoform DNAJB6b [RefSeq NP_005485; also known as 
MRJ(S)] contains 241 amino acids and has a molecular weight of 27 kDa. The two 
isoforms share their 231 N-terminal amino acid residues, which are followed by 
unique C-terminal tails (Hanai & Mashima 2003).
A schematic view of DNAJB6 is shown in Fig. 5.
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Figure 5. Structure of DNAJB6
The DNAJB6 protein comprises an N-terminal J-domain, a glycine/phenylalanine-rich (G/F) domain 
harbouring the LGMD1D-causing mutations, and a C-terminal domain (CTD) containing a serine-rich 
region. Alternative splicing results in two isoforms DNAJB6a and DNAJB6b, with different 
C-termini. The location of the known LGMD1D-causing mutations, the HPD tripeptide mediating the 
interaction with HSPA8, and the lysine residues K225 and K232 corresponding to the acetylatable 
residues in DNAJB8 are indicated.
Adapted from Sarparanta et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle 
muscular dystrophy. Nature Genetics, 2012; 44: 450–455. © 2012 Nature America, Inc.
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2.6.3 Tissue distribution of DNAJB6
The expression of DNAJB6 is widespread, if not ubiquitous. Seki et al. (1999) de-
tected expression of DNAJB6b by RT-PCR in all human tissues analyzed, where-
as nothern blotting experiments by Chuang et al. (2002) revealed variable levels 
of the DNAJB6b transcripts in different bovine and human tissues, with highest 
 expression in brain and retina. Western blotting of rat tissue extracts, while sup-
porting the enrichment of DNAJB6b in the central nervous system, showed detect-
able levels of the protein only in a subset of rat tissues (Chuang et al. 2002). The 
tissue distribution of the DNAJB6a isoform has not been reported.
2.6.4 Subcellular localization of DNAJB6
Most of the knowledge on the subcellular localization of DNAJB6 has been obtained 
from overexpression experiments in cell cultures. Based on such trans fection stud-
ies, DNAJB6a is exclusively localized to the nucleus; this localization depends on 
the strong nuclear localization signal near the C-terminus of the protein (Hanai & 
Mashima 2003, Mitra et al. 2008). DNAJB6b constructs show mainly diffuse cyto-
plasmic localization, but they can also exhibit nuclear localization of different de-
grees, ranging from minor to predominant (Chuang et al. 2002, Hanai & Mashima 
2003, Dai et al. 2005, Andrews et al. 2012, Gillis et al. 2013).
The few published studies are insufficient for reliably establishing the locali-
zation of endogenous DNAJB6. The studies by Izawa et al. (2000) and Watson 
et al. (2007) have both indicated cytoplasmic localization—albeit with somewhat 
differing staining patterns—and this is in line with the substantial amount of evi-
dence supporting the roles of DNAJB6b in the cytoplasm (discussed below). In 
contrast to the aforementioned results, Dey et al. (2009) showed DNAJB6 tightly 
associated with nucleoli of HeLa cells during interphase and dispersed between 
the chromosomes in mitotic cells. Both cytoplasmic and nucleolar localization of 
 DNAJB6b have gained support from transfection studies (Chuang et al. 2002, 
 Hanai & Mashima 2003, Dai et al. 2005, Andrews et al. 2012).
2.6.4.1 Nuclear relocation of DNAJB6b
DNAJB6b relocates to the nucleus following heat shock and hypoxia, and returns 
to the cytoplasm within hours after the removal of the stress stimulus (Dai et al. 
2005, Andrews et al. 2012). However, the localization within the nucleus is not 
 established, as transfection studies with different DNAJB6b constructs have shown 
either homogeneous nuclear staining with apparent exclusion from the nucleoli 
(Dai et al. 2005), or nucleolar enrichment (Andrews et al. 2012).
The mechanism for the nuclear localization of DNAJB6b is unknown, but in the 
absence of a nuclear localization signal, it is likely to depend on cotransport with 
another protein. HSPA seems to play a role in the process, since partial  J-domain 
deletions and the H31Q mutation, preventing the interaction with HSPA, have 
been reported to disrupt the nuclear localization of DNAJB6b in both baseline and 
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heat-shock situations (Dai et al. 2005). Also the twenty C-terminal amino acid resi-
dues of DNAJB6b, containing a putative nuclear export signal, are required for the 
stress-induced relocation, although deletion of these residues does not prevent the 
nuclear localization in unstressed cells (Andrews et al. 2012).
2.6.5 Functions of DNAJB6
As a member of the J-protein family, DNAJB6 is a HSPA co-chaperone. It also has 
HSPA-independent chaperonal activity, reflected by its ability to suppress protein 
aggregation. In addition, both DNAJB6 isoforms have been shown to have various 
functions in cellular signalling. The reported functions of DNAJB6 are reviewed 
below.
2.6.5.1 HSPA co-chaperone activity
As expected for a J-protein, DNAJB6 interacts with HSPA chaperones in a pull-
down system, and a specific interaction with HSPA8 (Hsc70) has been demon-
strated in a yeast two-hybrid assay. The J-domain alone is sufficient for HSPA8 
binding, but presence of the G/F domain may promote the interaction (Izawa et 
al. 2000). Consistent with the interaction with HSPA8, DNAJB6 can stimulate the 
ATPase activity of this HSPA chaperone in vitro (Chuang et al. 2002). In addition 
to full-length and N-terminal constructs, also a C-terminal construct lacking the 
J-domain has shown ATPase stimulatory activity (Chuang et al. 2002), but this has 
been suggested to reflect the presence of contaminant bacterial DnaJ in the protein 
preparations rather than a true function of the C-terminal part (Fayazi et al. 2006). 
While HSPA8 is the only HSPA chaperone directly demonstrated to  interact with 
DNAJB6, it is possible that DNAJB6 could act as a co-chaperone also for other 
HSPAs.
2.6.5.2 Anti-aggregation activity
Among a wide range of heat shock proteins studied by Hageman and colleagues 
(2010), members of the DNAJB6-like cluster in the DNAJB family were unique in 
their ability to counteract protein aggregation, with DNAJB6 and its closely related 
paralogue DNAJB8 showing the highest anti-aggregation activity. As the expres-
sion of DNAJB8 is testis-specific (Hageman et al. 2010), DNAJB6 could be one of 
the most important suppressors of protein aggregation in our body.
The anti-aggregation activity of DNAJB6 is demonstrated by its effects on 
aggregation-prone proteins containing polyglutamine (polyQ) stretches (Chuang 
et al. 2002, Hageman et al. 2010). Aggregation of such proteins is inhibited by 
DNAJB6b overexpression in cell cultures and in vivo in Xenopus tadpoles, and in-
creased by DNAJB6 knockdown (Chuang et al. 2002, Hageman et al. 2010). While 
most of the experiments have utilized huntingtin fragments containing expansions 
of 119–150 glutamine residues, anti-aggregation activity has also been demonstrat-
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ed against polyQ-containing ataxin 3 and androgen receptor, as well as isolated 
polyQ peptides (Chuang et al. 2002, Hageman et al. 2010, Gillis et al. 2013). 
The anti-aggregation mechanisms of DNAJB6 and DNAJB8 have been char-
acterized by Hageman et al. (2010) and Gillis et al. (2013). Although some of the 
experimentation has only been performed with DNAJB8, the same mechanisms 
are inferred to apply for both of the proteins. DNAJB6 and DNAJB8 suppress ag-
gregation of polyQ proteins by two mechanisms. A minor, HSPA-dependent com-
ponent was concluded to reflect proteasomal degradation of the client proteins, 
and will be discussed later (Hageman et al. 2010). The major part of the anti- 
aggregation activity is, however, HSPA-independent, as it is unaffected by deletion 
of the  J-domain or by a point mutation inactivating its functional interaction with 
HSPA (Hageman et al. 2010, Gillis et al. 2013). This major anti-aggregation activ-
ity is mediated by the C-terminal part of the proteins and, as shown for DNAJB8, 
depends on deacetylation of lysine residues located near the C-terminus (Hageman 
et al. 2010). The critical residues are K216 and K223, the former having a greater 
impact on the activity. Substituting these lysines with alanines abolishes the anti-
aggregation activity, whereas substitution to arginines, mimicking the deacetyl ated 
state, retains it (Hageman et al. 2010). The corresponding residues in DNAJB6b 
are K225 and K232, the latter one specific to the DNAJB6b isoform. 
The serine-rich region, required for the anti-aggregation activity, mediates the 
interaction of DNAJB8 with the histone deacetylases (HDACs) sirtuin 2, HDAC4, 
and HDAC6 (Hageman et al. 2010). Same HDACs interact also with DNAJB6, 
and a region overlapping with the serine-rich region has been shown to be im-
portant for HDAC4 binding (Dai et al. 2005, Hageman et al. 2010). The activ-
ity of  DNAJB8 is impaired by the HDAC inhibitor trichostatin A (TSA), and by 
knockdown of HDAC4 (but not of HDAC6 or sirtuin 2), demonstrating that the 
deacetylation needed for the anti-aggregation activity is mediated by HDAC4. Also 
DNAJB6 is inhibited by TSA, but the contribution of the different HDACs has not 
been reported (Hageman et al. 2010).
DNAJB8 assembles into polydisperse oligomeric complexes, as demonstrated 
by its wide distribution in density gradient centrifugation (Hageman et al. 2010). 
This oligomerization and colocalization of DNAJB8 with huntingtin aggregates are 
abolished by deletion of the serine-rich region but not affected by HDAC inhibition 
or substitution of the acetylated lysines (Hageman et al. 2010). Based on these 
observations, Hageman et al. (2010) suggested that oligomerization increases the 
binding area and affinity of DNAJB8 and DNAJB6 towards their client proteins—
in a fashion similar to small heat shock proteins—and deacetylation takes place 
after client binding to activate the anti-aggregation function. The importance of 
the serine-rich region for client binding was directly demonstrated by Gillis et al. 
(2013), who showed that deletion of this region abolishes the strong interaction 
DNAJB6b and DNAJB68 with polyQ peptides observed in a FLIM (Fluorescence 
Lifetime Imaging Microscopy) assay. Interestingly, localization of DNAJB6b and 
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DNAJB8 in polyQ aggregates was reported by Gillis et al. (2013) to be unaffected 
by the deletions, in contrast to the findings of Hageman et al. (2010) on polyQ-
huntingtin.
DNAJB6 and DNAJB8 are not able to dissolve existing aggregates—their anti-
aggregation activity reflects the ability to keep polyQ proteins in a soluble state 
(Hageman et al. 2010). Coexpression of either DNAJB6 or DNAJB8 decreases the 
amount of polyQ peptides in aggregates while increasing it in the soluble fraction, 
suggesting interference with aggregate formation at an early stage (Gillis et al. 
2013). In line with this, nuclear DNAJB6a is able to prevent also cytoplasmic ag-
gregation of polyQ peptides, indicating that it keeps the peptides soluble and thus 
capable of moving between the two compartments (Gillis et al. 2013). Notably, 
in contrast to the freely distributing polyQ peptides, aggregation of cyto plasmic 
polyQ-huntingtin is exclusively suppressed by the DNAJB6b isoform, whereas 
DNAJB6a is effective towards polyQ-huntingtin targeted to the nucleus (Hageman 
et al. 2010).
In addition to polyQ-proteins, DNAJB6 may also possess anti-aggregation 
 activity towards other proteins. Supporting this notion, DNAJB6b has been shown 
to suppress the aggregation of heat-denatured luciferase (Hageman et al. 2011) 
and an aggregation-prone point mutant of parkin (Rose et al. 2011). While it was 
not studied whether these effects are due to the HSPA-independent anti-aggrega-
tion activity or an HSPA-mediated process, the fact that a similar effect of DNAJB2 
on parkin required a functional J-domain supports the involvement of HSPA at 
least in the latter case (Rose et al. 2011).
2.6.5.3 HSPA-dependent degradation of client proteins
Although the anti-aggregation activity of DNAJB6 is mostly independent of the 
J-domain and hence of HSPA, a functional interaction of DNAJB6 with HSPA is 
required for the maximal effect of DNAJB6 on the aggregation of polyQ-proteins. 
The contribution of HSPA was reported by Hageman et al. (2010) to be more im-
portant for a long polyQ-huntingtin construct (119Q), while it had little effect on a 
shorter (74Q) construct. The HSPA-dependent component of the anti-aggregation 
effect was similarly inhibited by deletion of the entire DNAJB6b J-domain, the 
H31Q mutation disrupting the interaction with HSPAs, and coexpression of co-
chaperones antagonizing the ATPase cycle of HSPA (BAG1 and STUB1) (Hageman 
et al. 2010). As the effect was retained in macroautophagy-deficient cells but in-
hibited by proteasomal inhibition, the lower amount of huntingtin aggregates was 
concluded to indicate the ability of DNAJB6 and HSPA to together promote degra-
dation of polyQ-huntingtin through the ubiquitin–proteasome pathway. DNAJB6 
has also been proposed to promote proteasomal degradation of keratin (Watson et 
al. 2007), but this is not supported by adequate experimental evidence.
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DNAJB6 does not support refolding of heat-denatured luciferase, suggesting 
that its general function as an HSPA co-chaperone is to promote degradation of the 
client proteins rather than refolding (Hageman et al. 2011).
2.6.5.4 Inhibition of aggregate cytotoxicity
In addition to inhibiting the aggregation of polyQ-huntingtin, DNAJB6 suppresses 
its cytotoxic effects in cultured cells, as indicated by increased cell viability and 
reduced caspase 3 activation (Chuang et al. 2002, Hageman et al. 2010). Since in-
creased viability was seen even upon prolonged polyQ expression, where aggrega-
tion was no more efficiently suppressed, the cytoprotective effect was suggested to 
be independent from the anti-aggregation activity (Chuang et al. 2002). Consistent 
with this idea, overexpression of the Drosophila DNAJB6 orthologue dMRJ has 
been reported to decrease polyQ toxicity in the fly eye and central nervous system 
without a clear effect on aggregate formation (Fayazi et al. 2006).
DNAJB6 shows irreversible localization into the core of polyQ aggregates 
(Chuang et al. 2002, Fayazi et al. 2006, Hageman et al. 2010, Gillis et al. 2013), 
and it has also been found in the core of Lewy bodies in Parkinson’s disease 
( Durrenberger et al. 2009). While this was suggested by Gillis et al. (2013) to 
 reflect the trapping of DNAJB6 molecules failed in their anti-aggregation function, 
 localization into aggregates could be also related to the role of DNAJB6 in toxicity 
suppression.
The toxic effects of polyQ depend partly on sequestration of essential pro-
teins into the aggregates (Chai et al. 1999, McCampbell et al. 2000, Shimohata 
et al. 2000, Donaldson et al. 2003). HSPA8 and DNAJB1 can together modulate 
the  aggregation of polyQ-huntingtin, promoting the formation of SDS-soluble 
amorphous aggregates instead of insoluble amyloid inclusions. These unstruc-
tured  aggregates may be more readily degraded, and show lower cytotoxicity 
due to less efficient sequestration of other proteins (Muchowski et al. 2000). Al-
though  DNAJB1 lacks the HSPA-independent anti-aggregation activity seen in the 
 DNAJB6-like cluster (Hageman et al. 2010), the cytoprotective effects of DNAJB1 
and DNAJB6 could partly be based on a similar HSPA-dependent mechanism.
The cytoprotective effect of DNAJB6 has been suggested to involve its inter-
action with MLF1 (myeloid leukemia factor 1) (Li et al. 2008). Overexpression of 
Drosophila and human MLF1 orthologues suppresses polyQ toxicity in  neurons, 
reduces the number of inclusions, and diminishes the recruitment of CBP (CREB-
binding protein; a transcriptional coactivator often sequestered to polyQ aggre-
gates) and HSPA to them (Kim et al. 2005a). When overexpressed in mouse muscles 
or COS-7 cells, MLF1 forms large intracellular aggregates that also recruit DNAJB6. 
The MLF1-overexpressing mice do not show any signs of myopathy, in line with a 
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neutral or protective role rather than a harmful role for MLF1- containing aggre-
gates (Li et al. 2008). The molecular details of the DNAJB6–MLF1 inter action and 
its exact function in neutralizing aggregate toxicity remain to be elucidated.
2.6.5.5 Maintenance of the keratin cytoskeleton
The C-terminal half of DNAJB6b interacts with keratin 18 (K18), a major acidic 
(type I) keratin in epithelial cells (Izawa et al. 2000), and DNAJB6 is essential 
for the maintenance of the keratin cytoskeleton. Overexpression of either N- or C-
terminal half of DNAJB6b causes a collapse of K18-containing filaments (Izawa et 
al. 2000). Also the DNAJB6-deficient mouse trophoblasts show disruption of the 
keratin cytoskeleton, affecting both K8/K18 and K8/K19 filaments, and contain 
perinuclear filamentous keratin aggregates. The aggregates are toxic to the placen-
tal cells and they are considered to underlie the embryonic lethality of DNAJB6 
knockout in mice (Watson et al. 2007). 
The molecular details of how DNAJB6 works to maintain the keratin filaments 
are unclear. Based on its colocalization with the 20S proteasome subunits and the 
observation that proteasome inhibition mimics the effect of DNAJB6 knockout on 
keratin cytoskeleton, DNAJB6 was suggested to mediate proteasomal degradation 
of keratin (Watson et al. 2007). However, no direct evidence exists to support this 
hypothesis. Moreover, microinjection of a DNAJB6 antibody in HeLa cells causes a 
collapse of keratin filaments already within one hour (Izawa et al. 2000). The half-
life of soluble keratin in unstressed cells has been reported to be 10 h (Jaitovich et 
al. 2008), whereas the keratin cycle, or continuous recycling of keratin sub units by 
disassembly and assembly of keratin filaments, is a considerably quicker  process 
(Kölsch et al. 2010). The rapid effect of DNAJB6 blocking could hence suggest 
participation of DNAJB6 also in keratin recycling instead of, or in addition to, 
 proteasomal degradation.
Importance of DNAJB6 for keratin maintenance in muscle is unknown. Ex-
pression of K18 has not been detected in striated muscle, but K19 forms keratin 
 filaments with K8 at the costameric regions (Abe & Oshima 1990, O’Neill et al. 
2002, Ursitti et al. 2004). While an interaction of DNAJB6 with K19 has not been 
demonstrated, the disruption of K19-containing filaments in DNAJB6 knockout 
cells suggests that DNAJB6 could regulate also this type of keratin (Watson et al. 
2007). Of note, yeast two-hybrid and co-sedimentation analyses by Izawa and 
coworkers (2000) failed to show an interaction of DNAJB6 with desmin, the most 
abundant intermediate filament protein in muscle.
Based on the observation that DNAJB6 is upregulated and assumes a localiza-
tion reminiscent of cytokeratins in mitotic cells, Dey and colleagues (2009) pro-
posed that DNAJB6 could play a role in the reorganization of the intermediate 
filament cytoskeleton during mitosis.
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2.6.5.6 Functions of DNAJB6 in signalling and gene regulation
In addition to the deacetylation of DNAJB6 required for the anti-aggregation func-
tion, the interaction of DNAJB6 and HDACs seems to play a role in transcriptional 
regulation. By interacting with HDAC4 (and other type II HDACs) and NFATc3 
through its C-terminal domain, DNAJB6b recruits HDACs to NFAT-regulated 
promoters and induces chromatin remodelling, repressing calcineurin/NFATc3-
dependent gene expression (Dai et al. 2005). DNAJB6b has been shown to block 
calcineurin-induced hypertrophy in cultured cardiomyocytes (Dai et al. 2005), 
and it could also affect the targets of calcineurin signalling, such as hyper trophic 
response and fibre type transition, in skeletal muscle. The histone demethy-
lase  ALKBH1 (Ougland et al. 2012) also interacts with the C-terminal domain of 
 DNAJB6 and competes with HDAC4 for DNAJB6 binding (Pan et al. 2008). It 
could thus functionally antagonize the repressive function of both by displacing 
HDAC4 from DNAJB6 (Pan et al. 2008) and through its own chromatin remodel-
ling activity. A role in transcriptional regulation is also suggested by the binding 
of DNAJB6b to BRMS1 (breast cancer metastasis suppressor 1), a member of the 
mSin3/HDAC transcription co-repressor complex (Hurst et al. 2006), but the im-
portance of this interaction has not been further studied.
In T-cells, DNAJB6 mediates the nuclear localization of the transcription factor 
Schlafen 1 (Slfn1), required for maintaining T-cells in a quiescent state. This in-
volves an interaction of Slfn1 with the C-terminal domain of DNAJB6. The effect is 
reproduced by constructs of the DNAJB6b isoform, but constructs sequestered to 
the cytoplasm are inefficient in this respect, suggesting that Slfn1 piggybacks to the 
nucleus with DNAJB6b (Zhang et al. 2008). DNAJB6b-overexpressing T-cells also 
show higher levels of Slfn1; this was stated by Zhang et al. (2008) to indicate that 
the co-chaperone activity of DNAJB6b stabilizes Slfn1 and inhibits its degradation, 
but the presented data were insufficient for excluding other explanations.
The only functional role so far demonstrated for DNAJB6a is the regulation of 
Wnt/b-catenin signalling, with implications on cancer biology. Advanced breast 
cancers show loss of DNAJB6a, and restoration of its expression in cancerous cell 
lines results in a phenotype shift from mesenchymal to epithelial, and diminished 
malignancy (Mitra et al. 2008, 2010). This depends at least partly on the ability 
of DNAJB6a to suppress Wnt/b-catenin signalling, important in maintaining the 
mesenchymal phenotype (Mitra et al. 2010, 2012). DNAJB6a interacts with glyco-
gen synthase kinase 3b (GSK3b) and promotes its dephosphorylation by protein 
phosphatase 2A (PP2A). This keeps GSK3b in an active state, capable of inducing 
the proteasomal degradation of b-catenin. As the effect is lost upon deletion of the 
DNAJB6a J-domain or mutation of the HPD tripeptide, and as also HSPA8 com-
plexes with both PP2A and GSK3b, it was proposed to reflect co-chaperone activity 
of DNAJB6a on HSPA8 (Mitra et al. 2012).
The significance of the stress-induced nuclear relocation of DNAJB6b (dis-
cussed in 2.6.4.1) is not known. Increase in the nuclear DNAJB6b concentration 
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could have an effect on the reported functions of this isoform in the regulation 
of gene expression. It has also been suggested to boost the nuclear functions of 
 DNAJB6a in stress situations (Andrews et al. 2012), but the apparently oppos-
ing effects of the two isoforms argue against this hypothesis. While DNAJB6a 
suppresses malignancy (Mitra et al. 2008, 2010, 2012), constitutive nuclear tar-
geting of DNAJB6b with an added nuclear localization signal causes increased 
clono genicity and proliferation, and invasive morphology in cultured cancer cells 
( Andrews et al. 2012).
DNAJB6 knockout mouse embryos show neural tube defects, and a reduction 
in the number and proliferation of neural stem cells, indicating that DNAJB6 is 
required for efficient self-renewal of neural stem cells (Watson et al. 2009). The 
molecular mechanism for this function and the identity of the relevant DNAJB6 
isoform remain unknown, but based on phenotypic similarities and gene expres-
sion changes, defective Notch signalling was proposed as a possible mechanism 
(Watson et al. 2009). As β-catenin signalling is also involved in stem cell self- 
renewal (Kalani et al. 2008), its deregulation could be a plausible explanation for 
the observed effect of DNAJB6 deficiency. Of note, GSK3β—acting through both 
β-catenin and NFATc3—affects also the self-renewal and differentiation of muscle 
satellite cells (Perez-Ruiz et al. 2008, van der Velden et al. 2008), and DNAJB6 
could thus play a role in muscle development and regeneration.
2.6.5.7 Functions of DNAJB6 in muscle
No specific functions in striated muscle have been previously established for 
 DNAJB6. In a recent yeast two-hybrid study by Blandin and coworkers (2013), 
aiming to elucidate the interactome network of proteins underlying LGMDs, high-
confidence interactions were identified between DNAJB6 and several muscle 
 proteins. Novel interaction partners included ANKRD1, myosin-binding protein C, 
myomesin 1, phosphoglucomutase 1, titin, dysferlin, and γ-sarcoglycan (Blandin et 
al. 2013); these could represent DNAJB6 clients or proteins involved in the regula-
tion of DNAJB6 in muscle.
2.7 Welander distal myopathy (WDM)
Welander distal myopathy (WDM, MIM #604454) is an autosomal dominant 
 distal myopathy described by Lisa Welander in 72 Swedish families (Welander 
1951). Linkage to 2p13 was established in 1999 (Åhlberg et al. 1999), but before 
this study the causative mutation remained unknown.
The mutation underlying WDM was identified by our group in the RNA-binding 
protein TIA1 and reported in publication III. The only known mutation,  accounting 
for all the described cases in Sweden and Finland, is the missense change c.1150G>A 
(RefSeq NM_022173.2) located in exon 13 of TIA1 (III). The mutation affects the 
third last amino acid of TIA1, causing a p.E384K (RefSeq NP_071505.2) change 
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of a conserved glutamate residue in the prion-related domain of the protein (III). 
The mutation has a semi-dominant effect: heterozygotes develop typical WDM, 
whereas homozygotes are more severely affected (III, Welander 1957,  Åhlberg et 
al. 1999).
WDM is most prevalent in central and northern parts of Sweden. The frequency 
in Sweden is 1/10,000, and regionally as high as 1/70 (Åhlberg et al. 1999), whereas 
the approximate frequency in Finland is >2/100,000 (Bjarne Udd, personal com-
munication). Outside Sweden and Finland, one family in Great Britain has been 
confirmed with the same mutation (III). From the length of linkage disequilibrium, 
Klar et al. (2013) estimated the age of the WDM mutation to be ~1050 years.
2.7.1 Clinical picture of WDM
WDM has a late onset, typically after 40 years of age. The symptoms start usually 
with weakness of finger extensor muscles, causing first clumsiness in fine motor 
tasks and then inability to extend the fingers. Symptoms progress slowly to other 
distal muscles, finally involving all small muscles in hands and feet, and long ex-
tensor muscles in forearms and legs. Weakness in the lower leg, tibialis anterior in 
particular, impairs ankle dorsiflexion and causes difficulty in walking. Involvement 
of posterior muscles in the lower leg is frequently identified on muscle MRI, but 
is usually subclinical. Proximal muscles are rarely affected, and cardiomyopathy, 
dysphagia, or respiratory failure never occur (Welander 1951, Borg et al. 1998, Udd 
2013). The few described homozygous patients show a more severe disease with 
early onset (around 30 years), clear proximal involvement, and faster progression 
leading to loss of walking ability (Welander 1957, Åhlberg et al. 1999).
Some studies have suggested neural involvement in WDM (Borg et al. 1987, 
1989, 1991a). However, nerve conduction velocities are normal, and clear electro-
physiological signs of a neuropathy are absent even in homozygous patients (Bjarne 
Udd, personal communication), indicating that the muscle pathology in WDM is 
of myogenic origin.
2.7.2 Muscle pathology in WDM
Histopathology of WDM muscle shows typical myopathic changes such as internal 
nuclei, split fibres, fibre size variation, and fibre atrophy affecting both slow and 
fast fibres. Rimmed vacuoles are a typical finding, and they are present in both 
normal-sized and atrophic fibres (Åhlberg et al. 1994, Borg et al. 1998).
Electron microscopy of WDM muscle reveals autophagic vacuoles—ultra-
structural correlates of rimmed vacuoles. Tubulofilamentous inclusions composed 
of randomly dispersed or parallel filaments of 15–20 nm are found in association 
with the autophagic vacuoles, and less frequently in nuclei. Also fingerprint  bodies, 
honey comb structures, dense accumulations of Z-disc material, Z-disc stream-
ing, and mitochondrial abnormalities have been reported (Borg et al. 1991b, 1993, 
1998).
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2.8 TIA1
TIA1 is an RNA-binding protein with multiple functions in regulation of splic-
ing, RNA metabolism, and protein expression. It was initially described as “T-cell 
 restricted intracellular antigen”, a component of cytolytic granules of T-cells 
( Anderson et al. 1990). This was, however, based on misinterpretation of GMP-17 
as “p15-TIA1”, a splice variant or proteolytic product of the full-length “p40-TIA1” 
(Anderson et al. 1990, Medley et al. 1996). TIA1 immunoreactivity is still persist-
ently utilized in T-cell classification; such literature most likely irrelevant to the 
true functions of TIA1 will be excluded from the following review.
TIA1 shares its domain structure and many of its functions with its close homo-
logue TIAL1 (TIA1-like; also known as TIAR, TIA1-related protein) (Kawakami et 
al. 1992). The two will be here collectively referred to as the “TIA proteins”.
2.8.1 Structure of the TIA proteins
The TIA1 protein (shown schematically in Fig. 6) is composed of three RNA-binding 
domains (RNA recognition motifs, RRM), followed by a C-terminal glutamine-rich 
prion-related domain (PRD) (Tian et al. 1991, Kedersha et al. 1999). Two variants 
are generated through alternative splicing. The long isoform TIA1a ( designated 
splice variant 2; RefSeq NP_071505) contains 386 amino acids and has a theoreti-
cal molecular weight of 43.0 kDa. Exclusion of 11 amino acids, encoded by exon 5 
between the first two RRMs produces the short isoform TIA1b of 375 amino acids 
/ 41.8 kDa (splice variant 1; RefSeq NP_071320) (Tian et al. 1991, Kawakami et al. 
1994).
TIA1 and TIAL1 are highly similar in sequence, showing amino acid identity 
of ~80% in the whole sequence and ~50% in the prion-related domains. The two 
TIAL1 isoforms, TIAL1a of 392 amino acids (RefSeq NP_001029097) and TIAL1b 
of 375 amino acids (RefSeq NP_003243), are distinguished by a 17-amino-acid in-
sertion within the first RRM (Kawakami et al. 1992, Izquierdo & Valcárcel 2007a).
a: 386 aa / 43 kDa
b: 375 aa / 42 kDa
interaction with U1-C → splicing regulation
RNA binding
WDM mutation E384K
TIA1a-specific 11 aa
aggregation →
stress granule formation
RRM1N CRRM2 RRM3 PRD
Figure 6. Structure of TIA1
The TIA1 protein comprises three RNA-binding motifs (RRM1–3) followed by a glutamate-rich prion-
related domain (PRD). The WDM-causing mutation is located in the C-terminus of PRD. The region 
encoded by TIA1 exon 5, excluded from the TIA1b isoform, is shown in grey.
Adapted from Hackman et al. Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1. Annals of Neurology 
73(4): 500–509, 2013 © 2012 American Neurological Association. The material is adapted with permission of John Wiley & Sons, Inc.
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2.8.2 Expression and localization of TIA1
2.8.2.1 Tissue distribution
By western blotting of proteins immunoprecipitated with a TIA1/TIAL1 antibody 
from mouse tissue extracts, Beck et al. (1996) showed strong TIA1 expression in 
brain, spleen, and testis, while other analyzed tissues—including skeletal  muscle—
showed very low or absent signal. In contrast, WB analysis of human tissues 
(Izquierdo & Valcárcel 2007a) indicated a wider distribution: TIA1 protein was 
detected, at different levels, in virtually all analyzed tissues. In skeletal muscle, 
protein expression was moderate. On the mRNA level, northern blotting and RT-
PCR have shown TIA1 expression in several murine and human tissues, with no 
good correlation to protein expression levels. Both methods detected relatively low 
levels of TIA1 mRNA in skeletal muscle (Beck et al. 1996, Izquierdo & Valcárcel 
2007a). Given the universal functions of TIA1, and the observation that either TIA1 
or TIAL1 is required for cell viability (see 2.8.3.), expression of TIA1 at least on a 
basal level is likely to be more or less ubiquitous.
In most tissues and cells, the two TIA1 isoforms have been detected in a rough 
1:1 ratio (Beck et al. 1996, Izquierdo & Valcárcel 2007a). A notable exception is 
made by the HeLa cells, reported to predominantly express the TIA1a isoform 
(Izquierdo & Valcárcel 2007a).
2.8.2.2 TIA1 in muscle
The expression of TIA1 in muscle has not been specifically characterized. Masuda 
et al. (2009) studied the expression of RNA-binding proteins in different human 
tissues by immunohistochemistry on tissue microarrays. TIA1 expression was re-
ported to be relatively high in fetal skeletal muscle but decline during aging. Both 
the number of TIA1-expressing cells and the relative expression level in these cells 
showed a decrease, and less than 10% of cells in middle-aged and old subjects were 
scored as TIA1-positive. However, as the published results only included numerical 
expression scoring based on automated image analysis, the reliability of these data 
cannot be evaluated.
A study comparing the gene expression patterns in human post mortem muscle 
samples (Kang et al. 2005) reported TIA1 as a part of the expression signature of 
tibialis anterior (TA) in paediatric samples —i.e. TA showed higher TIA1 expres-
sion compared to the other analyzed muscles (gastrocnemius, quadriceps  femoris, 
and deltoideus). Although the detailed expression patterns in other muscles remain 
to be elucidated, the result indicates that TIA1 expression may vary significantly 
between muscles. The differential expression could have pathological relevance for 
WDM, and it could also explain the variability of the published results concerning 
TIA1 expression in muscle.
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2.8.2.3 Subcellular localization
TIA1 shuttles continuously between the nucleus and the cytoplasm (Kedersha et al. 
1999, Zhang et al. 2005). The localization in unstressed cells is primarily nuclear, 
but in response to cellular stress TIA1 quickly moves to the cytoplasm (Kedersha 
et al. 1999, 2000). The nuclear import requires RRM2 and the N-terminal half 
of PRD and is mediated by a Ran-GTP-dependent mechanism, whereas nuclear 
export is mediated by binding to target RNAs via RRM3 (Zhang et al. 2005). The 
re location to cytoplasm has been proposed to result from inactivation of nuclear 
import ( Kedersha et al. 1999), but the exact mechanisms have not been reported.
2.8.3 Importance of the TIA proteins for life
TIA1 knockout mice show partial embryonic lethality, but the surviving mice have 
normal life span and fertility (Piecyk et al. 2000). Of TIAL1 knockout mice, a high-
er proportion dies in utero, and survivors are sterile due to defective germ cell 
development affecting both sexes (Beck et al. 1998). The fact that single knock-
outs have deleterious effects with somewhat different phenotypes indicates that 
the functions of the two TIA proteins are at least partly separate, and loss of one 
cannot totally be compensated by the other (Piecyk et al. 2000).
In contrast to partly viable single knockouts, mice lacking both TIA proteins 
show early embryonic lethality (Piecyk et al. 2000). Similarly, chicken DT40 cells 
expressing either TIA1 or TIAL1 are viable, but disruption of both genes causes cell 
death unless TIA1 is ectopically expressed. This demonstrates that the proteins are 
partly redundant, and also suggests that the double knockout causes lethality in 
mice through a direct effect on cell viability rather than through interfering with 
developmental functions of the TIA proteins (Le Guiner et al. 2003).
2.8.4 Stress granules
TIA1 and TIAL1 are key components of stress granules (SGs)—cytoplasmic foci 
of mRNPs (messenger ribonucleoprotein particles)—that coordinate RNA meta-
bolism and protein synthesis in situations of cellular stress. SG formation can 
 occur in various types of stress such as heat shock, oxidative stress, starvation, ER 
stress, UV irradiation, ischemia, and cold stress. In experimental setups, an estab-
lished tool for SG induction is oxidative stress caused by sodium arsenite treatment 
( Anderson & Kedersha 2008, Buchan & Parker 2009, Thomas et al. 2011,  Hofmann 
et al. 2012). Microscopically visible SGs appear in 15–30 minutes after stress on-
set, and they gradually fuse into larger granules, typically a few micro meters in dia-
meter. During recovery from stress, SGs dissolve within 60–90  minutes (Kedersha 
et al. 2000, Anderson & Kedersha 2008). 
The defining components of SGs are non-translating preinitiation complexes, 
containing mRNA, small ribosomal subunits, early initiation factors, and poly-A 
binding protein 1 (PABP1). Beyond that, molecular composition of SGs can vary 
over time and in different types of stress. In total tens of different proteins have 
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been observed in SGs, many of them involved in regulation of mRNA stability and 
trans lation (Anderson & Kedersha 2008, Buchan & Parker 2009, Thomas et al. 
2011). 
Rather than static RNP aggregates, SGs are highly dynamic: proteins and 
mRNA continuously shuttle between SGs and the cytosol. Fluorescence recovery 
after photobleaching (FRAP) studies have indicated SG residence times of seconds 
to minutes for many of the protein components, as well as for reporter mRNAs 
(Kedersha et al. 2000, 2005, Mollet et al. 2008, Buchan & Parker 2009). TIA1 is 
among the most mobile SG proteins, showing ~90% fluorescence recovery within 
10 s after bleaching (Kedersha et al. 2000).
The dynamic nature of SGs is reflected in their ultrastructure lacking clear 
boundaries or defined internal structure. In electron microscopy, SGs appear as 
loosely organized, moderately electron-dense areas with fibrillo-granular fine 
structure that can be intermingled with cytoplasmic patches (Souquere et al. 
2009). IF microscopy has also indicated that individual SGs are heterogeneous in 
structure, with different components localizing to partially separate microdomains 
(Baguet et al. 2007).
2.8.4.1 Stress granule assembly and disassembly
A dynamic equilibrium exists between actively translated polysome-associated 
mRNPs, and SG-associated untranslated ones. SG formation is hence driven by 
any factor that causes cytoplasmic accumulation of non-translating (stalled) 
mRNPs (Kedersha et al. 2000, Anderson & Kedersha 2008). Stalling is usually due 
to reduced availability of the eIF2–GTP–tRNAi
Met ternary complex, required for 
normal translation initiation. This can be caused indirectly through phosphoryla-
tion of eIF2a in response to cellular stress, or possibly as a direct consequence of 
reduced GTP/GDP ratio in energy depletion (Kedersha et al. 1999, 2002, Anderson 
&  Kedersha 2002a). In the absence of the active ternary complex, translation ini-
tiation is in hibited, ribosomes run off the transcripts after completing their round 
of translation, and transcripts are stalled as non-canonical 48S* preinitiation com-
plexes devoid of eIF2 (Kedersha et al. 2002). SG formation can be also triggered 
independently of eIF2 phosphorylation by inhibiting translation initiation at a 
later stage, e.g. by interfering with functions of eIF4s (Dang et al. 2006, Mazroui et 
al. 2006). In  either case, untranslated mRNPs accumulate as stalled preinitiation 
complexes that are then assembled into SGs (Anderson & Kedersha 2008).
SG assembly is mediated by RNA-binding proteins capable of controlled 
 aggregation, among them the TIA proteins. According to a model proposed by 
 Anderson & Kedersha (2008), SG formation is initiated by recognition of stalled 
mRNPs by various of such SG-nucleating proteins, each binding preferentially to 
a subset of transcripts. Homotypic aggregation of the proteins assembles mRNPs 
into sub microscopic aggregates, which are then clustered into larger, microscopi-
cally visible SGs by heterotypic interactions between SG-nucleating proteins, and 
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by  association of some RBPs with multiple classes of transcripts (Anderson & 
 Kedersha 2008). Other proteins needed for SG functions are recruited by their 
interactions with RNA and the protein components (Anderson & Kedersha 2008). 
SG assembly and disassembly depend partly on active transport mediated by 
 molecular motors: both processes are perturbed by disruption of microtubule or 
microfilament cyto skeleton, or by depletion of motor proteins (Loschi et al. 2009, 
Thomas et al. 2011).
2.8.4.2 TIA1 in stress granules
TIA1 is the most extensively studied, and perhaps the most important, of SG-nucle-
ating proteins. The TIA1 self-assembly driving SG nucleation is mediated by homo-
typic aggregation of its prion-like domain, demonstrated by the fact that TIA1 lack-
ing the PRD is incapable of SG formation (Gilks et al. 2004). On the other hand, 
overexpressed PRD—capable of oligomerization but not of RNA binding— inhibits 
SG formation in arsenite-treated cells, likely by sequestering endogenous TIA 
proteins into insoluble microaggregates. (Kedersha et al. 1999, Gilks et al. 2004). 
The finding that PRD overexpression, while not affecting the solubility of other 
SG markers, inhibits formation of all eIF3-containing SGs (rather than a TIA1-
dependent subset) suggests a critical role for the TIA proteins in arsenite-induced 
SG formation (Gilks et al. 2004).
Although TIA1 and TIAL1 have been considered as invariant SG components 
(Kedersha et al. 1999), it is now known that neither protein is absolutely neces-
sary for SG formation. Cells depleted of TIA1 by RNAi can still assemble SGs in 
response to arsenite, heat shock, or the eIF4F inhibitor pateamine A (López de 
Silanes et al. 2005, Dang et al. 2006). Studies on embryonic fibroblasts derived 
from TIA1 knockout mice have, on the other hand, indicated impaired SG forma-
tion, with majority of the cells showing morphologically abnormal small SGs (Gilks 
et al. 2004, Dang et al. 2006). In yeast, the TIA1 orthologue Pub1 is required for 
SG assembly in response to glucose deprivation but not to heat shock (Buchan et 
al. 2008, Groušl et al. 2009). With regard to SG formation, TIAL1 seems to be less 
 important than TIA1:  Embryonic fibroblasts from TIAL1 knockout mouse show 
even enhanced SG formation, likely due to the compensatory TIA1 upregulation 
seen in the cells (Gilks et al. 2004).
The mechanisms by which different types of stress trigger TIA1 aggregation 
are not completely known. Aggregation could partly depend on the stress-induced 
increase of the cytoplasmic TIA1 concentration. However, SG formation can take 
place without a parallel change in the TIA1 distribution, demonstrating the impor-
tance of other factors (López de Silanes et al. 2005). Possible mechanisms pro-
posed to regulate TIA1 aggregation are based on the observation that HSPA1 inhib-
its aggregation of the TIA1 PRD (Gilks et al. 2004). In energy depletion, a shortage 
of ATP could decrease the ATP-dependent chaperone activity of HSPA1 and lead to 
TIA1 aggregation (Gilks et al. 2004). On the other hand, in cellular stress situations 
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causing protein denaturation such as heat shock or oxidative stress, cytoplasmic 
accumulation of unfolded proteins has been suggested to allow SG formation by 
diverting HSPA1 away from TIA1 (Anderson & Kedersha 2008).
2.8.4.3 Other central proteins in stress granule formation
In addition to TIA1 and TIAL1, a number of other proteins can nucleate SGs and 
modu late their assembly. Many of these are interaction partners of the TIA proteins.
The SMN (survival of motor neurons) protein interacts with TIA1 at least in-
directly, as demonstrated by coimmunoprecipitation of the two proteins. SMN has 
been proposed to initiate SG assembly, since its recruitment to SGs following stress 
precedes TIA1, and SMA (spinal muscular atrophy) cells lacking the functional full-
length protein show impaired SG formation (Hua & Zhou 2004).
RSK2 (ribosomal S6 kinase 2) interacts with the PRD of TIA1 in a manner 
 dependent on its kinase activity. As RSK2 is stably localized to SGs in stressed breast 
cells, and as knockdown of RSK2 or inhibition of its kinase activity decreases SG for-
mation, it has been suggested to act as an important regulator of SG formation and 
a scaffolding protein for other SG components (Eisinger-Mathason et al. 2008).
The helicase/endoribonuclease G3BP1 (RasGAP-binding protein 1; often re-
ferred to as G3BP), whose oligomerization is regulated by stress-induced Ras-
dependent dephosporylation, has been considered a central SG nucleator, as its 
overexpression causes SG formation (Tourrière et al. 2003). However, the recent 
results of Aulas et al. (2012) indicate a role for G3BP1 in SG fusion rather than 
nucleation. The homologous G3BP2 protein hetero-oligomerizes with G3BP1, and 
depletion of both severely impairs SG formation, suggesting that the two proteins 
have overlapping functions (Matsuki et al. 2013).
TARDBP (TAR DNA-binding protein, also known as TDP-43) associates 
with SGs in several cell types (Colombrita et al. 2009, Liu-Yesucevitz et al. 
2010,  McDonald et al. 2011). It binds TIA1 in an overexpression setup, but with 
physio logical protein concentrations the interaction may be RNA-dependent 
( Liu-Yesucevitz et al. 2010). TARDBP depletion has been reported to inhibit SG 
formation in HeLa and SK-N-SH cells, resulting in smaller, less defined SGs that 
fail to fuse and dissolve more quickly. This effect of TARDBP knockdown seems to 
be partly mediated by its negative effect on G3BP expression, but the protein may 
also play a direct role in SG formation (McDonald et al. 2011, Aulas et al. 2012). 
In the NSC34 moto neuronal cell line, TARDBP knockdown was not found to  affect 
SG formation (Colombrita et al. 2009), suggesting differences in SG assembly be-
tween cell types.
2.8.4.4 Functions of stress granules
As SG formation parallels stress-induced translational repression, SGs were 
first thought to mediate this silencing (Kedersha et al. 1999). However, general 
stress-induced repression does not require SG formation, and translation can be 
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restored without SG disassembly (Buchan et al. 2008, Loschi et al. 2009). More-
over, TIA1 silences translation of ARE (AU-rich element) -containing mRNAs both 
in unstressed and stressed cells (López de Silanes et al. 2005), and the silencing 
of 5’TOP (5’-terminal oligopyrimidine tract) mRNAs by TIA1 is not dependent on 
its aggregation capacity (Damgaard & Lykke-Andersen 2011). SGs are hence not 
the effectors of TIA1-mediated translation repression, a process discussed in more 
 detail below.
SGs are intimately connected to processing bodies (P-bodies; PB), RNP gran-
ules involved in mRNA decapping and 5’–3’ decay. As SGs and PBs share many of 
their components and intermediates can exist in some organisms, they have been 
suggested to constitute a continuum of mRNP granules (Buchan & Parker 2009, 
Thomas et al. 2011). PBs frequently form juxtaposed to existing SGs and vice versa, 
and the two types of granules can transiently dock with each other (Kedersha et 
al. 2005, Buchan et al. 2008, Mollet et al. 2008). Similarly to SGs, proteins move 
rapidly between PBs and cytoplasm (Kedersha et al. 2005).
The dynamic nature and the physical connection of the mRNP granules have 
led to the idea of a cytoplasmic mRNA cycle, or shuttling of mRNAs between poly-
somes, SGs, and PBs. In this model, the rates of translation initiation and termina-
tion, and association with SG and PB components affect the distribution of mRNAs 
between the different compartments, and remodelling taking place in the SGs and 
PBs determines whether the mRNP is returned to translation, stored, or degraded 
(Parker & Sheth 2007, Buchan & Parker 2009).
The roles of SGs and PBs and the directions of mRNP movement in the mRNA 
cycle are not established. Anderson & Kedersha (2002a, 2008) have proposed that 
SGs function as triage centres, where fates of untranslated mRNAs are determined 
by their interactions with stabilizing or destabilizing proteins. As the association 
of SGs and PBs is increased by overexpression of the mRNA-decay-promoting 
proteins TTP (tristetraprolin) and BRF1 (butyrate response factor 1), the docking 
has been suggested to mediate mRNA transfer from SGs for degradation in PBs 
( Kedersha et al. 2005).
On the other hand, Buchan & Parker (2009) have favoured a view where the 
triage takes place in PBs, and the primary movement of mRNPs is from PBs to SGs. 
In such a model, the function of SGs could be to modulate local concentrations of 
 mRNAs and proteins, thereby affecting their interactions and reaction rates. High 
concentrations of mRNPs and associated proteins would promote their reactions in 
SGs, whereas depletion of selected molecules from the cytosol would inhibit some 
reactions and retarget the limited resources, e.g. initiation factors, to the most es-
sential reactions (Parker & Sheth 2007, Buchan & Parker 2009). Specifically, SGs 
have been proposed to function as regions of enhanced translation initiation, as 
suggested by high concentrations of preinitiation complex components (Parker & 
Sheth 2007, Buchan & Parker 2009). Localization of silenced mRNAs into SGs 
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(López de Silanes et al. 2005, Damgaard & Lykke-Andersen 2011), however, argues 
against their role in translation initiation.
SGs have also functions unrelated to RNA metabolism, primarily acting 
through sequestration of proteins involved in stress signalling. Hence, SGs have 
been suggested to integrate and modulate stress response pathways (Anderson & 
Kedersha 2008). Sequestration of TRAF2 (TNF-a receptor associated factor 2) and 
ROCK1 (Rho-associated, coiled-coil containing protein kinase 1) into SGs blocks 
their association with downstream effectors, inhibiting proinflammatory and pro-
apo ptotic signalling (Kim et al. 2005b, Tsai & Wei 2010). Nuclear localization of 
RSK2 depends on its interaction with TIA1, and tight association with SGs inhib-
its its nuclear functions involved in regulation of cell proliferation and survival 
(Eisinger-Mathason et al. 2008). Finally, a recent study identified a role for SGs in 
redox regulation: the antioxidant activity of USP10 (ubiquitin-specific protease 10) 
is inhibited in unstressed cells by G3BP1, but localization of both proteins into SGs 
lifts the inhibition (Takahashi et al. 2013).
2.8.5 TIA1 as a translation regulator
TIA1 and TIAL1 are potent translation repressors, acting generally on most or all 
mRNA species, and specifically on mRNAs containing certain target sequence ele-
ments on their untranslated regions. As discussed above, this repressive activity is 
not dependent on stress granules, although silenced transcripts can localize to SGs.
The general translation-repressing function of TIA1 is demonstrated by its abil-
ity to inhibit the expression of cotransfected reporter genes (Kedersha et al. 2000). 
The repressive activity is thought to reflect functional antagonism with eIF2, as-
sociation of TIA1 with the mRNA 5’ region producing a translationally incompe-
tent initiation complex. TIA1 has been suggested to compete for mRNA binding 
with initiation factors, possibly the eIF2–GTP–tRNAi
Met ternary complex. The 
same competitive binding would hence account for TIA1-mediated repression, 
and recruitment of untranslated mRNAs to SGs (Anderson & Kedersha 2002a). 
In line with translation suppression occurring at the initiation stage, TIA1 is ex-
cluded from polysomes (Kedersha et al. 2000), and TIA1 depletion increases the 
polysome-associated fraction of its target mRNAs (Piecyk et al. 2000, Damgaard 
& Lykke-Andersen 2011).
2.8.5.1 TIA1 target sequences
AREs (adenine/uridine-rich elements) are regulatory sequence elements that con-
trol gene expression by decreasing the stability and translation efficiency of the 
mRNA transcript. They are typically composed of overlapping tandem repeats of 
the AUUUA pentamer present on 3’UTRs. Up to 10% of human genes contain AREs, 
but they are enriched in mRNAs requiring tight and rapid regulation such as those 
encoding cytokines (Halees et al. 2008). The TIA proteins bind AREs and suppress 
the translation of the respective transcripts; an effect first described for TNFa 
69
(tumor necrosis factor a) and COX-2 (cyclooxygenase 2; PTGS2, prosta glandin-
endoperoxide synthase 2) (Gueydan et al. 1999, Piecyk et al. 2000, Dixon et al. 
2003). The preferential silencing of ARE-containing transcripts implicates the TIA 
proteins in the regulation of genes involved in processes like apoptosis, inflam-
mation, and proliferation. Indeed, TIA1 knockout mice have a hyper inflammatory 
phenotype with increased cytokine production, and they develop arthritis (Piecyk 
et al. 2000, Phillips et al. 2004). TIA1 is also established as an apoptosis regulator; 
this function will be addressed in 2.8.7.
Sequence analysis of transcripts coimmunoprecipitated with TIA1 (López de 
Silanes et al. 2005) identified a recognition motif on TIA1 target mRNAs. This 
 motif of 30–37 nucleotides—termed URSL (uridine-rich stem-loop) by Yamasaki 
et al. (2007)—has a U-rich 5’ segment and an AU-rich 3’ segment, and forms a bent 
stem-loop structure. The URSL allows TIA1 binding to reporter mRNAs, and TIA1 
depletion increases expression of endogenous mRNAs containing the motif (López 
de Silanes et al. 2005). Whether the URSL alone is sufficient to induce silencing of 
the transcript, has not been investigated. The URSL was reported to exist on ~3% 
of transcripts in UniGene database, with enrichment in 3’UTRs. As it was present 
only on a subset of the analyzed TIA1-binding transcripts, other similar recogni-
tion motifs may exist (López de Silanes et al. 2005). The URSL was also found on 
TNFa and COX-2 transcripts. However, its relationship with the ARE  elements 
was not discussed (López de Silanes et al. 2005), and it is unclear whether the 
URSL-containing transcripts represent a subset of the ARE mRNAs, or a partially 
overlapping group of TIA1 target transcripts.
The silencing effect of 3’UTR sequences has been proposed to be mechanis-
tically similar to the general TIA1-mediated repression: association of TIA1 with 
the 3’UTR could increase its likelihood of binding to the initiation site, thereby 
enhancing its repressive activity (Anderson & Kedersha 2002b).
Another group of target mRNAs for TIA1-mediated silencing are those con-
taining a 5’TOP (5’-terminal oligopyrimidine tract). These mRNAs, encoding ribo-
somal proteins and translation factors, are highly expressed in unstressed cells. 
Their translation is selectively repressed during amino acid starvation or cell 
 cycle arrest, allowing the cell to drive down energetically demanding protein bio-
synthesis when resources are limited. TIA1 and TIAL1 were recently identified as 
effectors of this starvation-induced silencing (Damgaard & Lykke-Andersen 2011). 
Starvation increases binding of the TIA proteins to the characteristic oligopyrimi-
dine tracts on the 5’UTRs of the transcripts, inhibiting translation initiation. This 
leads to polysome dissociation and assembly of the untranslated target mRNAs to 
SGs. The detailed molecular mechanism of increased TIA1/TIAL1 binding is not 
known, but it requires activation of GCN2 and inactivation of the mTOR (mamma-
lian target of rapa mycin) pathway. Effects of TIA1 and TIAL1 on the 5’TOP mRNAs 
are redundant, but the effect of TIA1 is somewhat stronger (Damgaard & Lykke-
Andersen 2011).
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2.8.5.2 Multiple levels of regulation
The repressive action of TIA1 takes typically place at the translation level, as 
demonstrated by unaltered mRNA levels of its target genes (Piecyk et al. 2000, 
Dixon et al. 2003). However, TIA1-mediated silencing and polysome disassembly 
have also been reported to promote rapid decay of a subset of target mRNAs and 
TIA1-tethered reporter mRNA. This was proposed to depend on simultaneous or 
 sequential action of proteins regulating RNA stability, such as TTP, but the molec-
ular determinants for mRNA destabilization are not known (Yamasaki et al. 2007). 
Moreover, RNAi knockdown of both TIA proteins has been shown to cause changes 
both in steady-state levels and turnover rates of mRNAs (Reyes et al. 2009). In 
addition, TIA1 and TIAL1 have been suggested to regulate gene expression by sup-
pressing transcription, based on increased steady-state levels of many mRNAs and 
enhanced reporter gene induction in HeLa cells depleted of both proteins (Reyes 
et al. 2009)
The activity of TIA1 can be modulated by its interactions with other proteins. 
Inter actions of SRC-3 (steroid receptor cofactor 3) with the PRDs of TIA1 and TIAL1 
enhance their binding to AREs and promote their repressive function (Yu et al. 
2007). FASTK (Fas-activated serine/threonine kinase; also known as FAST, Fas-
activated serine/threonine phosphoprotein), an interaction partner of TIA1 PRD, 
increases expression of cotransfected and endogenous genes. As this effect is medi-
ated by the TIA1-interacting N-terminal part of the protein and inhibited by TIA1 
cotransfection, binding to FASTK was proposed to inhibit the translation repres-
sion activity of TIA1 (Li et al. 2004). However, a recent study identified FASTK as 
an eIF4E-binding protein, suggesting that FASTK, eIF4E, and TIA1 actually form a 
translation-inhibiting complex that prevents recruitment of eIF4G to the preinitia-
tion complex, and at the same time stabilizes mRNA by inhibiting its decapping. 
The apparent antagonistic effects of overexpressed FASTK and TIA1 could be ex-
plained by altered assembly or regulation of this complex (Li et al. 2013).
2.8.6 TIA1 as a splicing regulator
In the nucleus, both TIA proteins have been established to act as splicing regula-
tors. As the two proteins bind to the same intronic regions, their functions in splic-
ing have been suggested to be largely redundant (Wang et al. 2010). 
TIA1 exerts its effects on splicing by multiple mechanisms. The first and best 
characterized is its ability to activate weak 5’ splice sites (5’ss) immediately fol-
lowed by a U-rich sequence stretch (Del Gatto-Konczak et al. 2000, Le Guiner et al. 
2001, Förch et al. 2002, Gesnel et al. 2007). Binding of TIA1 to the U-rich  sequence 
recruits U1 snRNP to the 5’ss, thus promoting the inclusion of the weakly defined 
upstream exon. Binding of TIA1 and U1 snRNP to the mRNA is cooperative: asso-
ciation of TIA1 with the U-rich sequence is enhanced by an adjacent 5’ss or tether-
ing U1 snRNP to the vicinity, and impaired by depletion of U1 snRNA (Del Gatto-
Konczak et al. 2000, Gesnel et al. 2007). The binding of TIA1 to U1 snRNP depends 
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on a direct interaction between the TIA1 PRD and U1-C, a protein component of 
the snRNP, and also RRM1 contributes to U1-C binding and enhances U1 snRNP 
recruitment (Förch et al. 2002).
FASTK-mediated phosphorylation of TIA1 enhances U1 snRNP recruitment 
without affecting the RNA-binding properties of TIA1 (Izquierdo & Valcárcel 
2007b). Phosphorylation is known to occur during proapoptotic signalling (Tian 
et al. 1995), with implications on apoptosis regulation (discussed below), but its 
importance in other situations has not been reported.
While first studies focused on the effect of the TIA proteins on specific exons, 
more recent studies have suggested widespread involvement of the TIA proteins in 
the splicing of both alternative and constitutive exons (Aznarez et al. 2008, Wang 
et al. 2010). A large-scale bioinformatics analysis of intron sequences revealed en-
richment of U-rich motifs downstream of constitutive and alternative exons, par-
ticularly those where other splicing signals are weak (Aznarez et al. 2008). This was 
corroborated by transcriptome-wide mapping of RNA sequences immunoprecipi-
tated with TIA proteins, directly showing extensive association of TIA1 and TIAL1 
with U-rich sequences in 5’ ends of introns (Wang et al. 2010). The proportion of 
alternatively spliced cassette exons regulated by TIA proteins has been estimated 
to be 5–15% (Aznarez et al. 2008, Wang et al. 2010).
Knockdown experiments have supported the widespread functional signifi-
cance of TIA proteins in splicing. Depletion of TIA1 and TIAL1 in HeLa cells causes 
increased skipping in a majority of those alternative cassette exons that are fol-
lowed by a U-rich downstream sequence (Aznarez et al. 2008, Wang et al. 2010). 
The effect of TIA is correlated with the uridine content of the downstream sequence 
and the distance of the U-rich motifs from the 5’ splice site (Aznarez et al. 2008).
Analysis of TIA-depleted cells with a splice-junction microarray demonstrated 
that TIA proteins can also regulate variable-length exons by affecting the choice of 
alternative splice sites, and suppress the inclusion of the downstream alternative 
exons (Wang et al. 2010). The suppressive effect was suggested to reflect altered 
splicing kinetics, with enhanced splicing of the upstream exon leaving less time for 
defining the downstream exon (Wang et al. 2010). Changes in intron retention in 
TIA-depleted cells indicated that the TIA proteins can also enhance the splicing 
fidelity of constitutive exons (Wang et al. 2010).
In addition to direct recruitment of U1 snRNP, other yet unknown mechanisms 
are involved in the splice-regulating activity of the TIA proteins. For example, it is 
unclear how overall U-richness extending beyond the immediate vicinity of the 5’ss 
enhances splicing. It has been suggested that U-richness can increase the likeli-
hood of TIA binding close to the splice site, or facilitate cooperative binding of 
multiple TIA proteins on the mRNA (Aznarez et al. 2008). In the SMN2 gene, TIA1 
promotes the inclusion of exon 7 by binding two U-rich clusters separated from 
the 5’ss by a negative cis element. In this case, TIA1 has been proposed to induce a 
contextual change in the mRNA that inhibits recruitment of negative splicing regu-
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lators such as hnRNPA1. This effect requires the N-terminal half of PRD in combi-
nation with any of the RNA-binding domains (Singh et al. 2011). Furthermore, the 
TIA1 construct lacking the RRM1 and PRD, and thus incapable of U1-C binding, 
retains some of its splice-promoting activity towards the K-SAM exon of FGFR2, 
and this activity must thus depend on yet another mechanism (Gesnel et al. 2007).
The activity of the TIA proteins in splicing can be modulated by their other 
inter actions. TIA1 and TIAL1, together with U1 snRNP and other splicing factors, 
are physically associated with RNA polymerase II. This interaction with the tran-
scription machinery is suggested to enhance cotranscriptional recruitment of splic-
ing factors to the pre-mRNA (Das et al. 2007). TIA1 has also been shown to interact 
with genomic DNA in intronal regions of the COL2A1 gene—this was proposed 
to enhance alternative splicing by slowing down transcription or by enhancing 
 recruitment of TIA1 to the transcript introns (McAlinden et al. 2007).
2.8.7 TIA1 in apoptosis
TIA1 is linked to regulation of apoptosis through many lines of evidence, related to 
its functions both in splicing regulation and in stress granules.
A direct proapoptotic function for TIA1 was suggested by the early finding that 
purified recombinant TIA1 induces DNA fragmentation when introduced to per-
meabilized thymocytes. This nucleolytic effect has been demonstrated for the full-
length TIA1b and a 15-kDa C-terminal fragment comprising the PRD (Tian et al. 
1991), and for TIAL1 (Kawakami et al. 1992). TIA1 secretion was proposed to medi-
ate induction of apoptosis in cells targeted by cytotoxic T lymphocytes (Tian et al. 
1991), but this is now known not to be the case since TIA1 does not reside in cyto-
lytic granules. The biological importance of the nucleolytic activity is unclear, but 
given the widespread functions of the TIA proteins, it may simply be a consequence 
of misregulated RNA metabolism or protein expression.
Proapoptotic functions of TIA1 are modulated by its interaction with FASTK 
by complex mechanisms. FASTK was first described as a kinase activated during 
Fas-mediated apoptosis, an apoptotic pathway initiated by trimerization of the Fas 
receptor (CD95) on the cell surface. Following Fas ligation, FASTK is dephosphor-
ylated and activated, and it in turn phosphorylates TIA1 (but not TIAL1) on a serine 
residue located within the C-terminal ~15 kDa of the protein (Tian et al. 1995). 
Phosphorylation enhances the ability of TIA1 to recruit U1 snRNP to the splice 
sites, hence stimulating exon inclusion (Izquierdo & Valcárcel 2007b). An experi-
mentally demonstrated consequence is increased inclusion of FAS exon 6, lead-
ing to the production of the membrane-bound Fas receptor instead of the soluble 
decoy receptor. This implies a positive feedback loop, where proapoptotic signal-
ling further increases the expression of Fas on the plasma membrane (Izquierdo 
&  Valcárcel 2007b). The cytoplasmic pool of FASTK normally resides on mito-
chondrial outer membrane in complex with BCL-XL, but during proapoptotic sig-
nalling it is released into the cytoplasm, allowing binding to TIA1 (Li et al. 2004). 
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As FASTK overexpression increases the expression of antiapoptotic proteins and 
inhibits Fas-induced apoptosis, FASTK was suggested to antagonize with TIA1 in 
translation regulation (Li et al. 2004). However, the molecular details remain un-
resolved, with the recent results suggesting synergistic functions of FASTK and 
TIA1 in regulating translation and mRNA turnover (Li et al. 2013). With the cur-
rent knowledge, it is unclear whether the role of FASTK in this case is pro- or anti-
apoptotic. 
Also stress granules play a role in the regulation of apoptosis. In sublethal 
stress, transient SG formation enhances cell survival by sequestration of pro apo-
ptotic signalling proteins (Kim et al. 2005b, Arimoto et al. 2008, Tsai & Wei 2010), 
and by inhibiting the production of reactive oxygen species (Takahashi et al. 2013). 
On the other hand, SGs persist in cells exposed to lethal stress (Kedersha et al. 
1999); whether this plays a role in regulating entry into apoptosis in physiological 
conditions is not known.
2.8.8 Autoregulation of the TIA proteins
The TIA proteins can regulate their own expression and activity through intricate 
feedback loops acting on multiple levels, suggesting that their tightly controlled 
activity is essential for cellular homeostasis (Le Guiner et al. 2001, Izquierdo & 
Valcárcel 2007a, Pullmann et al. 2007).
TIA1 and TIAL1 activate weak 5’ splice sites followed by U-rich stretches also on 
their own mRNAs, promoting the inclusion of non-productive exons that intro duce 
in-frame stop codons or nonsense-causing frameshifts to TIA1 and TIAL1 tran-
scripts. As this leads to nonsense-mediated mRNA decay or production of non-
functional truncated proteins, TIA proteins are expected to negatively regulate 
their own expression (Le Guiner et al. 2001).
TIA1 exon 5, encoding the TIA1a-specific insert, is also regulated by TIAL1. 
 Depletion of TIAL1 increases skipping of this exon, leading to enhanced production 
of the short TIA1b isoform (Izquierdo & Valcárcel 2007a). TIA1b activates splicing 
more efficiently than TIA1a, and adjusting the isoform ratio has been proposed 
to fine tune splice-regulating activity of the TIA proteins. The two TIA1 isoforms 
show similar localization and RNA-binding; the higher activity of TIA1b is based 
on more efficient U1 snRNP recruitment (Izquierdo & Valcárcel 2007a). As other 
functional differences between TIA1a and TIA1b have not been reported, the two 
isoforms may exist to allow regulation of the splicing activity independently of 
 other TIA1 functions.
Yet another autoregulatory mechanism functions at the level of translation. 
Both TIA proteins associate with their own mRNAs, and RNAi knockdown of one 
increases the protein level of the other. Depletion of TIAL1 has been shown to 
 increase both the translation rate of endogenous TIA1, and the steady-state level 
of a GFP construct bearing the TIA1 3’UTR, demonstrating a suppressive effect on 
TIA1 translation (Pullmann et al. 2007).
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3 AIMS OF THE STUDY
This study aimed at elucidating the molecular mechanisms by which mutations 
in four different proteins with diverse functions—titin, calpain 3, DNAJB6, and 
TIA1—cause hereditary muscular dystrophies.
The specific objectives in each of the subprojects were:
I to identify proteins interacting with the extreme C-terminal part of titin and 
with calpain 3, to characterize the biological functions of the interactions, 
and to investigate their possible involvement in the pathogeneses of  
TMD/LGMD2J and LGMD2A.
II to obtain functional evidence for the pathogenicity of the LGMD1D-causing 
mutations newly identified by our research group in the co-chaperone 
DNAJB6, to characterize the role of DNAJB6 in skeletal muscle, and to 
understand how its functions are affected by disease mutations.
III to obtain functional evidence for the pathogenicity of the E384K mutation 
in the RNA-binding protein TIA1—newly identified by our research group—
and to elucidate the ensuing molecular events leading to Welander distal 
myopathy.
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4 MATERIALS AND METHODS
4.1 Plasmid constructs (I–III, unpublished)
Plasmid constructs used in the studies are listed in Table 3.
4.2 Antibodies (I–III, unpublished)
Primary antibodies used in the studies are listed in Table 4. Commercial  primary 
antibodies were acquired from Abcam plc (Cambridge, UK), Abnova (Taipei, 
 Taiwan), Calbiochem / Merck Millipore (Darmstadt, Germany), Cell Signaling 
Technology (Danvers, MA, USA), Covance Research Products (Berkeley, CA, USA), 
Dako  Denmark A/S (Glostrup, Denmark), Developmental Studies  Hybridoma 
Bank (DSHB, Iowa City, IA, USA), Epitomics (Burlingame, CA, USA), Invitrogen 
/ Life Technologies (Carlsbad, CA, USA), Novocastra / Leica Biosystems New-
castle Ltd. (Newcastle, UK), Novus Biologicals LLC (Littleton, CO, USA), Protein-
tech Group (Chicago, IL, USA), Roche Applied Science (Penzberg, Germany), 
Santa Cruz Biotechnology, Inc. (Santa Cruz, CA, USA), Sigma-Aldrich (St. Louis, 
MO, USA), Southern Biotech (Birmingham, AL, USA), Thermo Fisher Scientific 
(Waltham, MA, USA), and Triple Point Biologics, Inc. (Forest Grove, OR, USA).
4.3 Muscle material (I–III, unpublished)
Muscle biopsies used in microscopic, western blotting, and RT-PCR analyses were 
taken from various muscles of LGMD2J (I), LGMD1D (II), and WDM (III) patients, 
and healthy control individuals (I–III). Human tibialis anterior control muscle for 
stretch-fixed immunofluorescence samples (I) was obtained from an amputated 
leg. All samples were obtained with informed consent according to the Helsinki 
declaration.
Normal muscle tissue was collected from C57BL/6 mice (I) and Wistar rats (II) 
sacrificed for other experimental purposes. The effects of FINmaj mutation (un-
published) were studied on muscles from heterozygous and homozygous FINmaj 
KI mice (Charton et al. 2010) and wild-type littermates. Samples were collected 
from lower leg muscles (tibialis anterior, soleus, and gastrocnemius).
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Table 4. Antibodies
Target Clone / product Host Type Producer / reference Application Publ.
a-tubulin YL1/2 rt mAb Abcam WB II
a-tubulin T6074 ms mAb Sigma-Aldrich WB II
aB-crystallin G2JF ms mAb Novocastra IHC II
actin A2066 rb pAb Sigma-Aldrich WB I
BAG3 10599-1-AP rb pAb Proteintech IF, PLA, WB II
calpain 3 RP2 rb pAb Triple Point Biologics WB I
desmin Y66 rb mAb Epitomics IF II
DNAJB6 2C11-C1 ms mAb Abnova IF, WB II
DNAJB6 H00010049-A01 ms pAb Abnova WB, PLA II
dystrophin Dy4/6D3 ms mAb Novocastra IF I
eIF3 sc-16377 gt pAb Santa Cruz IF III
filamin F1888 ms mAb Sigma-Aldrich IF II
G3BP ab56574 ms mAb Abcam IF III
GFP ab6556 rb pAb Abcam WB I
GFP 66002-1-Ig ms mAb Proteintech WB III
GFP SC-8334 rb pAb Santa Cruz WB II
GFP G1544 rb pAb Sigma-Aldrich WB II
HA M4439 ms mAb Sigma-Aldrich WB II
HA tag HA.11 ms mAb Covance IF, WB III
HA tag 3F10 rt mAb Roche Applied Science IF I
Hsp90 SC-7947 rb pAb Santa Cruz WB II
HSPA8 ab1427 rb pAb Abcam IF, PLA II
HSPB8 ab79784 rb pAb Abcam PLA II
HSPB8 3059 rb pAb Cell Signaling WB II
HuR 3A2 ms mAb Invitrogen IF III
KRT18 ab52948 rb pAb Abcam IF II
LAMP2 H4B4 ms mAb Southern Biotech IF III
LC3 NB100-2331 rb pAb Novus Biologicals IF II
LC3b #2775 rb pAb Cell Signaling IF III
MLF1 ab70211 rb pAb Abcam IF II
Myc tag 9E10 ms mAb Abcam IF, WB I, II
Myc tag R950-CUS ms mAb Invitrogen WB I
Myc tag 9E10 ms mAb Roche Applied Science IF, WB I, II
Myc tag 9E10 ms mAb Santa Cruz IF, WB I, II
Myc tag E6654 rb agar. Sigma-Aldrich IP I
Myc tag NB600-342 gt agar. Novus Biologicals IP I
myosin heavy 
chain
F59 ms mAb DSHB IF II
myospryn Des122 rb pAb Benson et al. 2004 IF, PLA, WB I, u
myotilin 151 rb pAb Mologni et al. 2005 IF II
PGM1 15161-1-AP rb pAb Proteintech u
sarcomeric 
a-actinin
EA-53 ms mAb Sigma-Aldrich IF I, u
sarcomeric 
a-actinin
653 rb pAb van der Ven et al. 2000 IF I
SQSTM1 (p62) sc-28359 ms mAb Santa Cruz IF III
STUB1 PC711 rb pAb Calbiochem IF, PLA, WB II
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4.4 Cell culture and transfections (I–III, unpublished)
4.4.1 Cell lines (I–III)
The following mammalian cell lines were used in the study: COS-1 (ATCC, 
 Manassas, VA, USA), human embryonic retinoblast 911 (Fallaux et al. 1996), HeLa 
(ATCC),  T-REx 293 (Invitrogen, Life Technologies, Carlsbad, CA, USA), 293FT 
(Invitrogen), and C2C12 (ATCC). Cells were cultured at 37°C, 5% CO2 using stand-
ard techniques. Transient transfections were performed with FuGENE 6 (Roche 
 Applied Science, Penzberg, Germany; or Promega Corporation, Madison, WI, 
USA), or with Lipofectamine 2000 (Invitrogen).
4.4.2 Neonatal rat cardiomyocyte (NRC) cultures (I)
Neonatal rat cardiomyocytes (NRCs) were isolated using the Worthington Neo-
natal Cardiomyocyte Isolation System (Worthington Biochemical Corporation, 
Lakewood, NJ, USA), and transfected using the Escort III reagent (Sigma-Aldrich, 
St.  Louis, MO, USA) according to manufacturer’s instructions. Transfected NRCs 
were cultured for 1–2 days in maintenance medium (74.7% DMEM, 18.6%  medium 
M199, 3.8% horse serum, penicillin/streptomycin, 4 mM l-glutamine, 100 µM 
phenyl ephrine, 10 µM cytosine-β-d-arabinofuranoside) or for 5 days in trans-
fection medium with antibiotics (73% DBSS-K medium, 21% medium M199, 4% 
horse serum, 4 mM l-glutamine, penicillin/streptomycin).
4.4.3 C2C12 myotube cultures (unpublished)
C2C12 myoblasts were seeded on collagen-coated culture dishes and transfected 
using Lipofectamine 2000 within 2 h. For differentiation into myotubes, confluent 
cells were cultured in DMEM with 2% horse serum, l-glutamine, and penicillin/
streptomycin for 5–6 days.
TARDBP 2E2-D3 ms mAb Sigma-Aldrich IF III
TIA1 (C-term.) ab40693 rb pAb Abcam IF, WB III
TIA1 (C-term.) C-20 (sc-1751) gt pAb Santa Cruz WB III
TIA1 (central) ab61700 gt pAb Abcam IF III
TIA1 (N-term,) G-3 ms mAb Santa Cruz WB III
TIAL1 C-18 gt pAb Santa Cruz IF, WB III
titin (M-is4) T41 ms mAb Obermann et al. 1996 PLA I, u
titin (M10) M10-1 rb pAb Hackman et al. 2008 WB I
titin (M8) Tm8ra rb pAb Obermann et al. 1996 IF I
titin (M9) T51 ms mAb Obermann et al. 1996 IF, PLA I, u
ubiquitin Z-0458 rb pAb Dako IF III
V5 tag SV5-P-k ms mAb Invitrogen WB I, II, 
III
V5 tag NB600-387 gt agar. Novus Biologicals IP I, II
VCP MA3-004 ms mAb Thermo Fisher IF III
rt, rat; ms, mouse; rb, rabbit; gt, goat; agar, pAb agarose conjugate; u, unpublished
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4.5 Yeast two-hybrid studies (I)
4.5.1 Yeast two-hybrid screens (I)
The yeast two-hybrid screen for identifying interaction partners of the titin M10 
domain was performed at the two-hybrid core facility of Biocentrum Helsinki, 
 University of Helsinki. The bait encoding the wild-type human M10 domain in 
 pGBKT7 was screened against a human skeletal muscle prey library in pACT2 
(Clontech Laboratories, Inc., Mountain View, CA, USA). A total of 10.56 million 
yeast colonies were screened.
The yeast two-hybrid screen for identifying CAPN3 ligands was performed at 
Hybrigenics S.A. (Paris, France). A pB27 bait construct encoding residues T417–
S643 of CAPN3 was screened against a prey library consisting of a 1:1 mixture of 
human adult and fetal skeletal muscle poly(A) RNAs in pB6. A total of 106 million 
yeast colonies were screened.
4.5.2 Pairwise yeast two-hybrid analyses (I)
Pairwise yeast two-hybrid studies were performed with the mating strategy using 
the Matchmaker 3 system (Clontech) according to the manufacturer’s instructions. 
AH109 strains carrying pGBKT7 bait constructs were mated with Y187 strains car-
rying pGADT7 prey constructs, and activation of HIS2 and ADE2 reporter genes 
was assayed on selection plates lacking histidine and adenine. Activation of the 
LacZ reporter was separately assayed with an X-gal overlay assay.
4.6 SDS-PAGE and western blotting (I–III)
SDS-PAGE was performed with standard methods with self-cast Tris-glycine gels 
or precast TGX gels (Bio-Rad Laboratories, Hercules, CA, USA). Western blotting 
was performed with standard methdods, with chemiluminescent detection on film 
or on a ChemiDoc XRS+ system (Bio-Rad), or with fluorescent detection on an 
Odyssey Infrared Laser Imaging System (LI-COR Biosciences, Lincoln, NE, USA).
4.7 Coimmunoprecipitation (CoIP) (I–II)
For coimmunoprecipitation studies without crosslinking (I–II), cells were lysed 
by resuspending in ice-cold hypotonic gentle lysis buffer (10 mM Tris-HCl pH 7.5, 
10 mM NaCl, 2 mM EDTA, 0.5% Triton X-100, 1× Complete Protease Inhibitor 
Mixture [Roche Applied Science]; supplemented to 150 mM NaCl after 10 min of 
lysis). Insoluble material was pelleted by centrifugation (15 min, 16,000×g at 8°C). 
For coimmunoprecipitation with crosslinking (II), cells were lysed by resus-
pending in ice-cold PBS / 0.5% Triton X-100 / 1× Complete, and triturating through 
a 27G needle. Insoluble material was pelleted by centrifugation as described above. 
Proteins in the cleared lysates were crosslinked with 1 mM dithiobis(succinimidyl 
81
propionate) (Pierce, Thermo Fisher Scientific, Waltham, MA, USA) for 30 min on 
ice, and crosslinking was quenched with 20 mM Tris-HCl, pH 7.4 for 15 min on ice.
Lysates were incubated with antibody-conjugated agarose beads 2 h to over-
night at 8°C. The beads were washed several times with NET-2 (50 mM Tris-HCl, 
pH 7.5, 150 mM NaCl, 0.05% Triton X-100; in CoIP without crosslinking) or RIPA 
(50 mM Tris-HCl, pH 7.5, 150 mM NaCl, 1% NP-40, 0.5% Na-deoxycholate, 0.1% 
SDS; in CoIP with crosslinking). Bound proteins were eluted in SDS sample buffer 
by heating 5 min at 95°C and analyzed by western blotting.
4.8 Immunofluorescence microscopy (I–III, unpublished)
4.8.1 Preparation of muscle samples
Tissue samples from human muscle biopsies or dissected mouse muscles were 
freshly embedded in Tissue-Tek O.C.T (Sakura Finetek Europe B.V., Zoeterwoude, 
The Netherlands), frozen in isopentane chilled with liquid nitrogen, and stored at 
–80°C until use.
For preparation of stretched muscle samples (I–II, unpublished), rodent or 
human muscle pieces were pinned on cork or held with surgical retractors in a 
stretched position (~1.5× slack length), fixed in 4% PFA for 30 min at RT, and cryo-
protected in glucose in PBS (10% for 1 h, 20% for 1 h, 30% overnight). The muscles 
were then embedded in Tissue-Tek and frozen as described above.
Frozen muscles were cut to transverse or longitudinal cryosections of 8–10 µm. 
Sections were stored frozen in –20°C (short term) or –80°C (long term) until use.
4.8.2 Immunofluorescent (IF) stainings
For cultured cells and muscle sections, indirect immunofluorescent (IF) stainings 
were performed with standard techniques, using secondary antibodies labelled 
with Alexa Fluor (Molecular Probes, Life Technologies) or CyDye dyes (Jackson 
ImmunoResearch Laboratories, Inc., West Grove, PA, USA).
Zebrafish embryos were fixed in 4% PFA overnight and stored in 100% metha-
nol at −20°C. Embryos were rehydrated with PBS, washed in 0.1% Tween-20, 1% 
BSA / PBS for 10 min at RT, blocked in 10% fetal calf serum / 1% BSA / PBS for 1 h 
at RT. Whole-mount indirect IF staining was performed with antibodies diluted in 
blocking buffer.
4.8.3 Fluorescence microscopy (I–III, unpublished)
Wide-field fluorescence microscopy was performed using Zeiss Axioplan 2 (Carl 
Zeiss MicroImaging GmbH, Göttingen, Germany) or AZ100 (Nikon Instruments 
Inc., Melville, NY, USA). Confocal microscopy was performed using LSM 510 Meta 
or LSM 780 confocal microscopes (Carl Zeiss MicroImaging) with 63× / NA 1.4 and 
40× / NA 1.3 objectives. 
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4.9  In situ proximity ligation assay (I–II, unpublished)
Cryosections of stretch-fixed mouse and rat muscles were prepared and permea-
bilized as for the IF stainings. PLA experiments were performed with the Duolink 
system and the Duolink fluorescent detection kit 563 (Olink Bioscience, Uppsala, 
Sweden) with minor modifications to the manufacturer’s instructions. Alexa Fluor 
488-conjugated phalloidin (Molecular Probes) was added 1:100 to the primary 
anti body solution as a counterstain.
4.10 DNAJB6 knockdown and expression in zebrafish (II)
Zebrafish (Danio rerio) were maintained with standard methods. For knockdown 
of dnajb6b, fish embryos (1- or 2-cell stage) were injected with 6 ng of a splice-
blocking morpholino oligonucleotide targeted against the gene. For ectopic ex-
pression of human wild-type or mutant DNAJB6, the embryos were injected with 
50–100 pg of in vitro transcribed, capped mRNA.
Fish embryos at 48 hours post-fertilization were fixed in PFA, and slow myo-
fibres visualized with whole-mount IF staining of slow myosin heavy chain. Based 
on microscopic evaluation, embryos were categorized as normal (no discernible 
muscle defects), class I (complete or partial detachment of fibres from the vertical 
myosepta affecting 1–2 somites) or class II (affecting multiple somites). Phenotype 
distributions were analysed with the χ2 test.
4.11 Filter trap assay (FTA) (II)
For testing the anti-aggregation activity of DNAJB6 in filter trap assay (FTA), 
T-REx 293 cells were co-transfected with pcDNA5/TO-DNAJB6 and pEGFP/HD-
120Q (mass ratio 7:1) in duplicate. DNAJB6 expression was induced 7 h post-trans-
fection in one of the duplicate wells with 1 μg/ml tetracycline. Cells were harvested 
48 h post-transfection, and FTA was performed according to a protocol adapted 
from Hageman et al. (2010). The cells were lysed in FTA buffer (10 mM Tris-HCl 
pH 8.0, 150 mM NaCl, 50 mM dithiothreitol) containing 2% SDS and 1× Complete, 
by triturating through a 27G needle, sonicated for 1 min at RT in a bath sonicator 
and heated to 98°C. Samples for quantification of SDS-soluble huntingtin were 
removed form lysates and analysed by western blotting. For the trapping of ag-
gregated huntingtin, samples of remaining lysates were filtered through a cellulose 
acetate membrane (pore size 0.2 μm, Whatman plc, Maidstone, UK), followed by 
three washes with 300 μl FTA buffer containing 0.1% SDS.
Immunostaining and fluorescent detection of FTA membranes and western 
blots of SDS-soluble huntingtin was performed as described elsewhere. Amounts 
of aggregated (aggr.) huntingtin on FTA membranes and soluble (sol.) huntingtin 
on WB were quantified with the Odyssey software.
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Antiaggregation effect of the DNAJB6 construct was expressed as aggregation 
score [(aggr./sol)induced/(aggr./sol.)uninduced], calculated for each transfection pair. 
Results were analysed with the two-tailed Mann–Whitney U-test using the Bon-
ferroni correction.
4.12 Density gradient centrifugation (II)
The density gradient centrifugation procedure for the analysis of DNAJB6 oligo-
merization was adapted from Hageman et al. (2010). Sucrose gradients in 10 mM 
Tris-HCl pH 8.0, 50 mM NaCl, 5 mM EDTA were prepared by layering sucrose 
 solutions (80–10%, with 10-% intervals) in ultracentrifuge tubes. Cells were lysed 
in 10 mM Tris-HCl pH 8.0, 150 mM NaCl, 0.5% NP-40, 3% glycerol, 1× Complete, 
by triturating through a 27G needle, and centrifuged 15 min at 300×g. Super natants 
were loaded on sucrose gradients and ultracentrifuged for 18–20 h, 100,000×g at 
8°C.
After centrifugation, 12 fractions of equal volume were collected from the bottom 
of the gradients. Proteins were precipitated by mixing 1:1 with 25% trichloro acetic 
acid and incubating 30 min on ice, pelleted by centrifugation (15 min, 16,000×g 
at 8°C), washed twice with 80% acetone, air dried, dissolved in a 1:1 mixture of 1% 
SDS / 0.1M NaOH and 2× SDS sample buffer, and analyzed by western blotting.
4.13 Protein turnover assays (II)
The turnover of DNAJB6 was studied with a cycloheximide (CHX) chase assay on 
293FT cells. Cells were transfected with HA- or GFP-tagged DNAJB6 constructs, 
and after 48 h treated with 50 μg/ml CHX to block synthesis of new proteins. 
 Optionally, protein turnover pathways were inhibited by adding 20 μM lactacystin 
(EMD Millipore, Billerica, MA, USA) or 100 nM bafilomycin A1 (Sigma-Aldrich) 
together with CHX. After various durations (0–7 h) of drug treatment, cells were 
washed with PBS and lysed in RIPA buffer. DNAJB6 constructs were quantified 
from soluble fractions of the cell extracts by western blotting, and normalized to 
a-tubulin or HSP90, depending on the molecular weight of the construct.
4.14 Stress granule analyses (III)
4.14.1 Induction of stress granules by arsenite treatment (III)
To induce stress granule assembly, HeLa or C2C12 cells were treated with 500 µM 
sodium arsenite (Sigma-Aldrich) in normal medium for 45 min prior to cell  fixation.
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4.14.2 High-content analysis of stress granules (III)
HeLa cells were seeded on 24-well plates and transfected with TIA1 constructs 
(GFP-TIA1, HA-TIA1, or HT-TIA1). For fluorescent labelling, HT-TIA1-transfected 
cells were treated overnight with HaloTag TMRDirect Ligand (Promega) diluted 
1:2000 in normal medium. The next day (18 h after transfection for GFP-TIA1 and 
HA-TIA1, 20 h after transfection for HT-TIA1), the cells were treated with 500 µM 
sodium arsenite or control medium for 45 min and fixed with 4% PFA. Cells were 
permeablized with 0.2% Triton X-100 / PBS, and stained with Hoechst for label-
ling the nuclei. HA-TIA1 proteins were visualized with an indirect IF staining with 
an anti-HA antibody as described elsewhere.
Fluorescent images of 200 fields per well were captured with the CellInsight 
 instrument (Thermo Fisher) using a 10× / NA 0.3 objective and fixed exposure 
times. Automated image analysis for quantification of stress granules was per-
formed with the SpotDetector.V4 BioApplication in vHCS Scan 6.2.3 software 
(Thermo Fisher). Cells expressing moderate levels of TIA1 constructs were selected 
for analysis based on mean fluorescence intensity of the whole cell, and fluorescent 
spots fulfilling empirically determined criteria of size, shape, and intensity were 
analyzed from a region of interest surrounding the nucleus. The mean results of 
each well (number of spots and total spot area per analyzed cell) were normalized 
to the mean of untreated wild-type wells on the same plate.
4.14.3 Fluorescence recovery after photobleaching (FRAP) (III)
HeLa cells, transfected with GFP-TIA1a constructs, were cultured on Lab-Tek II 
chambered coverglass (Nunc A/S, Roskilde, Denmark) in phenol-red-free medi-
um. Stress granule formation was induced 22–25 h post-transfection with sodium 
arsenite. FRAP measurements were performed either at 35–36°C or at 37°C, 5% 
CO2, within the time window of 30–60 min after arsenite addition.
FRAP was performed with an LSM 510 Duo confocal microscope equipped with 
an LD C-Apochromat 40× / NA 1.10 water immersion objective (Carl Zeiss Micro-
Imaging). Using an instrument zoom factor of 20× and frame size of 88×88 pixels, 
a circular target region of 8 pixels (approx. 1 µm) in diameter was centered on a 
stress granule and bleached by point scanning with 405-nm, 458-nm and 488-nm 
laser lines. A time series of 60 frames (10 frames before and 50 after bleaching) was 
captured with maximum acquisition speed and frame interval of 250 ms.
Images were analyzed with ImageJ. Mean fluorescence intensity was measured 
from the FRAP target region, a reference region containing a non-bleached SG, and 
a background region from outside the cell. For each frame, background- subtracted 
intensity of the target region was normalized to that of the reference region (to 
 correct for acquisition bleaching), and these values were expressed relative to the 
initial prebleach value of the target region. Image series where stress granules 
moved partly away from measurement regions or bleaching caused a clear inten-
sity drop in the reference region were omitted from analysis.
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4.15 Image processing and analysis (I–III)
Image processing and analysis were done using the LSM 510 Meta 3.2 software 
(Carl Zeiss MicroImaging), Odyssey software (LI-COR), vHCS Scan 6.2.3 software 
(Thermo Fisher), Adobe Photoshop (various versions; Adobe Systems Inc., San 
Jose, CA, USA) and ImageJ (various versions; US National Institutes of Health, 
Bethesda, MD, USA).
4.16 Miscellaneous methods (I–III)
4.16.1 Protein modelling (I)
A structural model for the C-terminal FN3 domain in myospryn was generated at 
the Swiss-Model workspace (Arnold et al. 2006) by homology modelling, using the 
Protein Data Bank structure 2dmk as template.
4.16.2 Electron microscopy (II)
Transmission electron microscopy of muscle samples was performed using stand-
ard techniques.
4.16.3 RNA isolation and RT-PCR (III)
Muscle RNA was isolated with the Dr. P Kit (BioChain Institute, Inc., Newark, CA, 
USA) and reverse transcribed using SuperScript Reverse Transcriptase (Invitro-
gen). Regions of interest were PCR-amplified from muscle cDNA, and isoform 
 ratios were assessed from agarose gels visually or quantified from gel images.
4.16.4 Antibody epitope mapping (III)
For epitope mapping of C-terminal TIA1 antibodies, a SPOT peptide array cover-
ing the 69 C-terminal amino acid residues of human TIA1 as 15-mers was synthe-
sized at the peptide synthesis unit, Haartman Institute, University of Helsinki. The 
peptides containing the WDM mutation site were included as both wild-type and 
E384K mutant forms. The array was probed with TIA1 antibodies using ECL detec-
tion, and minimal antibody binding sites were inferred from the sequences of the 
reactive peptide spots.
4.16.5 In vitro translation (III)
Wild-type and E384K mutant HA-TIA1 were translated in vitro from the pAHC-
TIA1 constructs with the TnT T7 Quick Coupled Transcription/Translation System 
(Promega) according to the manufacturer’s instructions, and analyzed by western 
blotting.
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5 RESULTS AND DISCUSSION
5.1 Titinopathies TMD/LGMD2J and calpainopathy LGMD2A
5.1.1 Search for novel interaction partners of C-terminal titin and calpain 3
When mutations causing TMD/LGMD2J were first identified in titin (Hackman et 
al. 2002), no proteins were known to interact with the M10 domain harbouring the 
mutations. For the identification of interaction partners, potentially affected by the 
disease mutations, a yeast two-hybrid interaction screen was performed using the 
M10 domain as bait. 
The M10 interaction screen yielded 84 positive prey clones coding for 21 dif-
ferent proteins. Six putative interaction partners represented by more than one 
prey clone (CMYA5, PGM1, RANBP9, RING1, FHOD1, and KTN1) were chosen 
for further analysis in pairwise Y2H studies: The cDNA inserts were moved to the 
pGADT7 vector and tested in Y2H against wild-type and FINmaj mutant versions 
of the original M10 bait construct, as well as the empty bait vector. Four clones, 
encoding RANBP9, RING1, FHOD1, and KTN1, showed reporter gene activation 
also in combination with the empty bait vector, and were discarded as false positive 
hits. Two prey clones encoding phosphoglucomutase 1 (PGM1) also showed auto-
activation, but the interaction warranted further studies due to the high number 
of recovered clones and the biological plausibility of the interaction (discussed be-
low).
The interaction of the titin M10 domain and myospryn (CMYA5) was supported 
by pairwise Y2H studies. In parallel, myospryn was also identified as a putative 
interaction partner for the protease calpain 3 (CAPN3) in another yeast two-hybrid 
screen. This screen was performed as a part of an interactome project for LGMD-
associated proteins, coordinated by Dr. Isabelle Richard’s laboratory in Généthon, 
Evry, France. The interactions of myospryn with titin and CAPN3 will be further 
discussed in 5.1.3.
Since the initation of our interaction study in 2004, the titin M10 domain has 
been reported to bind the obscurin proteins OBSCN/OBSL1 (Fukuzawa et al. 
2008) and nuclear lamins (Zastrow et al. 2006). In addition, a small C-terminal 
titin fragment was found to interact with the KY protease, but as the interaction 
was not reproduced with Y2H constructs containing the entire M10 domain, it was 
deemed physiologically irrelevant (Beatham et al. 2004, 2006). Interactions of 
MURF1 and MURF2 with the titin domains M8–M10, were identified by Witt et al. 
(2008) in a Y2H system, but further studies have not been reported. None of these 
confirmed or putative interaction partners were among the clones recovered in our 
inter action screen. At least for the large obscurin proteins, known to interact with 
titin through their N-terminal domains (Fukuzawa et al. 2008), this is likely to 
reflect the lack of N-terminal clones from the oligo-dT-primed prey library.
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5.1.2 Putative interaction of PGM1 with the titin M10 domain (I, unpublished)
The most frequent hit in the M10 interaction screen, represented by 19 prey clones, 
was phosphoglucomutase 1 (PGM1), a metabolic enzyme catalyzing the inter-
conversion of glucose 1-phosphate and glucose 6-phosphate. Recovered PGM1 
clones spanned 77–107 C-terminal amino acid residues of the protein. Prey con-
structs encompassing 77 or 89 C-terminal residues were tested in further Y2H 
studies, where both showed reporter activation with the empty bait vector, strongly 
suggesting a false positive hit. However, in combination with the FINmaj M10 bait, 
the longer prey construct showed a lower level of reporter activation compared to 
either the wild-type bait or the empty vector, which could reflect a true interaction 
with the M10 domain.
PGM1 has not been reported as a frequent false positive in GAL4-based Y2H 
screens, which could be expected for a strong autoactivating protein. It was report-
ed as an interaction partner of the Z-disc protein ZASP, based on a Y2H screen uti-
lizing the same Matchmaker 3 system that was used in our experiments (Arimura 
et al. 2009). Also in this screen, PGM1 was the most abundant hit, with the amino 
acid range of the positive clones (74–162 C-terminal residues) very similar to ours. 
Testing the recovered prey clones in Y2H against a negative-control bait was not 
reported, but the interaction with ZASP was supported by mammalian two-hybrid, 
CoIP, and cell biological studies, suggesting that the finding was not a mere result 
of prey autoactivation (Arimura et al. 2009). On the other hand, PGM1 was also re-
covered in a Y2H screen with LRRC39 (interestingly, another M-band protein) as 
bait (Jenniches 2012). Here, PGM1 was classified as a probable false positive due to 
promiscuity, but experimental evidence behind this judgement was not discussed.
Solely based on the Y2H findings, the putative interaction of PGM1 with titin 
M10 seems thus questionable. Other pieces of evidence, however, support the pos-
sibility of a true interaction. Firstly, other metabolic enzymes (enolase, creatine 
kinase, adenylate kinase, and phosphofructokinase) are targeted to the M-band, 
in part by titin and FHL2 (Keller et al. 2000, Lange et al. 2002). This is suggested 
to concentrate the enzymes to regions of high metabolic activity, and in this con-
text the interaction of PGM1 with M-band titin would be functionally plausible. 
Secondly, also PGM1 shows partial localization to the M-band. This was particu-
larly evident in cardiomyocytes transfected with a GFP-tagged C-terminal PGM1 
construct ( Arimura et al. 2009), although the authors did not discuss the M-band 
localization. Also in our preliminary IF studies on mouse muscle, variable amounts 
of PGM1 were present at the M-band. This M-band signal did not appear disrupted 
in homozygous FINmaj knock-in muscle, indicating that the M-band targeting 
does not depend on the putative interaction with M10 (Fig. 7, unpublished data). 
Further CoIP experiments performed in our group have so far failed to provide 
conclusive evidence for the titin –PGM1 interaction (Anni Evilä, unpublished data). 
Additional studies would thus be needed for definitively proving or disproving the 
putative interaction.
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5.1.3 Novel interaction of myospryn with C-terminal titin and CAPN3
Myospryn (CMYA5, cardiomyopathy-associated 5), identified in the Y2H screens as 
an interaction partner for C-terminal titin and calpain 3, is a large multi functional 
protein related to the tripartite motif (TRIM) family. Its expression on transcript 
and protein levels was initially characterized as restricted to skeletal and cardiac 
muscles (Benson et al. 2004, Durham et al. 2006), but moderate myospryn expres-
sion in the brain has been recently reported (Chen et al. 2011).
The official symbol CMYA5, suggesting an association with cardiomyopathy, 
was originally coined on hypothetical grounds, based on coexpression with known 
cardiomyopathy genes (Walker 2001). Aliases genethonin-3 (Tkatchenko et al. 
2001) and stretch-responsive 553 or sr553 (McKoy et al. 2002) have been used in 
individual early studies. Although lacking the RING domain present in canonical 
TRIM proteins, myospryn is also classified as TRIM76 (HGNC Database).
Human myospryn, comprising 4069 amino acid residues, has a predicted mo-
lecular weight of 449 kDa (Fig. 8). Its C-terminal region of ~600 amino acids has a 
domain architecture resembling the TRIM proteins: The region contains a B-Box’ 
domain (a variant of the B-Box zinc finger domain containing two instead of four 
Zn2+-coordinating residue pairs), a BBC (B-Box C-terminal coiled-coil), two FN3 
domains, and a SPRY (SPlA and RYanodine receptor) domain (Benson et al. 2004). 
According to Y2H and CoIP studies, the TRIM-like region is capable of self-associ-
ation, suggesting that the protein may exist as a homodimer (Benson et al. 2004). 
The TRIM-like region of myospryn is highly conserved in evolution, with ~90% 
identity between the human and murine orthologues. Another region showing evo-
lutionary conservation is a stretch of ~100 amino acid residues near myospryn 
N-terminus, but the domain structure and functions of this part of the protein are 
currently unknown. Most of myospryn is comprised of repetitive, glutamate-rich 
sequence without predictable domains (Benson et al. 2004); this low-complex-
ity region shows variation in length and repeat composition between myospryn 
 orthologues in different species, and could thus serve as a flexible linker between 
the conserved N-and C-terminal regions.
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Figure 7. Phosphoglucomutase 1 in muscle
Confocal microscopy of PGM1 and the Z-disc marker a-actinin in mouse muscle. PGM1 was mostly 
localized around the Z-disc, but it also exhibited variable degrees of M-band localization, ranging 
from undetectable to prominent (exemplified here), No obvious difference was seen between  
wild-type (not shown) and homozygous FINmaj KI (FINmaj / FINmaj) muscles. Scale bar, 10 mm.
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5.1.3.1 Myospryn interacts in Y2H with wild-type but not FINmaj mutant M10 (I)
In the M10 interaction screen, myospryn was represented by two recovered prey 
clones, spanning 259 (A3811–CT) and 210 (L3860–CT) C-terminal residues of 
the protein. Pairwise Y2H studies (I: Fig. 2) replicated the interaction of the two 
recovered myospryn prey clones with the wild-type M10 bait, while no reporter 
activation was seen with the empty bait vector. Moreover, both myospryn clones 
failed to cause reporter activation in combination with the FINmaj mutant M10 
bait, suggesting that the interaction is specific and requires a correctly folded M10 
domain. Additional Y2H experiments with deletion constructs showed that half of 
the C-terminal FN3 domain and the SPRY domain of myospryn are required for 
the interaction with titin M10. Progressively weaker reporter signals obtained with 
a series of deletion constructs starting in the region L3860–Y3875 suggested that 
this region may contain amino acid residues directly participating in titin binding 
(I: Fig. 1–2).
5.1.3.2 A larger C-terminal part of titin participates in myospryn binding (I)
To confirm the interaction of myospryn with titin, CoIP experiments were carried 
out in COS-1 cells. The myospryn constructs utilized in these studies covered three 
different C-terminal regions: A3811–CT of human myospryn (corresponding to the 
longer prey clone recovered in the M10 screen), as well as G3039–CT (MD7) and 
Y2731–CT (MD9) of the murine protein (Benson et al. 2004). In contrast to expec-
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Figure 8. Structure and reported interactions of myospryn
Most of the myospryn (CMYA5) protein is composed of repetitive, acidic sequence with no 
recognizable domains. The C-terminal part of the protein contains a TRIM-like domain structure 
with BBox’ (BB), coiled-coil (BBC), FN3, and SPRY domains. Sites of reported protein interactions 
are indicated.
Adapted from Sarparanta J: Biology of Myospryn: What’s Known? Journal of Muscle Research and Cell Motility, 2008; 29:177–180 
with kind permission from Springer Science and Business Media. © 2009 Springer Science and Business Media B.V.
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tations from the Y2H studies, none of the myospryn constructs showed binding 
to a GFP-tagged M10 construct in the tested CoIP conditions. All were, however, 
pulled down with a longer (is6–M10-V5 is7+) titin construct, supporting the inter-
action of the proteins but suggesting that myospryn binding is not limited to the 
M10 domain (I: Fig. 3).
Additional CoIP studies were performed with the myospryn construct MD9 
and a series of V5-tagged titin constructs of different lengths. Either V5 or Myc 
antibodies were used for immunoprecipitating the titin or myospryn constructs, 
respectively. In these experiments—in addition to is6–M10-V5 is7+—also titin 
constructs spanning the regions is6–M10 (is7–) and is6–is7 showed clear bind-
ing to myospryn MD9, whereas for is6–M9 and is6–M8, the interaction was weak 
or undetectable (I: Fig. 3). The difference between is6–M9 and is6–is7 indicates 
that the is7 region participates in the interaction. The binding seen with is6–M10 
is7– but not with M10 alone, on the other hand, demonstrates the contribution of 
the M9 domain. In conclusion, the whole C-terminal region M9–is7–M10 in titin 
is involved in myospryn binding (Fig. 9).
In CoIP experiments the FINmaj mutation failed to disrupt the interaction of 
is6–M10 constructs with myospryn, but rather seemed to increase the binding. 
This discrepancy between CoIP and Y2H results is likely due to preserved inter-
action of M9–is7 with myospryn despite the mutation. The apparent increase in 
binding could be explained by unspecific adhering of proteins to the unfolded M10 
domain.
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Figure 9. Interactions between myospryn, C-terminal titin, and CAPN3
Summary of the novel and previously reported interactions between myospryn (CMYA5),  
C-terminal titin (TTN), and CAPN3. Regions participating in the interactions, as defined by Y2H  
and CoIP assays, are indicated by black bars.
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5.1.3.3 The interaction of CAPN3 and myospryn is supported by CoIP (I)
The interaction of myospryn with CAPN3, identified in the Y2H screen for CAPN3 
ligands, was confirmed by CoIP studies in COS-1 cells, where both myospryn con-
structs MD7 and MD9 pulled down the proteolytically inactive CAPN3 C129S 
 construct with comparable efficiencies (I: Fig. 3). Based on the regions covered 
by the Y2H bait construct and the recovered prey clones, the interaction involves 
the C2-like domain and IS2 of CAPN3, and a myospryn region encompassing the 
BBox’, coiled-coil, and the first FN3 domain (Fig. 9). As this was not refined further 
with deletion constructs, the minimal interacting regions could be smaller.
5.1.4 Subcellular localization of myospryn
5.1.4.1 Localization of myospryn in muscle fibres (I, unpublished)
To obtain support for its interaction with M-band titin, the localization of myo-
spryn in muscle fibres was studied by immunofluorescence microscopy. In mouse 
and human muscle samples fixed in a stretched position, the Des122 antibody 
 revealed myospryn predominantly as broad doublet bands flanking the Z-disc. In 
addition, fainter striations were sometimes discernible at the M-band level, com-
patibly with an interaction with C-terminal titin (I: Fig. 4). The M-band staining 
was most prominent at fibre periphery, whereas the major doublet bands were of 
similar intensity throughout the fibre. In non-stretched muscle samples fixed as 
sections, the M-band localization was not detectable, which could be due to lower 
resolution of sarcomeric regions or poor preservation of the structure in the  sample 
preparation procedure.
In situ proximity ligation assays (PLA) on mouse muscle sections were em-
ployed as a complementary method for studying the colocalization of myospryn 
and M-band titin. This technique, based on oligonucleotide-conjugated anti bodies, 
visualizes the spatial proximity of two primary antibodies in situ as fluorescent 
dots. In wild-type muscles, positive PLA signals demonstrated the proximity of the 
antibody binding sites in C-terminal titin (antibodies T51 and T41) and myospryn 
(Des122), consistent with an interaction between the two proteins (I: Fig. 5). The 
predominant localization of PLA signals at the fibre periphery was in line with the 
localization of myospryn in IF microscopy.
The subcellular localization of myospryn observed in our studies is consistent 
with the staining pattern previously seen in skeletal muscle with the same anti-
body (Matthew Benson and Derek Blake, personal communication). The published 
reports on myospryn localization, however, rely on three different antibodies, 
and the results are partly inconsistent (Benson et al. 2004, Durham et al. 2006, 
 Kouloumenta et al. 2007, Reynolds et al. 2007).
With the antibody Des122, also utilized in this study, Benson et al. (2004) 
showed myospryn in transverse rat skeletal muscle sections mostly at the myo-
fibre periphery, with weaker staining inside the fibre. While this is in line with the 
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 localization reported by Durham et al. (2006) on transverse mouse muscle sec-
tions, the patterns obtained with the same antibodies on the longitudinal sections 
are different: The major cross-striations detected with Des122 flank the Z-disc as 
doublet bands in skeletal muscle and coincide with the Z-disc in cardiac muscle, 
thus reflecting the position of T-tubules and terminal cisternae of SR in these tis-
sues (this study and Matthew Benson and Derek Blake, personal communication). 
The antibody utilized by the Naya group was, on the other hand, reported to pro-
duce cross-striations overlapping the Z-discs in both cardiac and skeletal muscle, 
suggesting a lozalization in the costameric Z-disc domains (Durham et al. 2006, 
Reynolds et al. 2007). Costameric localization was also favoured by Kouloumenta 
et al. (2007), who reported Z-disc-overlapping cross-striations present exclusively 
at the subsarcolemmal level in cardiac muscle, as well as prominent staining of 
inter calated discs and perinuclear regions. The subcellular localization of myo-
spryn is hence not established, and elucidating the genuine localization would re-
quire validation and cross-comparison of the antibodies, ideally on knockout ani-
mal tissues.
5.1.4.2 Localization of myospryn in neonatal rat cardiomyocytes (I)
To study the M-band localization of myospryn with an independent method, IF 
micro scopy of endogenous and transfected myospryn was performed in cultured 
neo natal rat cardiomyocytes (NRCs) (I: Fig. 6). Staining with the Des122 antibody 
revealed endogenous myospryn in a granular or reticular pattern, and—in cell re-
gions with best-organized sarcomeres—cross-striations overlapping the Z-discs. 
Less frequently, another set of striations of lower intensity was seen at the M-band 
level.
Localization of GFP- or Myc-tagged myospryn constructs (human CMYA53811–CT
and mouse MD9) in NRCs was investigated 1–5 d post-transfection. CMYA53811–CT 
constructs typically showed strong targeting to Z-discs, stress-fibre-like structures, 
and intercalated discs. The localization of MD9 was reminiscent of the endogenous 
protein—a granular–reticular pattern, with cross-striations sometimes present at 
both Z-disc and M-band levels. Partial localization of both endogenous and trans-
fected myospryn at the M-band level in cardiomyocytes paralleled the findings in 
skeletal muscle, and was consistent with an interaction with C-terminal titin.
Transfections of HA-tagged titin is6–M10 is7+, alone or together with myo-
spryn constructs, were performed for investigating whether C-terminal titin and 
myo spryn could affect the localization of each other. The titin construct exhibited 
cytotoxicity in a subset of cells, but in surviving cells it typically showed a diffuse lo-
calization without a dramatic effect on the localization of endogenous or transfected 
myospryn. Interestingly, in cotransfections with CMYA53811–CT, the titin construct 
gave an impression of increased association with the Z-discs, suggesting that the 
myospryn construct could modulate its localization. This phenomenon could not, 
however, be analyzed statistically due to the low number of double-transfected cells.
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5.1.4.3 Localization of myospryn is not disrupted by FINmaj (I, unpublished)
To investigate the effect of the FINmaj titin mutation on myospryn localization, IF 
studies were performed on muscle samples from a LGMD2J patient and the TMD/
LGMD2J mouse model (FINmaj KI). In LGMD2J muscle, the major doublet bands 
seemed normal, but the status of the M-band striation could not be determined on 
the non-stretched standard biopsy material (I). In stretched and immersion-fixed 
muscle samples of both heterozygous and homozygous FINmaj KI mice, myospryn 
localization was indistinguishable from wild-type controls, including a clear stria-
tion at the M-band level (Fig. 10; unpublished data) 
While the IF results indicated a preserved M-band localization of myospryn in 
FINmaj KI muscles, a submicroscopic effect on the colocalization of myospryn and 
titin was not excluded. To investigate this possibility, in situ PLA studies were per-
formed with the myospryn antibody Des122 in combination the titin antibody T41, 
whose epitope in M-is4 is outside the region disrupted in TMD/LGMD2J (Anna 
Vihola, personal communication). PLA showed similar signals in the muscles of 
control and FINmaj KI mice (Fig. 10; unpublished data), indicating that the physi-
cal proximity of myospryn with the remaining part of C-terminal titin is not dra-
matically affected by the mutation.
As the titin domains M9–is7–M10, constituting the entire myospryn-binding 
region defined in our CoIP experiments, are likely absent in homozygote FINmaj 
KI muscle (Charton et al. 2010), the apparently normal myospryn localization sug-
gests that the interaction with titin is not required for targeting of myospryn to the 
M-band level.
5.1.5 Reported interactions and functions of myospryn 
The C-terminal part of myospryn, identified in this study to contain the binding 
sites for titin and CAPN3, has been previously reported to interact with several 
other proteins. The reported interactions with α-actinin (Durham et al. 2006), des-
min (Kouloumenta et al. 2007) and dystrophin (Reynolds et al. 2008) connect 
myospryn with cytoskeletal components, whereas the interactions with dysbin-
din (Benson et al. 2004), protein kinase A (Reynolds et al. 2007), and calcineurin 
(Kielbasa et al. 2011) relate to the functions of myospryn in membrane trafficking 
and cellular signalling.
5.1.5.1 Interactions of myospryn with cytoskeletal proteins
Binding of myospryn to α-actinin 2, postulated based on their co-localization in the 
costameric Z-disc domain, has been demonstrated with CoIP studies of transfected 
proteins. α-actinin binding was reported for several constructs covering various 
regions within the C-terminal half of mouse myospryn (Durham et al. 2006). This 
complex interaction has not been confirmed with other methods, nor is its func-
tional significance known.
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Figure 10. Myospryn in muscles of control and FINmaj knock-in mice
A–B Confocal microscopy of myospryn (antibody Des122), with a-actinin as a Z-disc marker (A) 
or the titin M9 domain (antibody T51) as an M-band marker (B) in muscles of wild-type (+ / +), and 
FINmaj knock-in mice heterozygous (+ / FINmaj) or homozygous (FINmaj / FINmaj) for the titin 
mutation. The faint myospryn signal at the M-band level was not visibly affected by in the FINmaj KI 
muscles, while negative T51 staining confirmed the absence of C-terminal titin in the homozygous 
mutant mice. The images show a single optical section. Scale bars, 10 mm. Insets show twofold 
magnifications of the boxed regions.
C In situ proximity ligation assay (PLA) with antibodies against myospryn (Des122) and titin M-is4 
(T41) in muscles of wild-type and homozygous FINmaj KI mice. The combination of the two 
antibodies (Des122 / T41) produced numerous punctate PLA signals indicating spatial proximity of 
their binding sites, with no difference between wild-type and FINmaj KI. The negative control 
reaction with the myospryn antibody alone (Des122 / –) produced few background spots on  
wild-type mouse muscle. The images show maximum-intensity projections through z-stacks of  
15 optical sections. Scale bar, 10 mm.
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Binding of myospryn to the N-terminal domain of desmin has been identified 
in a Y2H screen for desmin ligands, and defined with deletion constructs to involve 
the extreme C-terminal 24 amino acids of myospryn (Kouloumenta et al. 2007). In 
support of this interaction, desmin antibodies were shown to coimmunoprecipitate 
myospryn from heart homogenates. In desmin-deficient cardiomyocytes, myo-
spryn was reported to lose its enrichment in the perinuclear region and to adopt a 
diffuse cytoplasmic localization, while localization to costameres and intercalated 
discs was not disrupted (Kouloumenta et al. 2007).
Interaction of myospryn and dystrophin has been identified by CoIP of endo-
genous proteins from a skeletal muscle extract and shown by pulldown experi-
ments to involve two separate regions in C-terminal myospryn and the C-terminal 
part of dystrophin (Reynolds et al. 2008). Of the reported interactions of myospryn 
with cytoskeletal proteins, the one with dystrophin is supported by the most con-
vincing in vivo evidence: In dystrophin-deficient mdx mice, proteolytic degrada-
tion of myospryn and its selective mislocalization from the subsarcolemmal region 
suggested that the interaction with dystrophin is responsible for the costameric 
localization of myospryn (Reynolds et al. 2008). The mdx mice also showed down-
stream changes in protein kinase A signalling, in line with the disturbed signalling 
functions of myospryn, discussed below.
5.1.5.2 Myospryn as a signalling scaffold
By interacting with protein kinase A (PKA) and calcineurin (protein phosphatase 
2B, PP2B), myospryn regulates the activity of these signalling molecules in  muscle 
(Reynolds et al. 2007, Kielbasa et al. 2011). Regulation of PKA is mediated by 
inter action of the PKA regulatory subunit RIIα with myospryn through three 
amphi pathic helices located in the TRIM-like region (Reynolds et al. 2007). Func-
tional relevance of myospryn as an A-kinase anchoring protein (AKAP) is demon-
strated in muscles of the dystrophin-deficient mdx mice, where both myospryn 
and PKA RII are mislocalized, PKA activity is reduced although its expression level 
is normal, and several target genes of the PKA–CREB pathway are dysregulated 
( Reynolds et al. 2008).
The TRIM-like region of myospryn contains also three binding regions for 
calci neurin (Kielbasa et al. 2011). This calcium-activated protein phosphatase 
 activates NFATc and MEF2 (myocyte enhancer factor 2) pathways, playing impor-
tant roles for example in muscle regeneration, hypertrophy and fibre type deter-
mination (Sakuma & Yamaguchi 2010). Binding to myospryn inhibits calcineurin 
activity both in vitro and in vivo: Myospryn represses the calcineurin-mediated 
expression of NFATc reporter construct in cell cultures, and overexpression of the 
myospryn TRIM-like region in mouse muscles reverses the fast-to-slow fibre type 
switch caused by constitutively actively calcineurin, as well as attenuates muscle 
regeneration after cardiotoxin injection (Kielbasa et al. 2011).
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Importance of highly controlled myospryn-based signalling is highlighted by 
the fact that myospryn itself is regulated by the same pathways, suggesting the 
existence of feedback loops. Myospryn is a transcriptional target of MEF2A (Dur-
ham et al. 2006) and PKA–CREB pathways (Reynolds et al. 2008). Its expres-
sion is downregulated in mdx mice, where PKA activity is reduced (Reynolds et al. 
2008), as well as in DMD patients (Tkatchenko et al. 2001). The N-terminal part 
of myospryn is also directly phosphorylated by PKA (Reynolds et al. 2007), but the 
importance of this modification is currently unknown.
5.1.5.3 Myospryn and the BLOC-1 complex in vesicle trafficking
Myospryn is linked to vesicle trafficking by its interaction with dysbindin 
( DTNBP1), a subunit of the BLOC-1 (biogenesis of lysosome-related organelles) 
complex ( Benson et al. 2004). This hetero-octameric complex cooperates in mem-
brane trafficking and cargo sorting with the clathrin adaptor protein (AP) com-
plexes and actin cytoskeleton regulators, but its exact molecular function is unclear 
(Falcon-Perez et al. 2002, Setty et al. 2007, Sitaram et al. 2012, Ryder et al. 2013). 
BLOC-1 is best known for its essential role in the sorting of selected cargo pro-
teins from early endosomes to lysosome-related organelles (LROs)—specialized 
vesicular organelles that share some lysosomal features but also contain proteins 
needed for various cell-type-specific functions (Setty et al. 2007, Huizing et al. 
2008). Other demonstrated or inferred functions of BLOC-1 include sorting and 
transport of cargo from endosomes to ordinary lysosomes, the Golgi apparatus, 
and synaptic vesicles, and participation in neurite outgrowth (Ghiani et al. 2010, 
Marley & von Zastrow 2010, Larimore et al. 2011, Gokhale et al. 2012). An appar-
ently unrelated role in redox homeostasis was recently suggested by its interaction 
with peroxi redoxins and altered redox state in BLOC-1-deficient cells (Gokhale et 
al. 2012). Based on numerous identified protein interactions, dysbindin has been 
suggested to have additional functions e.g. in transcriptional regulation (reviewed 
by  Ghiani & Dell’Angelica 2011, Mullin et al. 2011), but the physiological relevance 
of inter actions and functions not validated in the context of BLOC-1 is questionable 
( Ghiani & Dell’Angelica 2011).
Mutations in dysbindin and other BLOC-1 subunits, leading to the secondary 
loss of the whole complex, cause the multisystem disorder Hermansky-Pudlak 
syndrome (HPS) in man and similar phenotypes in mice (Li et al. 2003, Morgan 
et al. 2006, Huizing et al. 2008, Cullinane et al. 2011). The symptoms are due to 
the defective biogenesis of the different LROs and include hypopigmentation, im-
paired blood clotting, and subtype-specific features such as pulmonary fibrosis and 
lipofuscin accumulation (reviewed by Huizing et al. 2008). The absence of overt 
symptoms in other cells and tissues, despite the ubiquitous expression of BLOC-1, 
suggests that while BLOC-1 is required for LRO biogenesis, its other functions are 
redundant (Dell’Angelica 2004). In muscle, specialized LROs are not known to 
exist. Skeletal muscle abnormalities have not been reported in HPS, and specific 
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efforts have failed to reveal any muscle involvement in the BLOC-1-deficient sandy 
and pallid mice (Li et al. 2003, Nazarian et al. 2006).
Dysbindin was initially characterized as a binding partner of dystrobrevins, 
cytoplasmic components of the DGC (Benson et al. 2001), but its dystrobrevin-
binding region was later found to be occupied in interactions with other BLOC-1 
components (Li et al. 2003, Nazarian et al. 2006). A stable association of dys-
bindin and BLOC-1 is also indicated by their practically complete co-fractionation 
in several tissues, and the secondary dysbindin deficiency caused by depletion of 
other BLOC-1 subunits (Li et al. 2003, Starcevic & Dell’Angelica 2004, Nazarian et 
al. 2006, Ghiani et al. 2010). The existence of a DGC-associated dysbindin pool is 
hence unlikely, and the interaction with dysbindin most probably links myospryn 
to BLOC-1. An association of myospryn and BLOC-1 is further supported by co-
immunoprecipitation of the BLOC-1 subunits dysbindin and pallidin with desmin 
and myospryn from heart extract (Kouloumenta et al. 2007) and by the possible 
genetic association of CMYA5 with schizophrenia—a condition to which dysbindin 
and other BLOC-1 subunits have been previously linked by genetic and functional 
evidence (Straub et al. 2002, Talbot et al. 2004, Morris et al. 2008, Chen et al. 
2011, Li et al. 2011, Furukawa et al. 2013).
The role of BLOC-1 in muscle has not been characterized, but the absence of 
muscle symptoms in HPS and in BLOC-1-deficient mice (Li et al. 2003, Nazarian 
et al. 2006) indicates that the complex is not required for normal muscle function. 
The partial co-localization of myospryn with lysosomes in cultured cardiomyocytes, 
and the altered localization of both myospryn and lysosomes in desmin-deficient 
cells do, however, suggest a connection between myospryn and the endosomal–
lysosomal system in muscle, possibly involving BLOC-1 (Kouloumenta et al. 2007).
5.1.6 Functional aspects of the novel interactions
5.1.6.1 Myospryn is a substrate and possible regulator of CAPN3
In order to assess the biological importance of the novel myospryn–CAPN3 inter-
action, cotransfection studies were performed in 911 cells. Coexpression of active 
YFP-CAPN3-CFP caused the disappearance of the full-length (115 kDa) form of the 
myospryn construct MD9 and the appearance of a ~40-kDa N-terminal fragment 
in western blot (I: Fig. 7). This identified myospryn as an in vitro proteolytic sub-
strate for CAPN3, with the cleavage site situated approximately 70–80 kDa from 
myospryn C-terminus (40–140 amino acid residues N-terminally from the BBox’ 
domain). In contrast, the shorter MD7 construct (80 kDa) was not cleaved by 
CAPN3, which could indicate that the cleavage occurs just N-terminally to the MD7 
region, or that the construct adopts a conformation not accessible to the protease.
Given the role of calpains as modulator proteases (Ono & Sorimachi 2012), pro-
teolytic cleavage by CAPN3 could serve to regulate the localization or interactions 
of myospryn. However, the physiological significance of the CAPN3 substrates 
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identified in vitro is unclear (see 2.4.6.), and the ability of CAPN3 to proteolyze 
myospryn in a coexpression setup does not necessarily identify myospryn as a 
physiological substrate.
In addition to demonstrating the proteolytic cleavage of myospryn, cotransfec-
tions suggested that myospryn attenuates the autolytic activation of CAPN3, as 
the ratio of the full-length YFP-CAPN3-CFP construct to its 80-kDa autolytic frag-
ment was increased in cells cotransfected with MD9 (I: Fig. 7). A simple explana-
tion would be that binding to myospryn through the IS2 segment causes structural 
changes in CAPN3 directly affecting its autolysis—a conceivable assumption con-
sidering the known ability of IS2 to modulate the autolytic properties of CAPN3 
(see 2.4.4.). This could either be a physiologically relevant phenomenon or a mere 
side effect of the coexpression.
The failure of the MD7 construct to attenuate the autolysis similarly to MD9, 
even though both myospryn constructs showed binding to CAPN3 in CoIP, could, 
however, favour a more complex mechanism, and imply that myospryn plays a spe-
cific role in regulation of CAPN3. This might, for example, involve phosphorylation 
or dephosphorylation events by PKA and calcineurin (see 5.1.5.2.). Phosphoryla-
tion of CAPN3 was suggested by Ermolova et al. (2011), but the phosphorylation 
site, the kinase(s) and phosphatase(s) regulating the modification, and its effect on 
CAPN3 activity are unknown.
It remains unknown whether both of the suggested functions of the CAPN3–
myospryn interaction bear physiological significance. A dual role of myospryn as 
both a substrate and a regulator of CAPN3 could provide a feedback system for 
autoregulation of either myospryn or CAPN3 activity.
5.1.6.2 Conclusions on the titin–myospryn interaction
Functional studies for demonstrating the biological importance of the discovered 
titin–myospryn interaction were beyond the scope of this study. However, the 
 presented results—binding of myospryn to M-band titin in Y2H and CoIP assays, 
the localization of myospryn at the M-band level, and the physical proximity of the 
two proteins demonstrated by PLA—strongly support a genuine interaction with 
likely physiological relevance.
This study adds titin to the list of structural proteins interacting with myospryn. 
The identified titin-binding region overlaps with all of the previously described 
binding sites, and at least some of the interactions may be mutually exclusive. In-
teractions are also limited by the subcellular localizations of the proteins: myo-
spryn can hardly interact with M-band titin and the Z-disc-associated proteins 
α-actinin and desmin at the same time. A simultaneous interaction of myospryn 
with titin and dystrophin could, on the other hand, be envisioned to take place 
at the costameric domains overlying the M-band (Porter et al. 1992). Indeed, the 
localization of myospryn at the M-band level and its interaction with titin seem to 
be restricted or enriched to the subsarcolemmal region (see 5.1.4.1.), suggesting a 
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connection between titin molecules in the peripheral myofibrils and myospryn in 
the costamere. The preserved localization of myospryn in the FINmaj KI mouse 
(this study) and its mislocalization in the mdx mouse (Reynolds et al. 2008) sug-
gest that myospryn is targeted to the costameric M-band domains by its interaction 
with dystrophin—and in this case, the interaction of titin and myospryn is likely to 
be functional rather than structural.
A functional interaction between C-terminal titin and myospryn could be in-
volved either in transmitting information from the titin filament system to the 
signalling pathways coordinated by myospryn, or in regulation of titin or other 
M-band components by these pathways. In line with these possibilities, both PKA 
RII (Reynolds et al. 2007) and calcineurin (Torgan & Daniels 2006) are partly 
localized at the M-band level.
With the current limited knowledge on the role of myospryn and BLOC-1 in 
membrane trafficking, a possible role of M-band titin in these functions cannot be 
excluded. However, vesicles of the endosomal–lysosomal system in muscle fibres 
are mostly found at the I-band, notably in association with the T-tubules (Kaisto 
et al. 1999), suggesting that, in terms of trafficking, the myospryn pool localized in 
this region might be more important than the M-band-associated pool.
5.1.6.3 Relationship of the novel interactions
The similar localization of myospryn and CAPN3 at the I-band and M-band regions 
(this study, Ojima et al. 2007) would allow the proteins to interact at either of these 
locations. However, since C-terminal titin, CAPN3, and myospryn can all interact 
with each other, the three proteins could conceivably form a ternary complex at 
the M-band. As triple CoIP experiments performed for addressing this possibility 
were inconclusive (unpublished results), the existence of a ternary titin–CAPN3–
myospryn complex awaits confirmation. This could be achieved for example with 
crosslinking experiments.
5.1.7 Role of myospryn in muscular dystrophies
CoIP studies demonstrated that the binding of myospryn to titin is not directly 
prevented by the TMD/LGMD2J-causing FINmaj mutation, and IF microscopy in-
dicated apparently normal targeting of myospryn to the M-band level in muscles of 
the FINmaj knock-in mouse. However, as FINmaj and other titinopathy mutations 
ultimately lead to the absence of the entire myospryn-binding region from mutant 
titin (Hackman et al. 2002, 2008, Charton et al. 2010), partial or total disruption 
of the functional titin–myospryn interaction is a likely consequence of the muta-
tions.
The downstream effects of the disrupted titin–myospryn interaction cannot be 
directly studied before the biological function of the interaction is elucidated. As 
circumstantial evidence favours the possibility that titin participates in the signal-
ling functions of myospryn (see 5.1.6.2), perturbed PKA and/or calcineurin signal-
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ling could be a possible consequence of TMD/LGMD2J mutations. Interestingly, 
preferential disorganization of the costameric M-band domains (Williams & Bloch 
1999), and myospryn mislocalization coupled with compromised PKA signalling 
(Reynolds et al. 2008) in mdx mice provide a tentative pathomechanistic link 
 between dystrophinopathies and TMD/LGMD2J.
Although the functions of myospryn in membrane trafficking seem less likely to 
be important at the M-band, their impairment as a consequence of titin mutations 
could also potentially contribute to the pathogenesis of titinopathies. For example, 
the rimmed-vacuolar pathology in TMD might reflect a mild defect in autophagy 
caused by impaired trafficking.
As far as LGMD2A is concerned, loss of CAPN3 activity is predicted to have 
widespread downstream effects on the regulation of its proteolytic substrates. If 
myospryn is a physiological CAPN3 substrate, its processing is likely to be com-
promised in LGMD2A, which may for its part contribute to the pathogenesis. The 
importance of myospryn relative to other substrates in this respect cannot be as-
sessed until more is known about the physiological substrates and the effects of 
CAPN3-mediated cleavage on their functions.
5.2 LGMD1D
Identification of the first LGMD1D-causing DNAJB6 mutations by our group 
(II: Table 1, Suppl. Fig. 2) necessitated functional studies for evaluating the patho-
genicity of the novel changes and allowed, for the first time, the investigation of the 
pathways underlying the disease on the molecular level.
5.2.1 Localization of DNAJB6 to the Z-disc and protein aggregates (II)
The subcellular localization of DNAJB6 in muscle had not been reported previ-
ously. To characterize DNAJB6 localization in normal muscle and to investigate 
the pathological changes in LGMD1D, muscle biopsies were studied by IF micro-
scopy. Control muscles showed DNAJB6 predominantly in the Z-discs (II: Fig. 1). 
This localization was not altered in the regions of LGMD1D muscle having pre-
served sarco mere structure, but DNAJB6 was also often found in intracellular 
protein accumulations of variable size and shape. Other proteins detected in the 
accumulations by IF stainings included binding partners of DNAJB6 (HSPA8 and 
MLF1), typical components of protein aggregates in myofibrillar myopathies (des-
min, filamin, myotilin, and αB-crystallin), and a reported client protein of DNA-
JB6 (KRT18) (II: Fig. 1, Suppl. Fig. 4). These results were in line with previous 
findings on light microscopic level (Sandell et al. 2010) and IF studies later pub-
lished by others (Harms et al. 2012, Sato et al. 2013). Double stainings indicated 
that the accumulations varied in composition, as all did not stain positive for the 
same proteins. DNAJB6 was typically detected in the periphery of these structures, 
co localizing only partially with the other accumulation components. This was 
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in  contrast to a primary myotilinopathy sample, studied for comparison, where 
 DNAJB6 and myotilin appeared more perfectly colocalized throughout the accu-
mulations (II: Suppl. Fig. 4).
Transmission electron microscopy of LGMD1D muscle revealed regions of dis-
organized myofibrillar structure, with an increase and dispersion of electron-dense 
Z-disc material likely corresponding to the accumulations seen in IF microscopy. 
EM also showed vacuolar changes indicating autophagic pathology, in agreement 
with regions of LC3 accumulation and rimmed vacuoles seen in immunohisto-
chemistry and light microscopy (II: Fig. 1, Suppl. Fig. 3).
5.2.2 Pathogenicity of DNAJB6 knockdown and mutations in zebrafish (II)
To understand the mode of action of LGMD1D-causing mutations, in vivo studies 
were carried out in zebrafish, an inexpensive model organism well suited for rapid 
functional screening of mutations.
First, the importance of DNAJB6 in muscle was studied by knocking down the 
expression of dnajb6b, the zebrafish orthologue of the co-chaperone, with splice-
blocking morpholino oligonucleotides. Knockdown of dnajb6b produced a muscle 
defect, with ~30% of injected morphant embryos showing detachment of myo fibres 
from vertical myosepta (II: Fig. 2), indicating that dnajb6b is required for muscle 
integrity in developing zebrafish. Specificity of the phenotype was demonstrated by 
efficient rescue by co-injection of wild-type human DNAJB6b mRNA.
The effects of LGMD1D mutations were then explored by ectopic expression of 
wild-type and mutant human DNAJB6 in fish embryos. Injection of mRNAs en-
coding wild-type DNAJB6a or DNAJB6b in the embryos, even at high doses, did 
not cause any observable muscle phenotype. In contrast, F89I and F93L mutant 
forms of DNAJB6b led to a muscle defect similar to that seen in dnajb6b mor-
phants, consistent with their dominant pathogenic effect in humans (II: Fig. 3). 
The phenotype was reproduced by DNAJB6b F93A and F93G, suggesting that 
the loss of phenylalanine residue, rather than the gain of leucine, is the critical 
pathogenic change. The F89G change in human DNAJB6b, on the other hand, did 
not cause a phenotype, possibly reflecting the fact that the zebrafish protein has a 
glycine residue at this position. No muscle defects were observed in embryos ex-
pressing the different mutations in DNAJB6a, indicating that the pathogenicity is 
mediated by the DNAJB6b isoform.
Interestingly, equimolar co-injection of wild-type DNAJB6b with either of the 
LGMD1D mutant proteins accentuated the muscle defect caused by the mutations, 
as indicated by a higher proportion of severely affected embryos (II: Fig. 3). This 
phenomenon was further studied by co-injections of wild-type and F93L DNAJB6b 
at various ratios. The severity of the muscle defect increased with higher amounts 
of mutant mRNA, whereas higher amounts of wild-type mRNA rescued the pheno-
type (II: Suppl. Fig. 5).
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5.2.3 Characterization of mutant DNAJB6 in cell cultures (II)
Transfection studies of V5-tagged and untagged DNAJB6 constructs on different 
cell lines were performed in order to identify differences in the properties of wild-
type and mutant DNAJB6. Subcellular localization of the constructs was investi-
gated by IF microscopy, and expression and solubility analyzed by western blot-
ting. This basic characterization did not reveal any obvious differences between the 
wild-type and mutant proteins. In some experiments, however, mutant DNAJB6b 
constructs showed increased steady-state levels compared to wild-type.
5.2.3.1 Oligomerization of DNAJB6 is not affected by LGMD1D mutations
Oligomerization of DNAJB6 was suggested by its similarity to DNAJB8, previously 
shown to from polydisperse complexes (Hageman et al. 2010), and interfering with 
the oligomer formation was thus a potential mechanism for the dominant negative 
effect of disease mutations. This possibility was tested in CoIP experiments, where 
V5-tagged and untagged DNAJB6b were coexpressed in COS-1 cells as different 
combinations of wild-type and F93L mutant, and immunoprecipitated with V5 
anti body beads (II: Suppl. Fig. 6). Untagged DNAJB6b was coimmunoprecipitated 
with the tagged construct, indicating that DNAJB6b is capable of self-association 
as proposed. However, presence of the F93L mutation in either one or both con-
structs did not have any effect on coimmunoprecipitation efficiency. Oligomeriza-
tion was also studied by sucrose density gradient centrifugation of proteins ex-
pressed in COS-1 cells, a setup previously used by Hageman and colleagues (2010) 
for DNAJB8. Similar fractionation of wild-type and F93L DNAJB6b-V5 indicated 
that, in line with the CoIP results, the size distribution of DNAJB6 oligomers was 
not affected by the mutation (II: Suppl. Fig. 6). These results indicated that the 
dominant negative effect of the LGMD1D mutations is not due to altered oligo-
merization properties.
5.2.3.2 Mutant DNAJB6 reduces the turnover of the entire complex
The higher levels of mutant DNAJB6 constructs seen in some transfection experi-
ments suggested that the mutations might affect the turnover of DNAJB6. This idea 
was supported by chase assays, where levels of DNAJB6 constructs in 293FT cells 
were followed while synthesis of new proteins was inhibited with cyclo heximide 
(CHX). F89I and F93L mutant DNAJB6b constructs showed significantly slow-
er turnover than the wild-type construct in CHX-treated cells (II: Fig. 3, Suppl. 
Fig. 7). The F93L mutation also decreased the turnover rate of DNAJB6a; the effect 
of F89I on this isoform was not determined.
Interestingly, in cotransfections of GFP- and HA-tagged wild-type and F93L 
mutant DNAJB6b, both constructs showed decreased turnover compared to single 
transfections. The effect was similar regardless of the construct carrying the mu-
tation (II: Fig. 3, Suppl. Fig. 7). This finding, consistent with the dominant nega-
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tive effect of the mutation, suggested that incorporation of mutant DNAJB6 to the 
oligo meric complex can affect the turnover of the whole complex.
Inhibitors of the major protein turnover pathways were used for investigating 
which pathway is responsible for the degradation of DNAJB6. Bafilomycin A1, an 
inhibitor of lysosomal acidification, efficiently blocked DNAJB6 turnover in CHX-
treated cells, indicating the DNAJB6 is turned over by the autophagic-lysosomal 
pathway. The proteasome inhibitor lactacystin did not increase the DNAJB6 level 
in CHX-treated cells, but rather decreased it compared to CHX alone, possibly due 
to autophagic activation following proteasome inhibition (II: Suppl. Fig. 7).
5.2.3.3 Mutations impair the anti-aggregation effect of DNAJB6
The aggregate pathology in LGMD1D suggested that the disease mutations might 
interfere with the ability of DNAJB6 to suppress protein aggregation, demonstrated 
in several studies (Chuang et al. 2002, Hageman et al. 2010, Hageman et al. 2011, 
Rose et al. 2011). This possibility was investigated by filter trap assays (FTA)  using 
polyQ-containing huntingtin as an aggregation-prone client protein—a method 
previously utilized for studying the anti-aggregation activities of DNAJB6 and 
other proteins (Hageman et al. 2010). The different DNAJB6 constructs were co-
expressed with GFP-tagged polyQ-huntingtin in T-REx 293 cells, and amounts of 
soluble and aggregated huntingtin determined from cell extracts by western blot-
ting and filter trap. To minimize the effects of transfection efficiency on the results, 
a novel robust measure of anti-aggregation activity, termed aggregation score, was 
established. This was based on a pairwise comparison of the aggregated-to-soluble 
ratios between induced and uninduced wells from duplicate transfections.
Compared to wild-type DNAJB6b, both F89I and F93L mutant proteins showed 
significantly impaired anti-aggregation activity, indicated by higher  aggregation 
scores (Fig. 11). This was reflected by both an increase in aggregated huntingtin 
and a decrease in soluble huntingtin compared to coexpression with wild-type 
DNAJB6b (II: Suppl. Fig. 8). Both mutants still retained activity, as they performed 
better than the nuclear DNAJB6a isoform used as a negative control. The impaired 
anti-aggregation effect did not depend on lower expression of the mutant proteins; 
on the contrary they showed somewhat higher steady-state levels than the wild-
type construct (II: Suppl. Fig. 8).
5.2.4 Association of DNAJB6 with the CASA pathway (II)
Chaperone-assisted selective autophagy (CASA) was recently described as impor-
tant for sarcomere maintenance (Arndt et al. 2010). This autophagic pathway is 
mediated by HSPA8 together with the co-chaperone BAG3 (BCL2-associated atha-
nogene 3), the small heat shock protein HSPB8, and the E3 ubiquitin ligase STUB1 
(STIP1 homology and U-box containing protein; also known as CHIP, C-terminus 
of Hsc70-interacting protein) (Arndt et al. 2010). The only hitherto established 
clients for CASA are filamins (Arndt et al. 2010, Ulbricht et al. 2013). In striated 
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muscle, the predominant member of this protein family is filamin C (FLNC, filamin 
2) that links the Z-discs to each other and to the sarcolemma (Arndt et al. 2010).
Filamins undergo conformational changes, including reversible unfolding, 
upon mechanical tension; this has been suggested to expose them to mechanically 
induced damage, necessitating efficient protein turnover (Arndt et al. 2010). The 
CASA proteins HSPA8, BAG3, and HSPB8—binding cooperatively to a mechano-
sensitive filamin region—sense the strain on the molecules and mediate their 
auto phagic degradation (Arndt et al. 2010, Ulbricht et al. 2013). In mechanically 
stressed cells, BAG3 facilitates the release of damaged filamin from the cyto skeleton. 
Following polyubiquitination by STUB1, both filamin and BAG3 are engulfed in 
autophagosomes for degradation. This involves recruitment of phagophore mem-
branes through the recognition of polyubiquitinated proteins by SQSTM1 and the 
interaction of BAG3 with synaptopodin 2 (Arndt et al. 2010, Ulbricht et al. 2013).
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Figure 11. Impaired anti-aggregation activity of mutant DNAJB6
The anti-aggregation activity of DNAJB6 on GFP-tagged polyQ-huntingtin protein was studied in a 
filter trap assay.
A Filter trap assay. T-REx 293 cells were cotransfected with GFP-tagged huntingtin and V5-tagged 
DNAJB6 constructs, and DNAJB6 expression was induced (+) or left uninduced (–). Aggregated 
(aggr.) and soluble (sol.) huntingtin in cell extracts were analyzed on a filter trap membrane and on 
western blot, respectively. Expression of DNAJB6 constructs (V5) and equal protein loading 
(a-tubulin) were controlled on western blot.
B Aggregation scores. Aggregated and soluble huntingtin in induced and uninduced cells were 
quantified from filter traps and western blots, and aggregation scores were calculated as described 
in Materials and methods. Both mutant DNAJB6b constructs (F89I and F93L) were less efficient in 
preventing huntingtin aggregation than wild-type (wt) DNAJB6b, as indicated by higher 
aggregation scores. The nuclear DNAJB6a isoform, ineffective towards the cytoplasmic huntingtin 
construct, was used as negative control. For each construct, n = 12. Statistical significance was 
tested using the Mann–Whitney U test with the Bonferroni correction.
Adapted from Sarparanta et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle 
muscular dystrophy. Nature Genetics, 2012; 44: 450–455. © 2012 Nature America, Inc.
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BAG3 seems to be the rate-limiting component regulating the activity of the 
CASA pathway. Induction of the transcription factor HSF1 (heat shock factor 1) 
by mechanical tension upregulates BAG3 expression and activates CASA (Arndt 
et al. 2010, Ulbricht et al. 2013). The importance of BAG3 for skeletal and car-
diac  muscles is highlighted by its high expression in these tissues (Homma et al. 
2006) and by the effects of BAG3 depletion and mutations: BAG3 knockout mice 
develop a severe skeletal and cardiac myopathy characterized by Z-disc disrup-
tion, myo fibrillar degeneration, and myonuclear apoptosis (Homma et al. 2006). 
The missense mutation P209L causes BAG3 myopathy—a severe dominant form 
of myo fibrillar myopathy (MFM) (Selcen et al. 2009)—while several other BAG3 
 mutations have been reported in dilated cardiomyopathy (DCM) (Norton et al. 
2011, Villard et al. 2011, Arimura et al. 2011).
5.2.4.1 DNAJB6 physically interacts with the CASA proteins
An connection of DNAJB6 with the CASA pathway was suggested by the known 
interaction of DNAJB6 with HSPA8, the colocalization of DNAJB6 and the CASA 
complex at the Z-disc, as well as the myofibrillar pathology of LGMD1D, indicat-
ing defective Z-disc maintenance and sharing pathological features with the BAG3 
myopathy.
To test the hypothesis that DNAJB6 and CASA could be linked, CoIP studies 
were carried out using V5-tagged DNAJB6b constructs overexpressed in COS-1 
cells (Fig. 12; III: Suppl. Fig. 9). DNAJB6b-V5 constructs, immunoprecipitated with 
anti-V5 beads, efficiently pulled down endogenous BAG3, and chemical crosslink-
ing of proteins in cell lysates prior to immunoprecipitation also allowed detection 
of endogenous HSPB8 in the immunoprecipitates. Furthermore, when BAG3 and 
Myc-tagged STUB1 were coexpressed with DNAJB6b-V5, both of them could be 
immunoprecipitated with it. The CASA proteins were not pulled down by anti-V5 
beads from cells expressing negative-control bait constructs (a V5-tagged titin 
 is6–M9 construct or an untagged DNAJB6b construct), indicating that the results 
were not due to unspecific binding of CASA components to irrelevant proteins or 
the antibody beads. Hence, CoIP supported the postulated association of  DNAJB6 
and the CASA pathway. The tested F93L mutation did not affect coimmunoprecipi-
tation of CASA proteins with DNAJB6, indicating that the pathomechanism is not 
likely to involve disrupted interaction with the CASA complex.
Interaction of DNAJB6 and the CASA components gained further support from 
in situ proximity ligation assays on rat muscle. In combination with a DNAJB6 
anti body, antibodies against BAG3, HSPB8, and STUB1 showed similar levels of 
PLA signals as the known DNAJB6 partner HSPA8 (III: Fig. 5).
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5.2.4.2 Functional interaction of DNAJB6 and BAG3 demonstrated in zebrafish
A possible functional interaction of DNAJB6 and CASA was investigated by ex-
pressing BAG3 and DNAJB6b in zebrafish embryos (III: Fig. 5). While injection 
of wild-type BAG3 mRNA alone into the embryos had no adverse effects on fish 
muscles, its co-injection aggravated the pathogenic effect of DNAJB6b F93L, as 
demonstrated by an increase in the proportion of severely affected embryos. In 
contrast, the P209L mutant form of BAG3, alone showing a toxic effect comparable 
to mutant DNAJB6b, did not show an additive effect with DNAJB6b F93L. These 
findings not only provided evidence for a functional connection between DNAJB6 
and BAG3, but also suggested that the BAG3 has plays an active role in the patho-
genesis of LGMD1D.
Notably, the different in vitro effects of BAG3 mutations causing MFM and 
DCM have suggested that the diseases are caused by distinct molecular path-
ways (Arimura et al. 2011). When expressed in cultured cardiomyocytes, BAG3 
constructs with DCM-associated mutations (R218W or L462P) inhibit Z-disc as-
sembly, show abnormal nuclear localization, and cause increased apoptosis upon 
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Figure 12. Coimmunoprecipitation of DNAJB6 and the CASA proteins
Wild-type (wt) or F93L mutant DNAJB6b-V5 constructs, or negative control constructs (DNAJB6b 
with no tag, or titin is6–M9-V5) were expressed in COS-1 cells and immunoprecipitated with V5 
antibody beads. Samples taken from cell extracts before immunoprecipitation (total), and proteins 
bound to the antibody beads (IP) were analyzed by western blotting.
A Proteins in cell extracts were crosslinked prior to CoIP, and endogenous BAG3 and HSPB8 were 
analyzed from the samples.
B BAG3 and Myc-STUB1 constructs were cotransfected with the different bait proteins, and CoIP 
was performed without crosslinking.
The CASA proteins BAG3 (A, B), HSPB8 (A), and STUB1 (B) were pulled down with the 
DNAJB6b-V5 constructs, with no difference between wild-type and F93L.
Adapted from Sarparanta et al. Mutations affecting the cytoplasmic functions of the co-chaperone DNAJB6 cause limb-girdle 
muscular dystrophy. Nature Genetics, 2012; 44: 450–455. © 2012 Nature America, Inc.
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serum starvation, whereas such effects are not seen with the MFM-causing P209L 
mutation (Arimura et al. 2011). The P209L mutant form of BAG3 is, on the other 
hand, unable to stimulate filamin degradation in smooth muscle cells (Arndt et 
al. 2010). The P209L mutation overlaps with one of the two Ile-Pro-Val motifs 
that mediate the interaction of BAG3 with HSPB8, and it has been suggested to 
interfere with HSPB8 binding (Fuchs et al. 2010). The faster migration of BAG3 
P209L in native PAGE analysis is also consistent with an absent protein inter action 
(Selcen et al. 2009). Together these findings suggest that while other functions 
of BAG3 are affected by DCM mutations, the MFM-causing P209L mutation spe-
cifically interferes with the CASA pathway, possibly by disrupting HSPB8 binding. 
By extension, the failure of BAG3 P209L to accentuate the toxic effect of mutant 
DNAJB6 in zebrafish implicates the CASA pathway also in the pathomechanism of 
LGMD1D.
While the results obtained in this study indicate an association of DNAJB6 with 
the CASA proteins, they provide little insight into its functional importance in the 
pathway. Further studies are hence needed for determining the role of DNAJB6 
in CASA. The simplest view, consistent with the published functions of DNAJB6b 
in preventing protein aggregation and promoting their degradation in an HSPA-
dependent manner, would be that DNAJB6 recognizes client proteins and presents 
them to the CASA machinery. However, other modes of action are also possible.
Although the functional link to the CASA pathway is underlined by the effect 
of the BAG3 P209L mutation, discussed above, the association of DNAJB6 with 
the CASA proteins could also reflect its participation in other functions of HSPA8, 
BAG3, STUB1, and HSPB8. In addition to filamin turnover through the HSPA8-
dependent CASA pathway, BAG3 and HSPB8 can promote autophagic degrada-
tion of polyQ-huntingtin in an HSPA8-independent manner. The induction of 
autophagy, accompanied by translation suppression, results from stimulation of 
eIF2α phosphorylation by the BAG3–HSPB8 complex. The activity requires the 
PXXP domain of BAG3 and is partly mediated by the GCN2 kinase (general control 
nonderepressible 2), but the molecular mechanism is currently unknown (Carra et 
al. 2008, 2009). Of note, as eIF2α phosphorylation status was not addressed in the 
studies describing the CASA pathway (Arndt et al. 2010, Ulbricht et al. 2013), it is 
possible that the autophagy stimulation by BAG3 in mechanically stressed cells is 
partly dependent on the same mechanism.
Another role of BAG3 in the Z-disc is to promote the interaction of HSPA8 with 
the actin-capping protein CapZ (Hishiya et al. 2010). This is required for the cor-
rect localization and stability of CapZ, and resistance of myofibrils to mechanical 
stress. BAG3-deficient cells subjected to mechanical stress show myofibrillar dis-
ruption, and the protective effect conferred by CapZ overexpression suggests this 
effect of BAG3 depletion indeed depends on CapZ rather than filamin deficiency 
due to impaired CASA (Hishiya et al. 2010).
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5.2.5 Conclusions on the pathomechanism of LGMD1D
Pathological findings in LGMD1D muscle—protein accumulations and rimmed-
vacuolar autophagy—point to a defect in protein quality control and turnover. The 
impaired ability of mutant DNAJB6b to suppress protein aggregation could direct-
ly lead to accumulation of unfolded proteins. A simple loss-of-function mechanism 
is, however, not consistent with the dominant effect of the mutations. It remains 
thus unclear if the impaired anti-aggregation activity of mutant DNAJB6, demon-
strated by the filter trap assays, has a causative role in the pathomechanism or if it 
simply reflects the otherwise altered properties of DNAJB6.
Observations of the zebrafish studies—the dominant effect of mutant DNAJB6b 
and its exacerbation by the wild-type protein—are compatible with a model where 
incorporation of mutant monomers to the oligomeric DNAJB6b complex renders 
a toxic function to the whole complex. In such a scenario, co-injection of wild-type 
protein with the mutant, although decreasing the proportion of mutant monomers, 
would increase the total amount of the toxic complex. Rescue of the phenotype 
with a further increase in the wild-type protein would imply that significant tox-
icity results only when the proportion of mutant monomers within the complex 
exceeds a certain threshold value. While attenuated autophagic turnover seems to 
be a property of the mutant DNAJB6 complex, it could be either the cause or a con-
sequence of the toxicity. Of note, the mutated DNAJB6a isoform, while not caus-
ing toxicity in zebrafish, still exhibited slower turnover. Hence, impaired turnover 
alone cannot alone explain the toxic effect of DNAJB6b mutations.
The increased severity of the zebrafish muscle defect observed in co-injections 
of BAG3 and mutant DNAJB6b suggests that the toxic function of the mutant 
DNAJB6 complex is mediated by BAG3. As the P209L mutation, predicted to 
inter fere with the binding of HSPB8 to BAG3 (Fuchs et al. 2010), prevents the ad-
ditive effect, it is conceivable that recruitment of HSPB8 to the mutant DNAJB6 
complex mediates the pathogenesis, either by conferring toxicity to the complex 
or due to sequestration of HSPB8. Such possibilities could be investigated e.g. by 
studying the combined effect of the DNAJB6 mutations and HSPB8 coexpression 
or knockdown in zebrafish.
5.3 Welander distal myopathy
The putative WDM-causing mutation was identified by our group in the prion-
related domain (PRD) of the RNA-binding protein TIA1 (III: Fig. 2). While the 
genetic evidence linking the identified E384K change to the disease was convinc-
ing, functional studies were initiated to demonstrate that the mutation affects the 
behaviour of TIA1 and to explore the possible pathogenic mechanisms.
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5.3.1 Biochemical characterization of wild-type and mutant TIA1 (III)
To identify any major effects of the E384K mutation on TIA1 behaviour, transfec-
tion studies of HA- or GFP-tagged TIA1 constructs were performed in HeLa cells. 
Cells transfected with wild-type or mutant TIA1a or TIA1b constructs were ana-
lyzed by western blotting of total cell extracts, or soluble and insoluble fractions. 
The wild-type and mutant constructs showed no obvious difference in solubil-
ity, and their steady-state levels were similar as judged by antibodies against the 
 N-terminal tag moieties or central TIA1. However, the two commercial antibodies 
raised against the C-terminal part of TIA1 showed dramatically weaker detection 
of the mutant constructs. The mutant constructs also tended to show slightly in-
creased mobility in SDS-PAGE, which—together with the difference in antibody 
detection—suggested a proteolytic cleavage or altered post-translational modi-
fication of mutant TIA1. The possibility of proteolytic cleavage was ruled out by 
analysis of double-tagged constructs, as the bands staining positive for both the 
N-terminal HA tag and the C-terminal V5 tag still showed a migration difference. 
Also  HA-tagged constructs translated in vitro showed the difference in migration, 
arguing against but not excluding the possibility of protein modifications. The mi-
gration difference was thus judged as a likely direct effect of the amino acid change.
5.3.2 Characterization of TIA1 and TIAL1 antibodies (III)
The different recognition of wild-type and mutant constructs by the C-terminal 
TIA1 antibodies, as well as expected cross-reaction problems due to high similarity 
of TIA1 and TIAL1, necessitated thorough characterization of the commercial TIA1 
and TIAL1 antibodies used in the studies.
The binding of the two C-terminal TIA1 antibodies (ab40693 and C-20) to wild-
type and E384K TIA1 was investigated by double labelling of GFP-TIA1a constructs 
in western blotting. Based on the TIA1/GFP signal ratios, both antibodies labelled 
the mutant constructs with 25–30% efficiency compared to wild-type. Testing both 
antibodies on a peptide array confirmed that their epitopes overlapped the mu-
tation site. Both showed weaker reaction with the mutation-containing synthetic 
peptides, indicating a direct effect of the mutation on antibody binding rather than 
a biologically relevant secondary change in the protein.
The specificity of the TIA1 and TIAL1 antibodies utilized in muscle WB studies 
was investigated by comparing their reactions with GFP-tagged TIA1a and TIAL1b 
constructs. The N-terminal TIA1 antibody G-3 showed similar reactivity towards 
both proteins, with GFP-normalized relative signals 100% for TIA1 and 112% for 
TIAL1. The C-terminal TIA1 antibody C-20 proved fairly TIA1-specific, with TIAL1 
constructs showing only 4% signal compared to TIA1. Also the TIAL1 antibody 
C-18 showed high specificity, with the TIA1 constructs showing 6% signal com-
pared to TIAL1.
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5.3.3 Expression analysis of the TIA proteins in WDM muscle (III)
To investigate whether the expression levels or isoform ratio of the TIA proteins 
were altered in WDM muscle, TIA1 and TIAL1 were analyzed from WDM and con-
trol samples by western blotting (III: Fig. 3). Both utilized TIA1 antibodies (G-3 
and C-20) detected a ~40-kDa band doublet representing the two TIA1 isoforms, 
as well as some presumably unspecific bands. In line with the impaired binding of 
C-20 to mutant TIA1, this antibody showed a slight reduction of the TIA1 doublet 
in WDM patients compared to control samples. The approximate 1:1 intensity ratio 
of the two doublet bands in both controls and patients indicated no major change 
in the isoform expression ratio.
With the G-3 antibody, comparison of TIA1b levels was precluded by cross-
reaction with the co-migrating TIAL1 band. The TIA1a-specific upper bands did 
not show any consistent difference between control and WDM samples. The TIAL1 
antibody G-18 detected a single strong band at ~40 kDa, again with no difference 
between WDM and control. As the two TIAL1 isoforms should migrate at differ-
ent speeds (Beck et al. 1996), the detected band presumably represents TIAL1b, 
reported to predominate on the protein level in many tissues and cells (Beck et al. 
1996, Li et al. 2002).
5.3.4 Microscopic analysis of TIA1 localization and pathology in WDM (III)
IF microscopy was used for studying the subcellular localization of TIA1 in nor-
mal and WDM-affected muscle, and for characterizing the pathological changes in 
WDM. In control muscles, TIA1 showed predominantly nuclear and weaker diffuse 
cytoplasmic localization. This appeared unchanged in most fibres of WDM sec-
tions, but some affected fibres showed an increase in cytoplasmic TIA1, with fo-
cal accumulations at the rimmed-vacuolar regions (III: Fig. 4). The stress  granule 
components TARDBP and G3BP1 showed accumulation and partial colocaliza-
tion with TIA1 in these regions, while eIF3 and HuR did not. Increased LC3b and 
SQSTM1 staining in the rimmed-vacuolar regions indicated ongoing autophagy 
and possibly reduced autophagic clearance, and ubiquitinated proteins were de-
tected either at the rimmed vacuoles or throughout the affected fibres (III: Fig. 4). 
The results on TIA1, TARDBP, G3BP1, and SQSTM1 were later perfectly replicated 
in immunohistochemical studies by Klar et al. (2013).
5.3.5 RT-PCR analysis does not indicate major splicing changes in WDM (III)
The role of TIA1 as a splicing regulator, involving the interaction of U1-C with 
the PRD (Del Gatto-Konczak et al. 2000, Förch et al. 2000, 2002, Aznarez et al. 
2008), suggested splicing defects as a possible pathomechanism for WDM. Splic-
ing changes in WDM muscle were investigated by RT-PCR analysis of a few se-
lected TIA1 target exons. A well-characterized effect of TIA1 is inclusion of FAS 
exon 6, generating the active isoform of the pro-apoptotic receptor Fas (Förch et al. 
2000, Izquierdo et al. 2005). Among the exons analyzed by Aznarez et al. (2008), 
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exon 13A of the procollagen lysine hydroxylase 2 (PLOD2) gene showed the high-
est (~10-fold) expression difference in response to TIA1 and TIAL1 depletion in 
HeLa cells, and the gene is also highly expressed in skeletal muscle (Valtavaara et 
al. 1997). Finally, TIA1 promotes the inclusion of stop-codon-containing exons 6A, 
6B, and 11A in TIAL1, negatively regulating its expression levels (Le Guiner et al. 
2001). Analysis of isoform ratios on agarose gels did not reveal consistent differ-
ences in the inclusion of these exons between control and WDM muscles.
Splicing of TIA1 itself in muscle biopsies and cultured myoblasts was studied 
from RT-PCR products spanning different parts of the transcript. In addition, in-
clusion of non-productive alternative exons (Le Guiner et al. 2001) was analyzed 
with RT-PCR primers overlapping exon boundaries. Neither approach indicated 
splicing changes in WDM. Analysis of muscle cDNA revealed a novel non-produc-
tive TIA1 splice variant, with the first 214 bases of intron 8 included between exons 
8 and 9, but also this product was found in both control and WDM samples.
As this preliminary analysis of selected target exons did not reveal splicing dif-
ferences, a general splicing defect was considered as an unlikely explanation for 
WDM pathogenesis, and splicing studies were not continued with more refined 
methodology. However, using quantitative real-time PCR, Klar and coworkers 
(2013) later detected in WDM muscle increased skipping of SMN2 exon 7, another 
reported target exon of TIA1 (Singh et al. 2011), and proposed that perturbed splic-
ing could contribute to the pathomechanism. It remains unclear whether the dif-
ferent outcomes of the two studies depend on the more accurate analysis  method 
used by Klar et al., or gene-specific differences in splicing. It is possible that a 
different quantification method would have allowed detection of splicing differ-
ences also in this study, but an effect as large as the threefold change reported for 
SMN2 would have hardly escaped detection even with the currently utilized tech-
niques. On the other hand, the SMN2 result was based on a rather small dataset 
of two WDM patients and three controls, and the reported difference could reflect 
 sample-to-sample variation rather than a disease-specific change. 
5.3.6 Mutant TIA1 has altered stress-granule-forming properties (III)
Aggregation of the TIA1 PRD mediates the formation of stress granules (SGs) (Gilks 
et al. 2004), suggesting that the WDM mutation located in this domain could  affect 
SG assembly or disassembly. The effects of the mutation on SG formation were 
studied in transfection experiments using constructs of both TIA1 isoforms N-ter-
minally tagged with GFP, HA tag, or HaloTag. The experiments were performed in 
HeLa cells, a cell line used in several published SG studies.
In line with published findings (Gilks et al. 2004), overexpression of TIA1 con-
structs induced SG formation in some cells. Oxidative stress caused with sodium 
arsenite treatment increased the SG number, with nearly all transfected cells con-
taining SGs. Visual inspection by IF microscopy did not reveal differences between 
wild-type and E384K constructs in the abundance, size, or localization of SGs 
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(III: Fig. 5). G3BP1, eIF3, and TIAL1 showed similar targeting to SGs containing 
wild-type and mutant TIA1 constructs. Localization of HuR and TARDBP to the 
SGs was more variable, but did not show any obvious difference between wild-type 
and mutant TIA1 SGs (III: Fig. 5, Suppl. Fig. 1).
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Figure 13. WDM mutation alters stress granule formation and dynamics of TIA1
A–B Quantification of stress granules from HeLa cells transfected with GFP-TIA1a (A) or GFP-TIA1b 
(B) by high-content image analysis. The E384K mutant constructs (mut) formed a higher number  
of stress granules compared to wild-type (wt), both in untreated and in arsenite-stressed cells.  
The graphs show the mean number of spots per analyzed cell (mean ± S.D. of well averages, 
normalized to the mean of wt untreated on each plate). Data for each group were pooled from  
12 wells of 3 plates in A and 9 wells on 2 plates in B, and significance levels calculated with  
the 2-tailed Mann–Whitney U test.
C FRAP analysis of wild-type and E384K mutant GFP-TIA1a in stress granules of arsenite-stressed 
HeLa cells. After bleaching, mutant GFP-TIA1a showed slightly lower average fluorescence recovery 
than wild-type, suggesting tighter binding of the mutant protein to the stress granules.  
The graph shows the fluorescence intensity of the FRAP target region relative to the initial 
prebleach value (mean ± S.D.). Asterisks indicate statistically significant differences (p < 0.05, 
2-tailed heteroscedastic t test) between wild-type (n = 26) and mutant (n = 29). Image frames 
were captured at intervals of 250 ms.
Adapted from Hackman et al. Welander distal myopathy is caused by a mutation in the RNA-binding protein TIA1. 
Annals of Neurology 73(4): 500–509, 2013 © 2012 American Neurological Association. The material is adapted with 
permission of John Wiley & Sons, Inc.
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High-content analysis on the CellInsight system was used for quantification 
of stress granules. To facilitate automated spot detection, analysis was restricted 
to cells expressing the constructs at moderate levels. The high-content analysis 
 revealed a minor wild-type–mutant difference affecting both TIA1 isoforms: both 
untreated and arsenite-treated cells expressing mutant TIA1 showed 10–20% 
more SGs compared to wild-type (Fig. 13). A similar difference was seen in both the 
number of SGs and their total area per analyzed cell, indicating an increase in SG 
formation propensity rather than attenuated clustering of small SGs (III: Suppl. 
Table 2). While GFP- and HaloTag-tagged TIA1 constructs showed similar behav-
iour, HA-tagged constructs failed to do so. This difference could be explained by 
lower and more variable expression of HA-TIA1, evident in WB analysis of the dif-
ferent constructs. Alternatively, the indirect immunostaining required for detec-
tion of the HA tag might result in an inferior signal-to-noise ratio, interfering with 
the image analysis.
Fluorescence recovery after photobleaching (FRAP) analysis in HeLa cells was 
used for investigating if the steady-state difference observed between wild-type 
and mutant TIA1 in SG number reflected altered dynamics of SG association/dis-
association. Fluorescence recovery of bleached SGs indicated rapid shuttling of 
wild-type GFP-TIA1a between cytosol and stress granules, consistent with previous 
findings (Kedersha et al. 2000), and the E384K construct showed slightly slower 
average recovery (Fig. 13). Similar results were obtained in FRAP experiments per-
formed at 37°C and at 35–36°C; in the lower temperature, both constructs showed 
slower recovery but the difference between wild-type and mutant was preserved. 
The lower recovery rate suggests tighter association of mutant TIA1 to the SGs, 
possibly indicating increased aggregation propensity of the prion-related domain.
In FRAP analysis of a hundred SGs in non-stressed cells, all analyzed granules 
exhibited rapid fluorescence recovery, in contrast to GFP-tagged huntingtin aggre-
gates that did not show any recovery during the follow-up period. This indicated 
that the increased SG number observed in high-content analysis was due to genu-
ine SGs rather than aggregation of mutant TIA1 to insoluble protein inclusions.
5.3.6.1 Stress granule studies in C2C12 myotubes (unpublished)
To investigate SG formation in a biological system more relevant to muscle dis-
ease, C2C12 myoblasts were transfected with GFP-TIA1 constructs and differen-
tiated into myotubes. The majority of transfected cells died or lost the plasmid 
expression during differentiation, but individual myotubes expressing GFP-TIA1 
survived. While in unstressed cells the localization of GFP-TIA1 was mostly dif-
fuse cytoplasmic, arsenite-stressed myotubes showed numerous stress granules 
(Fig. 14). Visual inspection did not show a dramatic difference between wild-type 
and mutant constructs. However, due to the small number and variable size of 
transfected myotubes, and the variable expression levels of the constructs in these 
cells, quantitative analysis of SGs was not possible. 
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5.3.7 Aggregation of SG proteins is a likely pathomechanism for WDM
The enhanced SG formation observed in high-content analysis and slower fluores-
cence recovery in FRAP experiments suggest that the E384K mutation, situated in 
the prion-related domain of TIA1, slightly increases its aggregation propensity. The 
accumulations of TIA1, TARDBP, and G3BP1 observed in the rimmed-vacuolar re-
gions of WDM muscles support the idea that aggregation of TIA1 plays a role in the 
pathogenesis of WDM. The relatively weak effect of the mutation on the behaviour 
of TIA1, observed in the functional studies, is consistent with the very late onset 
and slow progression of the disease.
The inherent ability of SG proteins to aggregate, while important for their bio-
logical functions, makes them also prone to undesired aggregation. Indeed, ag-
gregation of SG components is emerging as an important phenomenon in human 
diseases, most notably neurogenerative ones (Wolozin 2012, Kim et al. 2013). 
Disease-causing mutations may directly enhance the aggregation of the respective 
proteins and increase their recruitment to SGs (Johnson et al. 2009, Liu-Yesucevitz 
et al. 2010, Kim et al. 2013). Such mutations in TARDBP, most of them located in 
its prion-like domain, cause a familial form of amyotrophic lateral sclerosis (ALS) 
(Johnson et al. 2009, Liu-Yesucevitz et al. 2010). ALS-causing mutations have also 
been identified in FUS (fused in sarcoma), another RNA-binding protein showing 
SG localization. Rather than affecting the prion-like domain directly, these muta-
tions increase the cytoplasmic aggregation of FUS by interfering with its nuclear 
localization (Sun et al. 2011).
Figure 14. Stress granules in C2C12 myotubes 
C2C12 myotubes expressing wild-type (wt) and E384K mutant (mut) GFP-tagged TIA1a and TIA1b 
constructs were oxidatively stressed with 500 mM sodium arsenite for 45 min and fixed. Arsenite 
caused a clear recruitment of all TIA1 constructs to stress granules, but quantitative comparison 
between wild-type and mutant constructs was not possible. Scale bar, 20 mm.
untreated
wt
mut
wt
mut
arsenite-treated
G
FP
-T
IA
1a
G
FP
-T
IA
1b
116
Results and discussion
Aggregation-enhancing mutations in the prion-like domains of the heterogene-
ous nuclear ribonucleoproteins hnRNPA2B1 and hnRNPA1 were recently identified 
in ALS and multisystem proteinopathy (MSP), a syndrome with protein aggrega-
tion pathology involving muscle, brain, motor neurons, and bone (Kim et al. 2013). 
The analogy to WDM is particularly interesting due to the similar muscle pathology 
with rimmed vacuoles and TARDBP-positive inclusions (Kim et al. 2013).
Also normal SG proteins may contribute to inclusion formation by increasing 
the local concentrations of aggregation-prone proteins and cross-seeding their 
 aggregation (Wolozin 2012). In line with this, SG components have been seen to 
secondarily colocalize with various types of pathological inclusions. TIA1 and eIF3 
were detected in TARDBP inclusions in brain and spinal cord affected with ALS and 
FTLD-U (ubiquitin-positive frontotemporal lobar degeneration) (Liu-Yesucevitz et 
al. 2010). Brains from tauopathic mice, and from human patients with Alzheimer’s 
disease or FTDP-17 (frontotemporal dementia with parkinsonism 17), showed an 
increase of TIA1-positive inclusions whose size and colocalization with tau pathol-
ogy increased with disease severity (Vanderweyde et al. 2012). TIA1 and tau have 
also been demonstrated to promote the aggregation of each other in cell cultures 
(Vanderweyde et al. 2012). Finally, TIA1 is also recruited to polyQ-huntingtin ag-
gregates in cell cultures (Waelter et al. 2001). 
Pathogenicity of abormal SG formation may depend on sequestration of essen-
tial mRNAs and proteins, misregulation of RNA transport and translation, or by 
direct toxicity of the inclusions (Wolozin 2012), and increased aggregation of TIA1 
could cause muscle disease by any of these mechanisms. The simplest explana-
tion is that accumulation of TIA1, possibly seeding the aggregation of other pro-
teins, directly overburdens the protein turnover machinery in muscle fibres. Given 
the RNA-binding capacity of TIA1, the accumulation pathology could also involve 
 mRNAs. Interestingly, Nakano et al. (2005) found accumulation of the SG compo-
nents HuR and poly(A)-binding protein 1 (PABP1) together with poly(A) RNA at 
the rimmed-vacuolar regions in sporadic inclusion body myositis, and suggested 
that the pathomechanism may involve inhibition of mRNA degradation. Whether 
poly(A) RNA is also accumulating in WDM muscle, should be addressed by further 
studies.
In addition to a direct effect of the aggregates, increased TIA1 aggregation could 
lead to disease by interfering with multiple functions of the protein in translation 
control and RNA metabolism. Abnormal SG function could, for example, mildly 
impair the cellular response to oxidative or other types of stress, leading to proteo-
toxic stress due to accumulation of defective proteins. Another possibility would 
be specific or general suppression of protein expression due to sequestration of 
mRNAs in TIA1 accumulations.
Given the high degree of alternative splicing in skeletal muscle, defective regu-
lation of splicing could well play a role in the pathogenesis of WDM. While this 
study did not indicate general splicing abnormality of TIA1 target genes in WDM 
117
muscle, a pathogenic role of specific mis-spliced genes is not excluded. The pos-
sibility of splicing effects on individual genes is underlined by the SMN2 splicing 
difference later reported by Klar et al. (2013). However, as also pointed out by Klar 
and colleagues (2013), this specific splicing difference is not likely to be relevant 
in WDM. Impaired expression of SMN would be expected to cause a phenotype in 
motor neurons rather than in muscle, and splicing efficiency of SMN2 is in any case 
unlikely to be of importance in the presence of a functional SMN1 gene. To under-
stand the role of splicing changes in WDM, splicing of TIA1 target genes in WDM 
muscle should be systematically studied, for example on a microarray platform.
5.3.7.1 Muscle selectivity in WDM
Data on the tissue distribution of TIA1 are somewhat discordant, but according 
to WB and RT-PCR studies by Izquierdo and Valcárcel (2007a) TIA1 is widely ex-
pressed, and its level in muscle is not particularly high. The selective disease in-
volvement limited to a small group of skeletal muscles, with no symptoms in other 
tissues, is hence intriguing.
This study compared the SG-forming properties of wild-type and mutant TIA1 
only in the cellular context, i.e. in the presence of proteins possibly modifying TIA1 
behaviour. It is thus possible that the observed difference depends on an interaction 
with another SG component, and tissue selectivity could arise from differential ex-
pression of such a mediating protein. One candidate could be TIAL1 that according 
to Izquierdo and Valcárcel (2007a) is highly expressed in skeletal muscle. A weak 
interaction of soluble TIA1 and TIAL1 has been suggested by immunoprecipitation 
(López de Silanes et al. 2005), but studies addressing hetero-oligomerization of 
the two proteins in SGs have not been reported.
While differential TIA1 expression is unlikely to explain the specific disease in-
volvement of skeletal muscle, expression differences among muscles could con-
tribute to the muscle involvement pattern. The higher TIA1 expression in tibialis 
 anterior (TA) compared to gastrocnemius, quadriceps femoris, and deltoideus 
(Kang et al. 2005), is in line with marked involvement of TA in WDM. Expression 
levels of TIA1 in finger extensor muscles, first affected by WDM, have not been 
determined.
The muscle specificity could also reflect the unique stress exposure of skele-
tal muscle. Contractile activity causes thermal, mechanical, and oxidative stress 
(Close et al. 2005, Morton et al. 2009) that, together with the high content of 
 fibrous proteins, might make the post-mitotic muscle fibres generally susceptible 
to defects of protein turnover and accumulation of faulty proteins. Moreover, the 
afore mentioned recurrent stress exposure could cause relatively high levels of SG 
formation in muscle compared to other tissues, directly predisposing it to accu-
mulation of SG-derived aggregates. Another type of stress potentially contributing 
to the muscle selectivity could be exposure of distal muscles to cold temperatures, 
known to cause SG formation in cell culture (Hofmann et al. 2012).
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Conclusions and future work
6 CONCLUSIONS AND FUTURE WORK
The studies presented in this thesis aimed at elucidating molecular pathomecha-
nisms of muscular dystrophies. While the answers are far from complete, the stud-
ies gave important preliminary insight into the processes underlying LGMD1D and 
WDM, and provided new knowledge on the molecular biology of M-band titin and 
calpain 3, necessary for understanding the pathomechanisms of TMD/LGMD2J 
and LGMD2A.
Study I met its goal of finding novel interaction partners of C-terminal titin and 
calpain 3: myospryn was identified as a ligand for both proteins, and hence poten-
tially involved in the pathomechanisms of TMD/LGMD2J and LGMD2A. Although 
the FINmaj KI mouse model failed to show a direct downstream effect on myo-
spryn localization, loss of the functional interaction is an expected consequence of 
titin mutations, and this may be relevant in the pathogenesis of TMD/LGMD2J. 
While these initial studies did not reveal the biological function of the titin–myo-
spryn interaction, they established a good background for future functional work 
that is expected to complement the basic understanding of muscle biology and to 
elucidate the importance of myospryn in muscular dystrophies. Possible future 
studies could, for example, investigate the role of M-band myospryn in cell signal-
ling by analyzing local PKA and calcineurin activities in wild-type and FINmaj KI 
muscles and cell cultures. 
The proteolytic cleavage of myospryn, and its modulatory effect on CAPN3 auto-
lysis already provide clues about the possible functions of the CAPN3–myospryn 
interaction, but further studies will be needed for characterization of these effects 
on a mechanistical level and for determining their biological relevance. Quantifi-
cation of myospryn levels and turnover in normal and CAPN3-deficient cells and 
tissues could be used for investigating whether myospryn is a physiological sub-
strate for CAPN3. Possible regulation of CAPN3 activity could, on the other hand, 
involve phosphorylation or dephosphorylation events coordinated by myospryn. 
This possibility could be addressed by studying effect of myospryn coexpression on 
the phosphorylation state of CAPN3.
Study II identified mutations in DNAJB6 as the genetic cause of LGMD1D, 
unequivocally demonstrating the pathogenicity of the described mutations. The 
dominant toxic effect shown for mutated DNAJB6b is highly likely to be the major 
pathogenic factor underlying LGMD1D. It remains unclear whether the observed 
reduction of DNAJB6 anti-aggregation activity is an independent factor possibly 
contributing to the pathogenesis, or a direct cause or consequence of the toxicity. 
For understanding these effects, it should be first clarified whether the mutations 
affect the HSPA-dependent or -independent component of the anti-aggregation 
activity. This could be achieved by studying the relative effects of disease muta-
tions on DNAJB6 constructs defective either in the HSPA co-chaperone activity 
(deletion or inactivating H31Q mutation of the J-domain) or in the acetylation-
dependent anti-aggregation pathway (acetylation site mutations).
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Confirmation of the postulated link between DNAJB6 and the CASA pathway 
shed new light on the protein quality control and degradation pathways in muscle, 
although further studies are needed for characterizing the relationship of DNAJB6 
and CASA in healthy muscle and in LGMD1D. In this regard, the potential role of 
HSPB8 as the mediator of DNAJB6 toxicity is of particular interest and could be 
studied with overexpression and knockdown approaches in zebrafish. If the CASA 
machinery is necessary for the toxicity of mutant DNAJB6, its high expression in 
muscle (Ballinger et al. 1999, Kappé et al. 2001, Homma et al. 2006) is likely to ex-
plain the tissue-selective effect of the mutations at least partly. Also muscle- specific 
interaction partners of the mutated G/F domain or client proteins of DNAJB6 may 
play a role in the tissue selectivity, and their identification would be important for 
more complete understanding of the pathomechanism.
Study III demonstrated the TIA1 mutation E384K as the genetic cause of 
 Welander distal myopathy. A slightly increased aggregation propensity was identi-
fied for the mutant protein, suggesting altered stress granule dynamics to be a part 
of the pathomechanism of WDM. While this alone may be a sufficient explanation 
for the pathogenicity, the possible contribution of splicing changes should be kept 
in mind and investigated further, despite the negative results for the target genes 
studied here. Regarding the pathomechanism of WDM, the most important open 
issue is the selective involvement of a small subset of muscles, which could be elu-
cidated by identification of differentially expressed factors modifying TIA1 aggre-
gation. For assessing the contribution of complex environmental factors such as 
physical activity and temperature on TIA1 aggregation and WDM pathogenesis, an 
animal model for WDM would be an informative tool. While WDM itself is relative-
ly benign, detailed characterization of its pathomechanism may also be of interest 
with regard to other, more severe, diseases involving inappropriate aggregation of 
prion-like domains.
As a whole, these studies have augmented the knowledge on the molecular 
mechanisms of normal muscle function and disease pathogenesis. Understanding 
these mechanisms is a prerequisite for ultimately developing therapies to the stud-
ied disorders as well as other muscular dystrophies.
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